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Genomic imprinting is a process by which heritable epigenetic marks at a subset of genomic loci 
are established in a sex-specific manner in parental gametes and then maintained in nascent 
offspring. This study probes the poorly understood function of genomic imprints in placental 
biology. Genomic imprints are responsible for the regulation of parent-of-origin specific 
monoallelic expression of clusters of imprinted genes. The primary epigenetic mark that 
distinguishes parental alleles at imprinted loci is 5-methylcytosine in the context of cytosine-
guanine (CpG) dinucleotides within differentially methylated domains (DMDs). The Dnmt1 gene 
encodes the maintenance DNA methyltransferase, an enzyme responsible for replicating CpG 
methylation that is critical throughout the process of genomic imprinting. Genetic disruption of 
the oocyte specific isoform of Dnmt1 (Dnmt1o) results in partial and wide-spread loss of DMD 
methylation during preimplantation development and has strong effects on embryonic and 
extraembryonic development. In this dissertation the morphology of DNMT1o-deficient 
placentas is examined and their abnormal phenotypes correlated with loss of methylation at 
specific DMDs. A strong association between loss of methylation at the Kcnq1 DMD and 
accumulation of trophoblast giant cells was made. In addition, an association between loss of 
methylation at the Peg10 DMD and loss of fetal viability and placental labyrinthine volume was 
made. In conjunction with my study of the Dnmt1Δ1o model, I have engineered a novel targeted 
deletion of the imprinted Klf14 gene and found it has an effect on placental growth. My thesis 
unambiguously shows that genomic imprints are essential for placental development.  
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1.1.1  Discovery of genomic imprints 
In 1984 two different research groups firmly established that maternal and paternal genomes are 
non-equivalent in their developmental potential (1-4). These studies used pronuclear transfer 
techniques to remove one pronucleus and replace it with another to generate either bimaternal 
(gynogenetic) or bipaternal (androgenetic) genomes. They found that gynogenetic eggs are 
capable of developing into a 25-somite fetus but failed to properly generate extraembryonic 
tissue, whereas androgenetic eggs develop ample extraembryonic tissues but poorly developed 
fetuses. These results supported earlier research in mice that neither parthenogenetic (activated 
oocytes) nor gynogenetic conceptuses can survive (5-7). In addition, these results confirmed the 
clinical findings that parthenogenesis is not tolerated in human fetal development, and that 
androgenetic, dispermic conception results in molar pregnancies with excessive extraembryonic 
growth (6, 8, 9). In short, these studies found that the potential for embryonic development of 
male and female pronuclear genomes are different, with maternal genomes capable of initiating 
fetal but not extraembryonic development, and paternal genomes favoring extraembryonic 
growth.  
1.0  INTRODUCTION 
1.1  GENOMIC IMPRINTING 
2 
 
Around the same time mouse geneticists using different recombination driven models 
including uniparental disomies (UPDs), reciprocal translocations (symmetrical rearrangement of 
non-homolgous chromosomes) and Robertsonian translocations (fusion of two acrocentric 
chromosomes) identified chromosomes that are responsible for parent-of-origin effects (10, 11). 
Research on phenotypes observed from inheritance of Robertsonian reciprocal translocations, in 
which offspring had either two maternal or two paternal copies of a chromosomal segment, are 
particularly informative (12, 13). These studies recognized mouse chromosomes 2, 6, 7, 11 and 
17 as having parent of origin effects on fetal and/or placental growth (10). For example, in 
regards to chromosome 6, maternal uniparental disomy (matUPD) is lethal whereas paternal 
uniparental disomy (patUPD) is viable (10). Further studies into the early 90s using finer 
translocation breakpoints and chromosomal deletions narrowed down parent-of-origin effect 
regions (imprinted loci) to specific chromosomal bands (14, 15). This research led to speculation 
that these chromosomal regions have unique epigenetic marks that imprinted functionality based 
on which germline they passage through (16). 
 DNA methylation was determined to be the primary heritable epigenetic modification at 
endogenous genomic imprints in experiments using transgenes expressed from a single paternal 
allele under the control of upstream regulatory elements (17-22). It was found that DNA 
methylation at these transgene regulatory elements is established in germ cells (ie. oocytes and 
spermatocytes) in a sex-specific manner and that germline passage is associated with the allelic 
expression pattern in resultant offspring. For example, the RSVIgmyc transgene is a cloned DNA 
fragment that contains the RSV long terminal repeat (LTR) from the Rouse sarcoma virus (RSV) 
and the c-myc gene transposed within the immunoglobulin (Ig) locus. In this context, when 
integrated on an autosome, c-myc is expressed exclusively in myocardial tissue only when 
3 
 
paternally inherited; when maternally inherited it is not expressed. It was found that DNA 
methylation of the RSVIgmyc transgene occurs when the transgene is transmitted through the 
maternal germline but is erased (or not established) when transmitted through the paternal 
germline. Not only did this research establish DNA methylation as the key epigenetic mark in 
genomic imprinting, but it also provided evidence for erasure and establishment of imprinted 
DNA methylation during both male and female gametogenesis. 
 Through a combination of biochemical and genetic experiments endogenous genomic 
imprints were conclusively shown to be heritable DNA methylation marks at discrete loci 
scattered throughout the genome. Each chromosomal region identified as having parent-of-origin 
effects (10) was subsequently found to harbor one or more imprinted genes expressed from a 
single parental allele that are regulated by DNA elements methylated on one parental allele: 
mouse chromosome 2 harbors the Gnas and Nnat imprinted loci; mouse chromosome 6 harbors 
maternal imprints at the Peg10, Nap1l5 and Mest loci; mouse chromosome 7 contains three 
maternal imprints at the Kcnq1, Snrpn and Peg3 loci and one paternal imprint at H19; mouse 
chromosome 11 contains maternal imprints at the Grb10 and Zrsr1 loci; and mouse chromosome 
17 has a maternal imprint at the Igf2r locus. A summary of all known and putative imprinted loci 
can be found at the online mouse book resource (23). 
Imprinted regulatory DNA sequence regions have been named differentially methylated 
domains (DMDs), and alternatively called differentially methylated regions (DMRs), imprinting 
centers (ICs) and imprinting control regions (ICRs) in the scientific literature (24). There are 
subtle differences in the meanings of these terms; ICRs refer directly to the sequences controlling 
imprinted gene expression and often overlap with DNA binding sites for the insulator protein 
CTCF, whereas DMDs and DMRs refer to the larger imprinted methylated region including the 
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ICR. Confirmation of the role of DMDs was provided by the result of experimental insertion of 
Snrpn DMD sequences in place of the RSV sequences in the RSVIgmyc transgene; this 
SnrpnIgmyc transgene is consistently maternally imprinted in mice (25). Each set of imprinted 
genes and their regulatory DMD can be considered a single epigenetic unit termed an imprinted 
gene cluster. There are 24 imprinted clusters in the mouse with the majority of these conserved 
in humans (26). In section 1.5 I have reviewed 15 of the most functionally relevant clusters to 
placental biology. 
1.1.2  Establishment and maintenance of imprinted DNA methylation 
The DNA methyltransferase class of enzymes (DNMTs) catalyze the addition of methyl groups 
to the 5′ carbon of cytosine nucleosides (reviewed by (27)). This class of enzymes is divided into 
two groups. So called “de novo” DNA methyltransferases establish methylation in the absence of 
prior methylation and include the DNMT3a, DNMT3b and the non-catalytic DNMT3l. In 
contrast, the “maintenance” methyltransferase, DNMT1, along with its essential binding partner 
UHRF1, perpetuate CpG methylation after each round of DNA replication by recognizing and 
acting on hemi-methylated DNA templates. The DNMT2 enzyme, despite its homology and 
designated nomenclature, does not function to methylate DNA but rather acts on tRNA and other 
non-genomic substrates. The boundary between de novo and maintenance methyltransferases has 
recently become blurred, as they often work in tandem to establish and maintain DNA 
methylation. 
 The mammalian genome is methylated at roughly 70-80% of all CpGs in adult somatic 
tissues (28). However, during embryogenesis genomic methylation is dynamic as it is depleted 
during preimplantation and germ cell development and is then reacquired (29-32). DNA 
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methylation occurs at CpGs throughout the genome including intergenic regions, transposable 
elements, CpG islands (CGIs), gene bodies, inactivated X-chromosomes and imprinted DMDs 
(28, 33). Intergenic regions including microsatellites and other repetitive elements are sparsely 
populated with CpGs but are heavily methylated where they occur (28, 33). DNA methylation 
also occurs at endogenous retroviral elements and acts to suppress transcription and possibly 
transposition (34, 35). CpG islands are an interesting feature of the mouse genome because they 
are CpG rich sequences found at 70% of gene promoters but also within gene bodies, or at genic 
termini (36). They are largely unmethylated (at both active and inactive genes) except in some 
repressive heterochromatin contexts during development (31, 36). The majority of gene bodies 
outside of CGIs are highly methylated (33). In female conceptuses paternally inherited X 
chromosomes are inactive due to the absence of DNA methylation at the X inactivation center 
located at the promoter of the Xist gene (reviewed by (37)). The imprinted X-chromosome state 
is maintained in extraembryonic tissues (e.g. trophoblast) but is undone in the embryonic 
(epiblast) lineages of rodents prior to random X-inactivation (37). 
DNA methylation at imprinted DMDs occurs in a monoallelic manner based on allele 
parent-of-origin and is stably inherited through nearly all cell types (24). DMDs have many of 
the same features as CGIs and are located within gene promoters, introns and intergenic regions 
(36). However unlike non-imprinted CGIs and other types of genomic methylation, imprinted 
DMDs do not undergo the same dynamic changes in their methylation levels during development 
(30-32). Not surprisingly imprinted DMD methylation, unlike other types of genomic 
methylation, follows a unique developmental dynamic cycle during which DMD methylation is 
erased in primordial germ cells (PGCs), reestablished in a sex-specific manner within gametes, 
and then faithfully perpetuated throughout embryonic and postnatal development (24, 38). 
6 
 
Although DNA methylation is the primary epigenetic mark at DMDs, imprinted loci contain 
histone modifications on methylated alleles (e.g. H3K9me3) and on unmethylated alleles (e.g. 
H3K4me3) that are acquired during the normal genomic imprinting process (39, 40). 
 The experiments previously discussed using imprinted RSVIgmyc transgenes firmly 
established that imprinted methylation marks are erased in PGCs. There has been recent 
controversy as to whether this demethylation event is through passive or active mechanisms (41, 
42). PGCs are initially established in the proximal-posterior epiblast at embryonic day 6.25 
(E6.25) of mice and then proliferate and migrate up the genital ridges toward their somatic sex 
organ niches between E8.5 and E12.5 (43, 44). Both imprinted and non-imprinted CpGs are 
markedly demethylated in PGCs at E12.5 (44-47). The initial handful of cells, estimated to be 
approximately 6-32 in number at E7 undergo numerous rounds of cell division to establish the 
gametic stem cell pool. During this time maintenance DNA methylation activity does not occur, 
leading to passive loss of DNA methylation (41). It is postulated that an active de-methylation 
mechanism involving the cytosine deaminase AID, the glycosylases TDG and MBD4, and 
components of the base excision repair pathway PARP1, XRCC1 and APE1 are also involved to 
insure complete erasure of methylation patterns (48, 49). Aid1 homozygous null PGCs have three 
times more DNA methylation than controls (49). In addition, the 5-methylcytosine dioxygenase 
TET1 is present in PGCs leading to elevated levels of 5-hydroxymethyl-cytosine (5hmC) in PGC 
genomes (48). It is unclear if 5hmC is involved in active demethylation, as it is not a substrate 
for glycosylases, although both the 5hmC deamination product 5-hydroxymethyluracil and the 
TET catalyzed carboxylated nucleoside 5-carboxylcytosine are TDG substrates (41, 48, 50-52). 
Alternatively, it has been suggested that 5hmC and bound TET proteins may act to inhibit 
DNMT1 activity thereby leading to passive loss (42). 
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 The timing of DNA methylation acquisition in gametes, a process mediated by the de 
novo methyltransferases, differs between male and female germlines (53). The RSVIgmyc 
transgene experiments suggested that imprinted DNA methylation occurs during 
spermatogenesis by the pachytene stage prior to meiosis I, whereas in the female germline 
methylation is observed after meiosis I in mature (MII) oocytes (18). During spermatogenesis the 
H19 DMD is methylated on the paternally inherited allele in spermatogonia and acquires 
methylation on the maternally inherited allele by the pachytene stage (54). DNA methylation at 
various CGIs and repetitive elements also increases during transition between spermatogonia and 
pachytene spermatocytes (55). During oogenesis the Snrpn DMD is methylated gradually during 
postnatal development, increasing from minimal methylation at postnatal day 0, to 50% 
methylation at postnatal day 10 and full methylation in MII oocytes at maturity (56). Genome 
wide methylation analysis has confirmed that in female mice oocyte genomic methylation 
gradually increases from very low levels in immature (postnatal day 5) oocytes through the 
germinal vesicle (GV) and MII mature stages (32). The overall level of DNA methylation is 
higher in sperm than female pronuclei, however the paternal pronuclear genome is rapidly 
demethylated within hours of fertilization (30, 57). Methylation at DMDs is known to shift, 
expand and recede at different loci and is evident in the comparison of gametic and mid-
gestation embryonic DMD sizes (58). There are roughly 1600 CGIs (including imprinted and 
non-imprinted sequences) that are differentially methylated between sperm and oocytes, and 
roughly half of these are resistant to erasure during preimplantation development (59). 
 Maintenance of genomic imprinting during preimplantation development prior to zygotic 
Dnmt1 activation is dependent on maternally inherited DNMT1 protein that is stored in oocytes 
(60-63). Oocytes produce somatic (DNMT1s) and oocyte-specific (DNMT1o) isoforms that 
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function in the zygote. Oocyte produced DNMT1s is 1620 amino acids in length, is sequestered 
in ooplasm but migrates to the zygotic nucleus, and functions to maintain imprints during the 
first and second zygotic cell divisions (60, 61). Dnmt1 transcription from an upstream oocyte-
specific promoter generates the mRNA template for the DNMT1o isoform, which is shortened 
by 118 amino acids at the N-terminus, and is sequestered in the ooplasm until the 4th mitotic 
division (60, 62, 63). The combination of maternal DNMT1s and DNMT1o maintains imprints 
up to the 32 cell stage when zygotically produced DNMT1s acquires the full maintenance 
responsibility (60, 61).  
Imprinted DMD methylation is perpetuated on one parental allele of each genomic DMD 
during early mammalian development despite fluctuating levels of genomic methylation (29-32). 
The genome of mature spermatocytes contains higher overall levels of CpG methylation than 
oocytes (30, 57). Immediately following fertilization, the 5-methylcytosine sites within the male 
pronulclear genome are converted to 5hmC by the 5-methyl-cystosine dioxygenase TET3 (64-
68). The female pronuclear genome, and a minority of CpG sites within male pronuclei are 
protected by maternal and zygotic stores of DPPA3 bound to dimethylated histone 3 lysine 9 
(H3K9me2) chromatin (69, 70). Maternal deletion of Dppa3 results in increased 5hmC 
abundance in the maternal pronuclear genome (69, 70). Both parental genomes are demethylated 
during preimplantation at the majority of sites (except at imprinted DMDs), however the effect is 
more pronounced in male pronuclear genomes due to their higher initial DNA methylation levels 
and rapid reduction (30, 32, 64, 67). In addition to the mechanism involving DPPA3 it is thought 
that DMDs are also protected from demethylation, through the recruitment of DNA-binding 
protein ZFP57 and TRIM28 (71-76). Maternal-zygotic deletion of Zfp57 results in mid-gestation 
embryonic lethality with loss of methylation at the Snrpn, Peg1, Peg3 and Nnat DMDs but 
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normal methylation at the H19 and Dlk1 DMDs and repetitive Line1 and Iap elements (71, 72). 
Trim28 homozygous null embryos have a loss of methylation at the H19 and Snrpn but not Peg3 
DMDs (74). In ES cells Zfp57 deletion results in loss of DMD methylation whereas Trim28 
deletion results in decreased H3K9me3 (75). These results combined with recent biochemical 
and structural data provide a model whereby ZFP57 binds methylated DMDs at the 
hexanucleotide TGCCGC, recruits TRIM28 via its KRAB domain, which promotes 
heterochromatin formation through the recruitment of the H3K9 methyltransferase EHMT2, 
DNMT1 and DNMT3 isoforms (72-76). 
This preimplantation wave of demethylation occurs simultaneously with the phenomenon 
known as nuclear reprogramming whereby the zygotic genome transitions from a totipotent 
epigenetic state to a pluripotent state to be able to generate the many cell types required for 
embryonic and extraembryonic development (Recently reviewed in (77-79)). During cellular 
differentiation DNA methylation at various promoter CGIs is modulated (e.g. Oct4, Nanog and 
Ets5) thereby altering the expression of key components of important developmental programs 
(31, 80, 81). During the many waves of de novo methylation during the process of differentiation 
imprinted DMDs remain methylated only on one parental allele, indicating that there are 
mechanisms that prevent the establishment of methylation at unmethylated DMDs. The 
processes by which both de novo and maintenance DNA methyltransferases are regulated are the 
subjects of ongoing research in the field of epigenetics.  
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1.1.3  DNA methyltransferase mouse models 
Targeted mutation of members of the Dnmt gene family have major effects due to loss of DNA 
methyltransferase activity at critical times during gametogenesis and preimplantation 
development (reviewed by (27, 82)). All three classes of DNMTs contain a catalytic C-terminal 
S-adenyl-methionone (SAM)-dependent methyltransferase domain. Dnmt1 encodes a 1620 
amino acid protein with an extensive N-terminal domain containing a nuclear localization, 
replication foci targeting sequence (RFTS), a CXXC zinc finger that recognizes umethylated 
DNA and a tandem bromo-adjacent homology (BAH) domains (83-85). DNMT1 is understood 
to function as homodimer, mediated through interactions with its N-terminus, at hemimethylated  
DNA (86). The de novo methyltransferase genes Dnmt3a and Dnmt3b encode much shorter 
proteins (908 and 776 amino acids respectively) with a N-terminal DNA binding PWWP motif 
and an unmethylated H3K4 binding plant homeodomain like (PHD) domain (87-89). The 
Dnmt3l gene encodes a catalytically inactive methyltransferase lacking an N-terminal PHD 
domain that interacts, stimulates and co-localizes with DNMT3a and DNMT3b at 
heterochromatin loci (87, 90, 91). DNMT3A interacts with DNMT3L to form tetramers that can 
bind CpGs with a periodicity of 8-10 base pairs (92). 
Targeted mutations of the genes encoding de novo DNMTs (i.e. Dnmt3a, Dnmt3b and 
Dnmt3l) have profound developmental effects based on the failure to establish DNA 
methylation. Heterozygous null Dnmt3a and Dnmt3b as well as compound heterozygotes are 
normal and can be intercrossed to generate homozygous null offspring (93). Dnmt3a 
homozygous offspring die at 4 weeks after birth and are growth restricted but have normal 
imprinted and non-imprinted genomic methylation (93). Dnmt3b null mice die in late gestation 
and have reduced IAP and centromeric satellite DNA methylation similar to the loss-of-function 
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DNMT3B mutations associated with ICF syndrome (93). Compound homozygous 
Dnmt3a/Dnmt3b null mice die around gastrulation and have loss of IAP and centromeric DNA 
methylation (93). Methylation in each of these models does not affect imprints and is higher at 
repetitive elements than observed in Dnmt1 null models indicating that imprints and some 
genomic methylation established prior to implantation (i.e. in the germline) is maintained (93).  
Dnmt3l homozygous null mutants survive to adulthood but are infertile (91, 94). In males 
absence of DNMT3L results in germ cell mitotic catastrophe, lack of spermatocytes and 
infertility, and a lack of DNA methylation at the H19 paternal DMD and repetitive DNA 
elements (91, 95, 96). Female homozygous Dnmt3l dams generate oocytes that lack all maternal 
imprinted and non-imprinted DNA methylation and yield progeny that fail to develop past E9.5 
(91, 94, 97-99). This embryonic lethality is thought to be caused by extraembryonic defects 
including failure of chroio-allantoic fusion and trophoblast cell differentiation defects that are 
reviewed in comparison to my results in section 3.5.4 (94, 97, 99). Conditional germ cell deletion 
of Dnmt3a, but not Dnmt3b, recapitulates the many of the same phenotypes of Dnmt3l null 
models including a maternal effect from the maternal germline and mitotic catastrophe from the 
paternal germline providing definitive evidence that DNMT3A and DNMT3L work in concert 
(100). 
Targeted inactivation of Dnmt1 is severely detrimental to mouse embryonic development. 
The Dnmt1n allele is a N-terminal partial loss-of-function mutation (101). Homozygous Dnmt1n 
mice have a 70% reduction in total genomic methylation including at imprinted DMDs and arrest 
development at 9.5 primarily due to failure of hematopoiesis (101, 102). Two complete loss of 
function null alleles that target the replication targeting region (Dnmt1s) and the catalytic C-
terminus (Dnmt1c) respectively have even lower methylation levels (95% loss) and arrest 
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development in homozygous embryos at E8.5 (103). Residual genomic methylation is likely due 
to de novo methyltransferase activity (103). Intriguingly, despite the drastic loss of DNA 
methylation, homozygous Dnmt1 null embryonic stem cells are viable and proliferate until they 
are induced to differentiate (101, 103). This suggests that DNA methylation is not vital for stem 
cell survival and proliferation but is required for complex mammalian development. These 
Dnmt1 models are indicative of the importance of DNA methylation but cannot distinguish 
which types of genomic methylation targets are critical for mammalian development. 
Maternal homozygous deletion of the oocyte specific promoter of Dnmt1 (Dnmt1o) 
eliminates DNMT1o protein from resulting oocytes and preimplantation embryos and results in 
partial loss of DMD methylation, but normal non-DMD methylation levels (104). These 
conceptuses are mosaic for loss of imprinting and some survive to term (104). Many DNMT1o-
deficient mutants have severe fetal phenotypes, and preliminary findings also indicate placental 
defects (105). A detailed introduction of the Dnmt1Δ1o model is provided in Section 2.2. The 
Dnmt1Δ1o model is superb for investigating the direct effects of loss of DMD methylation 
because it specifically results in primary epigenetic mutations only at imprinted DMDs. The 
Dnmt1v allele constitutively expresses the Dnmt1o isoform in all tissues (106). Homozygous 
Dnmt1v/v mice are normal, however maternal-zygotic lethality is observed in compound Dnmt1v 
and Dmap1 null embryos (106, 107). This epistatic interaction is likely direct because the N-
terminus of DNMT1, which the DNMT1o isoform lacks, contains a DMAP binding motif, and 
their interaction is eliminated in compound mutant offspring (107).  
How DNMT1 is able to distinguish between imprinted and non-imprinted sequences 
during times of dynamic methylation changes is an important biological question. An interesting 
finding in homozygous Dnmt1c ESCs is that the majority of DNA methylation, but not imprinted 
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DMD methylation, returns after transfection of a functional Dnmt1 minigene, further validating 
that imprints require germline passage to be established (108, 109). Building on this finding a 
Dnmt1 TET-Off allele was engineered to suppress expression of Dnmt1 in vitro with addition of 
tetracycline to culture media, and then allow recovery of expression after replacement with 
tetracycline depleted media (110, 111). Similar to the minigene system genomic methylation 
largely recovers (110, 111). However imprints and a select group of promoter CGIs do not 
recover their methylation (110, 111). Many of these CGIs are located at developmentally 
important regulators, indicating that DNMT1 is required for maintenance of imprint-like 
sequences that are established in heterologous contexts.  
The DNMT1 protein contains an intrinsically disordered domain from amino acids 100-
400 that is a strong candidate for autoregulation of DNMT1 activity and its interaction with other 
proteins (110). This region has no predicted structure, is rich in charged amino acids (making it 
hydrophilic) and contains multiple proline residues that block secondary structures such as alpha 
helices (110). Amino acids 190-350 of DNMT1 within the disordered domain, like the process of 
genomic imprinting, is specific to mammals (110). Although deletion of the whole mammalian 
specific region has no effect on genomic methylation smaller deletions have distinct effects in 
ESCs (110). Deletion of the coding region for amino acids 255-291 results in loss of DMD and 
non-DMD methylation, deletion of amino acids 191-324 results in loss of DMD but not non-
DMD methylation and deletion of amino acids 297-309 results in loss of non-DMD methylation 
but normal DMD methylation (110). Furthermore replacement of murine Dnmt1 codons 328-333 
with a rat specific sequence, produces a hypomorphic allele with lower overall levels of 
methylation and embryonic growth restriction (112). These studies indicate that the mammalian 
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specific DNMT1 region is involved in distinguishing DMD and non-DMD sequences and has 
species-specific features. 
Because DNMT1 is able to distinguish between imprinted and non imprinted sequences 
during dynamic developmental processes it is speculated that it must be regulated in some 
allosteric manner. The structure of DNMT1 in the absence of DNA reveals that the RFTS 
domain is situated in the catalytic DNA interacting region (85). In complex with unmethylated 
DNA a DNMT1 autoinhibitory loop between the CXXC and BAH domains blocks catalytic 
domain access to CpG dinucleotides and a linker between the BAH2 and the catalytic domains 
blocks target recognition (83, 84). These allosteric auto-inhibitory conformations are relaxed at 
hemimethylated DNA and are likely modulated by interactions with multimeric heterochromatin 
protein complexes. DNMT1 interacts with multiple proteins including UHRF1, DMAP, ZFP57, 
TRIM28, DNMT3 isoforms and others (75, 76, 107). Mutations in the genes encoding the 
DNMT1 interactome not surprisingly alter genomic methylation. A better understanding of the 
complexes DNMT1 is part of will likely provide clues to how DNMT1 has differential activity at 
DMD and non-DMD CpG sites during periods of development when there is upheaval of 
genomic methylation patterns. 
One of the reasons it is important to study genomic imprints is because the etiologies of multiple 
severe congenital developmental disorders are based on genetic and epigenetic changes at 
imprinted genomic loci (Table 1). The Beckwith-Wiedemann (BWS), Silver-Russel (SRS), 
1.2  GENOMIC IMPRINTS IN HUMAN DEVELOPMENTAL DISORDERS 
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Prader-Willi (PWS), and Angelman (AS) syndromes are all classified as imprinting disorders. In 
addition both Pseudohypothyroidism Type I (PHP1a) and transient neonatal diabetes mellitus 
(TNDM) are metabolic diseases caused by loss of imprinting at other loci. It is clear from these 
disorders that the dosage of imprinted genes is critical, and that neither loss nor gain of imprinted 
gene expression is well tolerated. Because these disorders can be diagnosed and in some cases 
manifest symptoms prior to parturition it is plausible that the symptoms are in part based on 
placental dysfunction. It is my hope that some of my dissertation research on the role of genomic 
imprints in mouse placental biology will provide insight into the prenatal disease mechanisms of 
these disorders. 
1.2.1  Beckwith Wiedemann Syndrome 
Beckwith-Wiedemann Syndrome (BWS; OMIM 130650) is a neonatal overgrowth syndrome. It 
is characterized by the major traits of overgrowth (macrosomia), large tongue (macroglossia), 
protusion of the umbilical cord and/or gut (exomphalos), enlarged internal organs 
(visceromegaly), renal abnormalities and an increased incidence of embryonic tumors (e.g. 
Wilms tumor) (113, 114). Minor traits associated with BWS include enlarged placenta 
(placentamegaly), certain facial structures (e.g. anterior earlobe creases) and neonatal 
hypoglycemia (113, 114). The overgrowth seen in BWS children is often considered 
hemihyperplasitic and hemitrophic because overgrowth is confined to certain internal organs and 
uneven in extremeties. It is thought that hemihyperplasia can be caused by the development of 
mosaic early embryos composed of epigenetically normal and imprint-defective cells. 
  Both the clinical phenotypes and etiology of BWS are heterogeneous. The majority of 
BWS cases are sporadic with no apparent familial history (114, 115). The genomic region 
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involved in BWS is a large imprinted region on 11p15.5 that includes both the KCNQ1 and H19 
imprinting clusters (115-121). The rare heritable cases are usually attributed to maternal 
inheritance of loss of function mutations within the paternally imprinted CDKN1C gene (122). 
The majority of sporadic cases of BWS are caused by loss of DNA methylation on the maternal 
allele of the KCNQ1 DMD (clinically referred to as IC2 or KvDMR) (114). Gain of methylation 
on the maternal allele of the H19 DMD (clinically referred to as IC1 or H19DMR) is responsible 
for about 5% of sporadic BWS cases. Infrequent translocations, duplications and inversions of 
this region are also causative mutations of BWS. The loss of imprinting and paternalization of 
the 11p15.5 region results in loss of expression of one (e.g. CDKN1C) or more paternally 
imprinted genes within the KCNQ1 cluster and increased expression of the maternally imprinted 
IGF2 in the H19 cluster, manifesting in the abnormal growth phenotypes (115). The biallelic 
overexpression of IGF2, a potent mitogen, is a major factor in the overgrowth phenotype as well 
as the enhanced prevalence of fetal and infantile Wilms tumor in BWS. 
1.2.2  Silver-Russell syndrome 
The major clinical phenotypes of Silver-Russell syndrome (SRS; OMIM 180860) are intrauterine 
growth restriction and diminished postnatal growth along with minor traits such as facial 
disproportion, body asymmetry, syndactly and short stature. There is a broad spectrum of SRS 
and SRS-like clinical manifestations that include growth restriction to varying degrees in 
compilation with one or more minor traits (123, 124). Birth weights and postnatal growth greater 
than two standard deviations less than the mean are typical for SRS patients, and growth 
hormone is the standard treatment for this growth disorder (123, 124). Intriguingly the 11p15.5 
region (H19 DMD) implicated in the overgrowth syndrome BWS is also involved in SRS. The 
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majority (estimated at 31-55%) of SRS patients have loss of methylation at the H19 DMD, or 
maternal UPD11p15 (~4%), with subsequent downregulation of IGF2 (125-129). The abundance 
of IGF2 in BWS and its paucity in SRS demonstrates the strong influence of IGF2 levels on fetal 
growth. Although SRS and BWS are opposing imprinting disorders based at 11p15.5 (H19 
DMD), SRS appears to be a multi loci disorder with alternative etiologies based on molecular 
abnormalities on chromosome 7 in 7-10% of cases (125, 130). 
Maternal UPD7 is the genetic eitology of a minority of Silver-Russell patients (125, 130). 
Human chromosome 7 has three distinct imprinting centers at the GRB10 (7p12.1), PEG10 
(7q21.3) and MEST (7q32.2) loci. Reports of matUPD7p21 including GRB10 and the non-
imprinted insulin binding protein genes IGBP1 and IGBP3 in SRS patients is parsimonious given 
their role in IGF2 signaling (131, 132). Maternal duplication of the 7q31qter inclusive of the 
MEST imprinting locus has also been identified as a cause of SRS however it is unclear which 
imprinted genes within this cluster are directly involved (133). 
One explanation for the heterogeneity of clinical phenotypes and molecular etiologies in 
SRS and SRS-like cases is that it is a multigenic syndrome involving imprinting loci that co-
regulate key growth pathways. It has been shown that some SRS patients have tissue-specific 
epigenotypes at imprinted loci, suggesting that mosaic loss of methylation may occur early in 
development and perhaps modulate the SRS phenotypic outcome (134, 135). Quantitative 
methylation studies have been informative in making correlations between specific epigenetic 
loci involved in SRS and phenotypic traits (129). Hypomethylation at 11p15.5 is associated with 
the classical SRS phenotypes of facial asymmetry, 5th finger clindactyl, and congenital defects; 
whereas matUPD7 is associated with a triangular facial structure, global developmental delay 
and need for speech therapy (129). However, the degree of loss of methylation is not indicative 
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of the severity of SRS phenotypes (129). This study is proof that correlation of DMD 
methylation can be predictive of quantitative traits.  
1.2.3  Prader-Willi syndrome and Angelman syndrome 
Prader-Willi syndrome (PWS; OMIM 176270) and Angelman syndrome (AS; OMIM 105830) 
are reciprocal developmental disorders whose molecular etiologies are based on genetic or 
epigenetic abnormalities in the SNRPN imprinted cluster at 15q11.2 (reviewed by (136, 137)). 
PWS is characterized by prenatal fetal inactivity, neonatal muscular hypotonia, growth hormone 
insufficiency, hypogonadism and juvenile onset obesity. Hyperphagia-induced obesity in PWS is 
associated with elevated ghrelin orexigenic hormone levels that lower satiety sensitivity, and can 
be treated through a combination of recombinant growth hormone and behavioral therapy (137). 
Patients with AS have severe mental retardation with deficiencies in motor, balance, speech and 
language (136). Although both PWS and AS are primarily recognized as postnatal disorders, 
they appear to have fetal origins, therefore it is worthwhile to investigate whether the SNRPN 
cluster has a role in placenta development (136, 137). 
While PWS is based on the lack of expression of paternally expressed genes within the 
SNRPN locus, AS is caused by lack of expression of adjacent maternally expressed genes within 
the same genetic locus (136, 137). The molecular etiologies of both diseases range from de novo 
inherited deletions, UPD15q11-13, imprinting disorders and single gene mutations (136, 137). 
The majority (~70%) of PWS and AS cases are due to inherited de novo deletions of a 5-6 MB 
region encompassing the 2MB SNRPN imprinting cluster (136, 137). PWS patients inherit this 
deletion on the maternal allele whereas AS patients inherit the deletion from the paternal allele 
(136, 137). The large PWS and AS deletions arise from common recombination breakpoints 
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centromeric of the PWS paternally expressed genes and a series of three telomeric breakpoints 
telomeric to the AS genes (136, 137). Maternal UPD15q11-13 is the cause of approximately 20% 
of PWS cases whereas paternal UPD15q11-13 is a cause of approximately 1-2% of AS cases 
(136, 138, 139). 
A minority of PWS (~1-3%) and AS (~2-4%) cases result from loss of imprinting at the 
SNRPN locus (136, 137). This is primarily due to alteration of the genomic methylation patterns 
at the SNRPN DMD (136, 137). A small fraction (~15%) of loss of imprinting cases in PWS and 
AS have interstitial deletions ranging from a 10kb to 800bp that abolish imprinted expression 
patterns (140-143). These loss of imprinting deletions have identified non-overlapping IC 
sequences that are causative of PWS (when paternally inherited), or AS (when maternally 
inherited) (140-143). The PWS IC overlaps SNRPN exon 1, and the AS IC is centered at SNRPN 
upstream exon u5 (140-143). Normally these regions are oppositely methylated with the PWS IC 
methylated on the maternal allele and the AS IC methylated on the paternal allele.  
Single gene mutations of members of the SNRPN imprinted gene cluster are also causes 
of PWS and AS. Maternal inheritance of genetic mutation at UBE3A is a cause of 2-5% of AS 
cases (136, 144, 145). UBE3A encodes a ubiquitin ligase responsible for marking proteins for 
degradation that is up-regulated in neuronal tissues (144, 145). Roughly 10-15% of AS cases 
have unknown genetic etiologies suggesting the involvement of additional genes (136). 
Paternally inherited mutations in the maternally expressed small nucleolar RNA (snoRNA) gene 
116 (SNORD116) within the SNRPN locus has recently been identified as an etiology of a small 
minority of PWS and PWS-like cases (146, 147). The SNRPN locus is discussed in more detail in 
section 1.5.8 with emphasis on PWS and AS models that target the syntenic Snrpn region in 
mouse. 
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1.2.4  Pseudohypothyroidism type I 
Pseudohypothyroidism type Ia and Ib (PHP Ia; OMIM 103580 and PHP Ib; OMIM 603233) have 
etiologies based on alteration of the imprinted GNAS cluster at 20q13.32 (148).  PHP Ia, also 
known as Albright hereditary osteodystrophy, manifests in patients as short stature, obesity, 
round faces, sub-cutaneous ossification, brachydactyl and other skeletal abnormalities. These 
features arise due to resistance to parathyroid hormone (PTH), thyroid stimulating hormone 
(TSH) and gonadotropins. PHP Ia is caused by maternal inheritance of loss-of-function 
mutations in the gene encoding a variant guanine nucleotide exchange factor alpha subunit (149). 
In an opposite manner genetic mutation of paternally inherited GNAS allele is the cause of 
progressive osseous heteroplasia (POH; OMIM 166350) and pseudopseudohypothyroidism 
(PPHP; OMIM ) which show many of the same muscular and skeletal symptoms of PHPIa but 
without endocrine abnormalities (150). 
PHP Ib is characterized by obesity and resistance to parathyroid hormone within the renal 
proximal tubule. This results in hypocalcemia and hyperphophatemia, and compensatory 
increase in PTH levels. PHP Ib is caused by epigenetic mutation (loss of methylation) of the 
maternal exon 1a GNAS DMD, resulting in loss of GNAS-XL expression in a tissue specific 
manner (151). These results indicate that some tissues are more stringent in their exclusive 
parent-of-origin monoallelic imprinted gene expression. 
1.2.5  Transient neonatal diabetes mellitus Type 1 
Transient neonatal diabetes mellitus type I (TNDM1; OMIM 601410) is characterized by 
intrauterine growth restriction and hyperglycemic infancy that resolves in half of patients within 
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a few months but can reoccur in adulthood (152) . It is caused by loss of imprinting at 6q24 
including patUPD 6, 6q24 paternal duplications and maternal hypomethylation at the PLAGL1 
DMD (152-154). These changes result in a double dosage of the normally paternally expressed 
PLAGL1, a gene encoding a zinc finger transcription factor that controls a network of genes 
regulating insulin sensitivity (155). The prenatal and postnatal clinical phenotypes of TNDM1 
indicate that this disease may be in part modulated by the role of PLAGL1 in the placenta.  
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Imprinted Disease Clinical Phenotypes Genomic Loci & Molecular Etiologies DMDs 
Beckwith-Wiedemann Syndrome 
(BWS; OMIM 130650) 
Macrosomia, hemihyperplasia, 
visceromegaly, macroglossia, 
exomphalos, , embryonic tumors 
placentamegaly, neonatal hypoglycemia, 
facial characteristics 
11p15.5 
Genetic and epigenetic mutations; CDKN1C genetic mutations, 
loss of KCNQ1 DMD methylation, gain of H19 DMD 
methylation, paternal UPD of 11p15.5, 
KCNQ1, 
H19 
Silver-Russell Syndrome            
(SRS;OMIM 180860) 
Intrauterine and neonatal growth 
restriction, body asymmetry, syndactyl, 
triangular face, short stature 
11p15.5, 7q21.3, 7q32.2  
Loss of H19 methylation, matUPD11q15, matUPD7 
H19, 
GRB10, 
MEST 
Prader-Willi Syndrome                 
(PWS; OMIM 176270) 
Fetal inactivity, neonatal hypotonia, 
juvenile onset obesity,  hyperphagia, low 
GH levels, elevated ghrelin,  short 
stature, hypogonadism, small hands and 
feet 
15q11.2 
Paternal deletion of SNRPN imprinted cluster, matUPD15, 
SNRPN imprinting mutations, SNORD116 mutations  
 
SNRPN 
Angelman Syndrome                   
(AS; OMIM 105830) 
Mental retardation, motor and balance 
deficiency, language and speech 
problems 
15q11.2 
Maternal deletion of SNRPN imprinted cluster, patUPD15, 
SNRPN imprinting mutations, UBE3A mutations 
SNRPN 
Pseudohypothyroidism Type Ia 
(Albright hereditary 
osteodystrophy; 
PHPIA OMIM 103580) 
Short stature, obesity, PTH and TSH 
resistance, round faces, subcutaneous 
ossification, brachydactyl, skeletal 
abnormalities 
20q13.32 
Maternal inheritance of non-functional GNAS allele 
GNAS 
Pseudohypothyroidism Type Ib 
(PHPIB; OMIM 603233) 
Obesity, PTH resistance in renal PT, 
hypocalcemia, hyperphosphatemia 
20q13.32 
Loss of GNAS exon 1a DMD methylation 
GNAS 
Transient Neonatal Diabetes 
(TNDM1; OMIM 601410) 
Intrauterine growth restriction, infantile 
hyperglycemia 
6q24 
PatUPD6, paternal 6q24 duplications, loss of PLAGL1 DMD 
methylation 
PLAGL1 
Table 1.  Syndromes and disorders associated with genomic imprints. See section 1.2 for references  
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1.3.1  Requirements for prenatal development 
Normal fetal development and pregnancy outcome depends on the genetic integrity of the fetus, 
health of the mother and function of the placenta. Adverse pregnancy outcomes include 
miscarriages, malformations, pre-term delivery and low birth weight. Genomic disorders can be 
inherited or arise spontaneously in the germline and affect single genes to whole chromosomes 
(156). Chromosome imbalance (aneuploidy) in mammals originates from oocyte meiosis I non-
disjunction events, it affects roughly 5% of all pregnancies and usually results in miscarriage 
although a handful of trisomies are viable to birth including trisomy 13 (Patau syndrome), 
trisomy 18 (Edwards syndrome) trisomy 21 (Down syndrome) and sex chromosome trisomy 
XXY (Klinefelter syndrome), XXX and XYY (157-159). 
The fetal genome has a large contribution to pregnancy outcome, however it is not 
completely deterministic. It has been shown that birth weights of half siblings are more 
correlated when there is a common mother than when the father is common indicating that the 
maternal intrauterine environment is a major factor in fetal growth ((160) and references therein). 
Diet, obesity, insulin-resistance, hypertension, smoking, alcohol consumption and drug use are 
all strong maternal influences on pregnancy outcome. The placenta is the interface between 
mother and fetus and is critical for the exchange of nutrients, wastes and as an immunological 
barrier. The proper development and function of the placenta is therefore critical for optimal fetal 
1.3  PLACENTAL INFLUENCE ON PREGNANCY OUTCOME 
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health. Intrauterine growth restriction, preeclampsia and gestational diabetes mellitus are three 
common pregnancy complications that if left untreated lead to poor outcomes. 
1.3.2  Intrauterine growth restriction 
Intrauterine growth restriction (IUGR) is a term synonymous with fetal growth restriction (FGR) 
describing reduced growth of a fetus during pregnancy. IUGR often leads to pre-term delivery 
and small for gestational age (SGA; lowest 10th percentile of birth weights) babies. The causes of 
IUGR include conditions such as hypoxia, preeclampsia, genetic determinants and placental 
insufficiency (161). Maternal smoking causes placental hypoxia and IUGR without preeclampsia 
(162). Smoking during pregnancy also increases the risk for ectopic pregnancies, spontaneous 
abortions, teratogenesis, pre-term birth, and sudden infant death syndrome and is also associated 
with postnatal childhood obesity and diabetes mellitus and psychological problems (162). Fetal 
alcohol syndrome is a neurological and developmental disorder with IUGR (163). Illicit drug use 
also increases the risk of IUGR, pre-term birth and low birth weight (164). Many genetic IUGR 
determinants encode components of the insulin like growth factor (e.g. IGF1, IGF2, IGF2R and 
IGFBP1), placental growth factor (i.e. PGF), stress related cortisol (e.g. CRH and 11bHSD) and 
growth hormone (i.e. GH) signaling pathways (165). However, only IGF2 has been directly 
linked through genetic and epigenetic (i.e. H19 loss of methylation in SRS) mutations to cause 
IUGR (166). 
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1.3.3  Preeclampsia 
Preeclampsia (PE) is a maternal vascular disease associated with poor placental perfusion that 
occurs in roughly 3-5% of all pregnancies (167-169). Clinically, PE is defined by gestational 
hypertension and proteinuria after 20 weeks gestation. Risk factors for PE include a number of 
metabolic, coronary, genetic and environmental conditions. PE can have severe effects on fetal 
and neonatal morbidity and mortality and accounts for 30-40% of IUGR pregnancies, 25% of 
SGA babies and 15% of pre-term births. If left untreated PE can transition into maternal 
eclamptic seizures. It is thought that factors released from the placenta and the lack of 
trophoblast induced vascular remodeling and vascularization combined with maternal influences 
(e.g. obesity) results in maternal vasoconstriction and hypertension (170). Endothelial cellular 
signaling pathways influence PE including vascular endothelial growth factor and angiotensin 
signaling (171). In addition, there is evidence that fetal genetic determinants (e.g. STOX1, MMP-
9 and ANG) are predicative of PE pregnancies (171).  
1.3.4  Gestational diabetes mellitus 
Metabolic disease is a common occurrence in post-industrial societies and encompasses obesity, 
insulin resistance, dyslipidaemia and accompanying hypertension (172). During normal 
pregnancy maternal insulin levels generally rise and can induce maternal diabetes mellitus 
(GDM). Obese mothers (BMI>30) are at greater risk for the pregnancy complications gestational 
diabetes mellitus (GDM) and PE (172). An increase in fetal and neonatal body mass due to 
adipose deposition is observed in offspring from mothers with GDM (172). Although GDM 
26 
 
resolves after partition both the mother and offspring are at increased risk for metabolic disorders 
later in life (172). 
1.3.5  Fetal origins of adult diseases 
The period of prenatal development is a critical time that has great influence on the overall health 
of individuals throughout their lifetime (173-175). This concept of the fetal origins of adult 
diseases has a strong backing of evidence. For example, low birth weight is tightly correlated 
with hypertension and coronary-based mortality (173, 174). The placenta is the organ at the 
maternal-fetal interface and thus is intimately involved in fetal development and therefore the 
lifelong health of individuals (176). Placental characteristics such as weight, length and breadth 
have been linked with systolic blood pressure, and the adult diseases hypertension, asthma and 
colo-rectal cancer (176). It is therefore extremely important to understand how the placenta 
functions to support normal fetal growth and optimize the lifetime health of offspring. 
1.3.6  Maternal influences on placental function 
The placenta functions as a physical and immunological barrier between mother and fetus, as a 
transporter of nutrients, gasses and wastes as well as a site of active metabolism and hormone 
production (177, 178). Maternal physiology is known to influence placental development 
through blood flow, nutrition and toxicology. For example, obese mothers have increased 
placental triglycerides, malondialdehyde, carbonyl protein, and reduced glutathione, as well as 
increased placental oxidative stress response (179). Maternal smoking induces hypoxic responses 
(e.g. vascularization) within the placenta thereby decreasing the risk of PE, but increasing the 
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risk for placentaprevia and placenta abruptia (162). Alcohol exposure, a cause of IUGR in 
humans, has been shown in rats to modulate placental insulin like growth factor signaling (180). 
1.4.1  Comparison of human and mouse placental structure and development 
The placenta is a temporary organ that sustains and supports fetal growth during gestation and is 
a defining feature of mammalian development (177, 178). It is made up of cells derived from 
maternal, embryonic and extraembryonic origins. The primary extraembryonic cell lineage in the 
placenta is trophoblast. Human and mouse placentas are both defined as hemochorial because 
maternal blood is in direct contact with trophoblast. In both species during pregnancy, at the site 
of implantation, the uterine endometrium becomes the highly vascularized decidua basalis and 
bathes the placenta with maternal blood The human and mouse placenta share common genetic 
networks that regulate placental development. However, the placental structures of the two 
species are distinct. The human placenta consists of microvilli that branch from the chorionic 
plate and are bathed in maternal blood. Each microvillous consists of an outer 
syncytiotrophoblast (SynT) layer, a diploid columnar epithelium, and innermost fetal vessels and 
supporting mesenchyme. The mouse placenta on the other hand consists of three distinct layers 
with unique functions. The labyrinthine zone (LZ) layer is the site of nutrient and waste 
exchange while the junctional zone (JZ) and trophoblast giant cell (TGC) layers have endocrine 
functions.  
1.4  PLACENTAL DEVELOPMENT AND FUNCTION 
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Cytotrophoblast and SynT are two types of trophoblastic cells that are common between 
mouse and human placentas (177, 178). The cytotrophoblast are diploid single nucleated cells 
and are called spongiotrophoblast (SpT) in mouse. In humans there are three types of 
cytotrophoblast: the villous-cytotrophoblast separate the SynT from the villous mesenchyme and 
fetal endothelium; the extravillous-cytotrophoblast invade the maternal decidua; and the 
columnar-cytotrophoblast, which reside at the tips of the microvilli and abutting the maternal 
decidua serve as a source of precursors to other cytotrophoblasts and SynT cell types. The 
spongiotrophoblast in mouse similarly resides between the decidua and the labyrinth within the 
so called junctional zone (JZ), however they do not serve as precursors to SynT. In the mouse 
placenta the SpT performs many of the endocrine functions delegated to SynT in human placenta 
(178). 
The syncytiotrophoblast are multi-nucleated cells formed from cell fusion which funnel 
and contain maternal blood pools, transport nutrients and have active metabolism. There is only a 
single layer of SynT in human microvilli but a bilaminar layer in the mouse labyrinth. A third 
type of trophoblasts, trophoblast giant cells are polyploid and found only in mouse, they have 
similar function as extra-villous cytotrophoblast in induction of decidualization and maternal 
vascular remodeling. Arterial blood vessels extending from the umbilical cord into the chorionic 
plate (base of the placenta) and branching adjacent to SynT line maternal blood are composed of 
extraembryonic mesoderm derived fetal endothelial cells in both species.  
The common cell types and developmental processes make the mouse a superb model for 
placental research (177, 178). The genetic networks important in trophoblast differentiation and 
function are highly conserved in human and mouse (181, 182). Placental gene expression in 
human and mouse is greatly conserved, particularly for those genes with known placental 
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phenotypes associated with gene mutations (181). Intriguingly, both rodent-specific and primate-
specific genes, many of which originated from gene duplication, are enriched for preferential 
placental expression, indicating an organ undergoing recent evolutionary adaptation (182). The 
short generation time, and ease of genetic and physiological manipulations, are major reasons 
why the mouse is a superb system to study placental development. Targeted genetic studies have 
unearthed the central pathways in early trophoblast differentiation and placental function. 
However, there will also be incongruities in comparing placental development across 
mammalian species, and this must be kept in mind when extrapolating experimental data from 
mouse to discern the function of genes in human. 
1.4.2  Preimplantation development 
The period of time from fertilization to implantation is a critical time for the establishment and 
differentiation of trophoblast lineages (reviewed by (183-188)). After fertilization of an egg the 
maternal and paternal pronuclei replicate their haploid genomes, fuse and then undergo cell 
division (183, 189). Early rounds of mitotic cleavage are symmetric and produce totipotent cells 
(183). The earliest cell fate specification event, which distinguishes the trophectoderm (TE) from 
the inncer cell mass (ICM), occurs at the 8 and 16 cell stages (183). In the 8-cell embryo the 
outer apical surface of each blastocyst tightens and these cells become polarized, and divide into 
distinct outer and inner daughter cells (183). Expression of the TE specific transcription factor 
Cdx2 begins at the 8-cell stage in the outer cells concomitantly with expression of the ICM 
specific transcription factor Oct4 within the inner cells (190, 191). This initial fate specification 
event is mediated by the cell-contact dependent hippo signaling pathway kinases STK3 and 
LATS2, that suppress YAP1 through phosphorylation (192). YAP1 is the coactivator for the 
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transcription factor TEAD4, which is the master regulator of TE differentiation (192). The 
TEAD4/YAP1 complex promotes a cascade of transcription factors beginning with activation of 
the Cdx2, Gata3, Eomes and Tfap2a/c genes that define TE lineages, followed by transcriptional 
activation of genes that maintain TE fate including Ets2, Elf5, Essrb, Foxd3 and Sox2/3, and 
subsequently transcription factors such as Gcm1, Ascl2, Hand1 and Stra13 that promote specific 
trophoblastic lineage differentiation (183-185, 193, 194). 
At the 32 cell morula stage, the embryo begins to hollow out and compact to one pole to 
form a blastocyst by E4.5 (189). The blastocyst is a cellular sphere consisting of the outer TE 
layer, the ICM clumped at one pole and a cavity called the blastocoel (Figure 1). The ICM is 
subdivided into the epiblast, which generates the fetus, and the primitive endoderm, a layer of 
cells between the epiblast and the blastocoel that gives rise to the parietal and visceral endoderm 
as well as the yolk sac (183). The polar TE overlying the ICM is the progenitor of most 
trophoblast lineages, whereas the mural TE encasing the blastocoel generates only TGCs upon 
implantation (183, 185, 189). The TE, epiblast and primitive endoderm are comprised of 
pluripotent cells expressing distinctive lineage markers; they are called trophoblast stem cells 
(TSCs; marked by Cdx2), embryonic stem cells (ESCs; marked by Oct4, Nanog and Sox2) and 
extraembryonic stem cells (XEN; marked by Gata6) respectively (195). TSCs are a unique cell 
type that can be cultured from blastocyst and ectoplacental cone extracts up to E7.5 on 
inactivated fibroblasts in ESC conditioned media replete with serum and infused with FGF4 
(186, 196). 
 Expression of the growth factors Fgf4 and Nodal by the ICM sustain TSCs pluripotency 
and identity (186, 196-198). Following TE specification and up through postimplantation 
development FGF4 is required for the maintenance of TSCs (196). FGF4 is produced by ESCs in 
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the ICM, binds to the FGFR2 receptor on TSCs, thereby activating the RAS-MAPK signaling 
pathway promoting proliferation and inhibiting differentiation (186, 197, 198). Induced 
activation of Ras (iRas) can convert ESCs to TSC like states (198, 199). However, their 
trophoblast developmental potential is limited, indicating that earlier specification events trigger 
epigenetic barriers to full TSC induction (198, 199). The nodal signaling pathway is also 
required for TSC maintenance. Nodal is expressed by the ICM and is activated by proteases 
secreted by the TE (197). Preimplantation embryos with deletion of Spc1 and Spc4, two genes 
encoding nodal proteases secreted by TE, have a reduced population of TSCs and diminished 
expression of early trophoblast differentiation markers (197). The combined activity of Fgf4 and 
Nodal signaling on TE prevents terminal differentiation (197). 
1.4.3  Implantation 
At the time of implantation the polar TE is subdivided into the extraembryonic ectoderm (EXE) 
that is proximal to the ICM, and the ectoplacental cone (EPC) that is distal to the ICM (Figure 1) 
(185-188). The EXE is the default state of polar TE and expresses a transcription factor network 
including Tead4, Cdx2, Eomes, Tcfap2c, Gata3, Essrb, Elf5 and Ets2 (185-188). The EPC 
differentiates from this basal state and represses transcription of Cdx2 and Eomes while 
increasing expression of Tead4, Ets2 and Gata3, and gaining expression of Ascl2 and Tpbpa 
(185-188). The EXE is the progenitor of the chorion and syncytiotrophoblast, where as the EPC 
generates TGCs and SpT. Fgf4 and Nodal signaling continues to act on both the EXE and EPC to 
maintain TS populations in both through E7.5 (185-188). 
 Progesterone secreted by the corpus luteum following ovulation induces decidualization, 
a process by which the maternal uterine endometrium prepares for implantation by increasing 
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glandular secretion, vascularity and vascular permeability (200). Blastocyst implantation into the 
receptive maternal uterine endometrium (decidua) is mediated by the primary outermost parietal-
TGCs (P-TGCs) that have differentiated from the EPC and the mural TE. These P-TGCs 
integrate into the extracellular matrix in an interstitial manner and further remodel the uterine 
environment. Some TGCs (SpA-TGCs) invade into the maternal decidua and embedd within the 
spiral arteries where they remodel the vasculature to be dilated and fenestrated to increase 
placental perfusion. Prior to implantation the fetus survives on internal energy stores but 
postimplantation subsistence is dependent on the transfer of nutrients and wastes between fetus 
and mother as mediated by the placenta. Therefore it is not surprising that many targeted gene 
deletions are embryonic lethal immediately following implantation (~E9.5) due to placental 
defects (201, 202). 
1.4.4  Labyrinthine zone development 
The placental labyrinthine zone (LZ or labyrinth) layer is composed of cells derived from both 
the TE lineages and epiblast derived extraembryonic mesoderm fetal vessels extending from 
allantois (umbilical cord) (185, 201, 203-205). The mouse placental labyrinth is analogous to the 
single syncytial layer and vascular components of the human microvillous placental structure, 
and both function to mediate the exchange of nutrients and wastes between maternal and fetal 
circulation (177, 204, 205). Syncytiotrophoblast (SynT) are the primary trophoblast cell type 
found in the labyrinth layer. They are post-senescent, elongated and multinucleated cells formed 
from the fusion of multiple diploid EXE precursors (206). The transcription factor Gcm1 is a 
marker and master regulator for SynT lineages (188, 203-205). Targeted deletion of Gcm1 
results in greatly diminished branching of the SynT lined network of maternal blood passages 
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(207-209). Diminished GCM1 expression in humans is associated with an increase in fetal 
vascular tissue in microvilli (and a corresponding decrease in SynT), which is a placental state 
indicative of preeclampsia (209). The SynA and SynB genes, derived from retroviral envelope 
genes, code for coopted factors that enable the fusion of neighboring diploid EXE cells (210, 
211). The syncytiotrophoblast forms a bilaminar layer that channels and pools maternal blood. 
SynT layer I lines the maternal blood pools, whereas SynT layer II is in contact with fetal 
vasculature (204). Sinusoidal trophoblast giant cells (S-TGCs) and channel TGCs (C-TGCs) , 
derived from the EXE, form a thin layer adjacent SynT layer I at the borders of maternal blood 
pools and channels (204). 
The fetal vasculature within the murine placenta is derived from the allantois (212). The 
allantois is formed from the extraembryonic mesoderm at the posterior end of the primitive 
streak. It extends upwards from the dorsal aorta forming the umbilical cord and then fuses with 
the chorion at E8.5 and afterwards integrates into the chorionic plate and branches upwards to 
vascularize the placenta. Many of the genes involved in angiogenesis are involved during this 
process including members of the VEGF signaling pathway (e.g. Vegf, Flt, Flk) and other extra 
cellular matrix proteins and signal transducers (e.g. Fibronectin, Cathepsin, Mek1, Mek2) (213). 
The allantois and chorion also have limited hematopoietic properties (214).  
Because SynT is intimately involved in transferring nutrients across the maternal-fetal 
interface it expresses a multitude of facilitated and passive transporters along the polarized 
microvillus and basal membranes. Circulating levels of IGF2 and insulin among other effectors 
modulate the expression of glucose, amino acid and fatty acid transporters within the SynT 
(215). Trans-placental fatty acid transport is a complex process mediated by SynT involving 
uptake of triacylglycerides from maternal circulation, intracellular transport and lipolysis 
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(Reviewed by (216)). Free fatty acids generated by lipolysis undergo -oxidation in SynT 
mitochondria to supply acetyl-CoA for the TCA cycle, or can be stored within intracellular lipid 
droplets and eventually exported to fetal circulation (216). 
The peroxisome proliferator-activated receptor (PPAR) family of proteins is vital to 
placental labyrinth development (217). These nuclear receptors bind small molecule ligands and 
interact with co-activator nuclear factors (e.g. RXR, RAR and LCOR) to modulate gene 
expression patterns (217). Homozygous null Pparγ mutation is embryonic lethal at E10.5 due to 
lack of fetal vasculature and ruptured maternal blood sinusoids within the placental labyrinth in 
combination with fetal heart defects (218). One key SynT gene that PPARγ and RXR regulate is 
Muc1, which encodes a protein that coats the lining of the maternal blood pools; the lack of its 
expression may in part explain the hemorrhaging of these spaces in Pparγ homozygous null 
placentas (219). In addition to Pparγ, Pparδ and Rxrα are crucial to early placental development 
(217). The lethality of targeted Pparδ alleles is strain dependent. Targeted Pparδ mutation is 
embryonic lethal due to failure of full chorio-allantoic fusion at E8.5 and diminished JZ 
development on pure B6 and FvB strains but not on hybrid backgrounds (220). Homozygous 
Rxrα null placentas manifest labyrinth abnormalities at E14.5 with excessive pooling of maternal 
blood, thickened SynT lamina and thinner and necrotic fetal vessels (221). Both Pparγ and Rxrα 
null mice display a reduced amount of lipid droplets in SynT layers I and II (218, 221). 
The cell types within the labyrinth layer are marked by expression of different genes. 
Early in labyrinth development the chorion and early SynT are marked by the transcription 
factors Gcm1 and Tfeb expression. Later in development, at E12.5 and beyond, the leptin 
receptor (LepR) is strongly expressed in SynT. The markers of C-TGCs and S-TGCs are 
discussed in section 1.3.7. The fetal vasculature within the placenta, like most arterial vessels, is 
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marked by CD31 (VE-Cadherin). Interestingly, expression of the imprinted genes Mest and Dlk1 
are both highly expressed in fetal vessels and can be used as in situ lineage markers. Many 
targeted imprinted gene deletions have phenotypes that occur within the labyrinth including 
Peg10 and Rtl1, which are discussed in detail within section 1.5. 
1.4.5  Junctional zone development 
The junctional zone layer (JZ or spongiotrophoblast) is composed almost entirely of 
spongiotrophoblast (SpT), a diploid cell type derived from the ectoplacental cone (188, 203). It is 
structurally analogous to the columnar cytotrophoblast of human placenta that forms epithelium 
at the tips of each microvillus (177, 178). Expression of Ascl2 and Tpbpa is used to delineate 
SpT by in situ hybridization. The SpT lineage marker Tpbpa encodes a secreted peptide of the 
cathepsin family, and is expressed ubiquitously throughout gestation in all SpT subtypes (188, 
203). Ascl2 is an imprinted gene strongly expressed in the EPC and during early SpT 
differentiation. It encodes a basic helix-loop-helix transcription factor which inhibits the default 
EPC differentiation pathway leading to TGCs (222, 223). Deletion of Ascl2, results in 
placentation based prenatal lethality with pronounced reduction in both LZ and JZ layers and 
excessive accumulation of TGCs (222). Insertional mutagenesis of the Nodal gene has a similar 
early embryonic lethality as the Ascl2 null, with loss of SpT and expansion of TGCs, indicating 
the importance of the nodal signaling pathway in SpT specification (224). 
 The junctional zone has strong endocrine functions that support pregnancy through the 
secretion of members of the prolactin family, lactogens and other cytokines that stimulate corpus 
luteum progesterone expression and other maternal physiological responses (178, 225). Secretion 
of a soluble anti-angiogenic isoform of the VEGF receptor (s-Flt1), and the vasoinhibin 
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precursor proliferin (Plf1; Prl2c2) by SpT also inhibits maternal endometrial vascularization into 
the placenta (226, 227). 
Glycogen cells (GCs) are a specialized subtype of SpT that contain large glycogen stores 
and are marked by the expression of Pcdh12 and Igf2 (228, 229). Glycogen cells are detectable 
as early as E7.5, start accumulating glycogen by E10.5, proliferate rapidly at E12.5 and then 
migrate into the neighboring decidua around E14.5 (228, 229). By E17.5 GCs within the decidua 
undergo lysis and release their glycogen content into lacunae with maternal blood; this is thought 
to provide a burst of energy for the end stages of fetal growth and partition (229). Mouse GCs 
are analogous to human columnar cytotrophoblasts closest to the decidua, and interstitial decidua 
embedded cytotrophoblast both of which contain glycogen vacuoles (177). The imprinted genes 
Igf2, Igf2r, Ascl2, Cdkn1c and Phlda2 are known to influence SpT and GC development and are 
discussed in detail in section 1.5 (230).  
1.4.6  Trophoblast giant cells 
Trophoblast giant cells (TGCs) are polyploid cells formed via genomic amplification without cell 
division (endoreduplication) of diploid precursors (reviewed by (231, 232)). The polyploidy 
genomes of TGCs are also polytene, having distinct chromosome bands of both highly active and 
highly repressed chromatin. TGCs have extensive rough endoplasmic reticulum indicative of 
their elevated protein secretion pathways. In these respects, TGCs are similar to hepatocytes. 
TGCs are the default fate of TE development. In the absence of FGF4 and conditioned media 
TSCs differentiate within 4-5 days into TGCs (196). The expression of Ascl2 within the EPC 
(and in TSCs) suppresses the TGC differentiation programing. ASCL2 antagonizes the activity 
of HAND1, a basic helix-loop-helix transcription factor that promotes TGC differentiation, 
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either through transcriptional repression or competition for common promoters (233, 234).Tthe 
interacting HAND1 and STRA13 transcription factors negate FGF4 suppression of trophoblast 
terminal differentiation and promote differentiation into TGC (233-235).  
 There are four subtypes of TGCs found in the mouse placenta (reviewed by (231, 232)). 
They can be distinguished by their expression of different members of the prolactin/placental 
lactogen and prolactin-like gene family. Each of the 23 members of this family is a 22-33 kDa 
peptide related to growth hormone (225, 227). The earliest TGCs are formed from the mural TE 
and EPC just prior to implantation. These cells are parietal TGCs (P-TGCs) because they form 
the outermost surface of the placenta. P-TGCs express proliferin (Prl; Plf1; Prl2c2) and 
prolactin-1 (Pl1; Prl3d1) at E9.5, and then transition to primarily prolactin-2 (Pl2; Prl3b1) at 
E12.5 and later gestational time points (232). These cells are vital to implantation and 
decidualization. P-TGCs express a multitude of integrins that interact with maternal uterine ECM 
components fibronectin, laminin, vitronectin and collagen (231). Spiral artery TGCs (SpA-
TGCs) integrate into the maternal spiral arteries to remodel the vascular blood flow. These cells 
phenocopy many of the functions of normal endothelial cells and are analogous to human 
endovascular cytotrophoblast (201). The trophoblast decidual invasion is shallower in mice than 
in human pregnancy, and some of the vascular remodeling is thought to be instigated by uterine 
natural killer cells in mice (177). 
SpA-TGCs are present by E10.5 and express Prl2c2. The chorion gives rise to the C-
TGCs and S-TGCs starting at E10.5, these are marked by expression of Prl3b1 but can be 
distinguished by expression of Prl2c2 in C-TGCs and Ctsq in S-TGCs (231, 232). The 
expression of the prolactin gene family, which is found in large cluster of duplicated genes on 
mouse chromosome band 13qA1, is both a defining and functional feature of TGCs (227, 236). 
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Prolactins are secreted proteins with both paracrine functions that modulate decidualization and 
have endocrine functions that alter maternal physiology and behavior (225, 227). In the 
polypolid P-TGCs there is overamplification of genomic regions harboring gene clusters of the 
prolactin (including Prl2c2, Prl3b1, and Prl2d1), Cathepsin (including Ctsq1, and Tpbpa), Serpin 
(intracellular serine proteases) and NK/Clec (Natural-killer/C-type lectins) families (237). 
Although the human placenta does not have TGCs the extravillous cytotrophoblast provide many 
of the same functions during implantation and the more invasive cell types are polypoloid, 
although not to the same extent as mouse TGCs (238).  
 
 
Figure 1.  Mouse placental development from preimplantation to E12.5+. Abbreviations: 
Trophectoderm (TE), Epiblast (Epi), Visceral Endoderm (VE), Decidua (Dec), Spiral Artery 
(SpA),  Ecto Placental Cone (EPC), Chorion (Ch), Allantois (Al), Trophoblast Giant Cells 
(TGCs), Yolk Sac (YS), Fetus (Fe), Spiral Artery TGCs (SpA-TGCs), Parietal TGCs (P-TGCs), 
Sinusoidal TGCs (S-TGCs), Spongiotrophoblast (SpT), Glycogen Cells (GCs), 
Syncytiotrophoblast (SynT), Fetal Vessels (FV). In each stage cell populations are color coded 
based on lineage origin. At the preimplantation stage the Polar TE is light green, the mural TE is 
dark green, the Epi is blue and the VE is yellow. At the implantation stage Dec is orange, TGCs 
are dark green, the EPC is light green, the Ch is purple, the YS is yellow and the Fe and Al are 
blue. Postimplantation all TGCs are dark green (irrespective of origin), SpT is light green, GC 
are gray-green, SynT is purple and magenta, Fv are light blue and the chorion is Purple. Maternal 
and fetal blood (unlabeled are red and dark blue respectively. 
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I chose to study 15 out of the 24 known genomic imprints based on their known involvement in 
prenatal fetal and placental phenotypes. These genomic imprints and the genes within the 
clusters they regulate are discussed in detail below. Many of these imprinted gene clusters harbor 
genes that exhibit parent-of-origin specific monoallelic expression exclusively in extraembryonic 
tissues. Different types of mouse models have been instrumental in providing insight the role of 
each genomic imprint and the imprinted genes they regulate. The study of mouse embryos with 
UPDs and robertsonian translocations revelaed parent-of-origin specific prenatal developmental 
effects attributable to specific imprinted genomic regions. Targeted mouse genetic approaches 
including gene deletions and transgenic duplications identified the role of single imprinted genes. 
Similarly, targeted deletion of DMDs in mice has been used to investigate imprinting 
mechansism and their functional significance in development. Although the research reviewed 
herein has brought to light unique placental functions of imprinted loci, the integrated role of 
individual imprinted clusters and imprinted DNA methylation per se is largely unknown.  
1.5.1  Nnat 
The neuronatin (Nnat) imprinted gene cluster is a microimprinted domain found on mouse 
chromosome band 2qH4 with a syntenic region on human chromosome 20q11.2-12 (239-242). 
The Nnat gene resides within the single intron of the much larger Blcap (239). The Nnat DMD is 
located at the Nnat  promoter, which transcribes in reverse orientation relative to Blcap (239). 
1.5  GENOMIC IMPRINTS WITH POSSIBLE PLACENTAL FUNCTIONS 
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Expression of Nnat is silenced on the methylated maternal allele, whereas the unmethylated 
paternal allele is transcriptionally active (239). Mice with matUPD of distal chromosome 2 are 
deficient in Nnat, expression, are growth restricted and have decreased cerebral folding (243). 
The expression of neither Blcap nor any other gene in the local vicinity is imprinted (239). 
Hypomethylation of the Nnat DMD and resultant overexpression of Nnat is known to occur in 
Wilms Tumor, similar to the effects on the H19 DMD and Igf2 expression (244). There is 
evidence that the Nnat DMD is hypermethylated in term mouse placenta (245). 
The NNAT protein is a plasma membrane bound proteolipid cation channel (240). It is 
involved in both neural development and regulation of metabolic pathways including 
gluconeogenesis and glucose transport (recently reviewed in (246)). In pigs (Sus domesticus), 
NNAT is paternally expressed during gestation in uterine glandular and luminal epilethelial cells, 
and in the placental chorionic plate (247). The expression of porcine NNAT in utero is co-
regulated with many components of metabolic pathways (e.g. GLUT1, AKT, IRS1, MTOR and 
PI3K) indicating either a downstream or congruent regulation (247). Based on the parent-of-
origin growth effects of proximal chromosome 2, the expression profile of Nnat and potential 
role in placental metabolism it would be of interest to determine if loss of the Nnat imprint 
influences mouse placental development.  
1.5.2  Gnas 
The Gnas imprinting cluster resides on mouse distal chromosome band 2qH4 within the region 
identified in recombination models as having parent-of-origin effects. A homologous region is 
located on human chromosome band 20q13. The Gnas transcriptional unit produces three unique 
isoforms: the biallelically expressed (except in kidney proximal tubule) Gnas, the paternally 
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expressed Gnas-xl and the maternally expressed Nesp from unique promoters that share a 
common exon 2 (248). Additionally, Nesp has an antisense transcript (Nespas) that initiates 
transcription from a promoter that is adjacent and in opposite orientation to the Gnas-xl promoter 
(249). Gnas encodes a guanine exchange factor -subunit (250). The Gnas-xl isoform also 
encodes the cell membrane bound ALEX protein from an alternative open reading frame (250). 
The Nesp gene encodes a neuropeptide of unknown function (248). 
Several targeted mutations at the Gnas locus have been generated to model PHPIa and 
PHPIb. Targeted deletion of maternally inherited Gnas-xl results in reduced viability, with the 
few surviving pups having lower adiposity, increased lean mass, increased glucose tolerance, 
low insulin levels and altered sympathetic neuronal activity (251, 252). Heterozygous deletion of 
the Gnas exon 2 has different effects based on parental inheritance (253). Similar to the 
difference in PHPIa and PPHP patients, maternal null mouse pups have both skeletal defects and 
are PTH resistant, whereas paternal null pups have skeletal defects, do not suckle, but are not 
PTH resistant (253). Further parental inheritance experiments established that Gnas is imprinted 
in a tissue specific manner in the kidney (254). In the distal tubule and collecting ducts Gnas is 
not imprinted and has no parent-of origin-effects when Gnas exon 2 is deleted (254). However, 
in the proximal tubule Gnas is imprinted and PTH resistance occurs with maternal but not 
paternal inherited Gnas exon 2 deletion (254). Two models of Exon1a deletion manifest in 
postnatal growth retardation when paternally inherited (255). The Ex1a-T model truncates 
transcripts originating from both Gnas exon 1a and Gnas-xl promoters has along-term phenotype 
with hyperactive metabolism and decreased bone growth, whereas a mutation of Gnas exon 1a 
eliminates all transcription from that promoter but enables both Gnas exon 1 and full length 
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Gnas-xl transcription, which results in transient postnatal growth retardation during the first 6-10 
weeks after birth (255). 
The Gnas cluster harbors three imprinted DMDs. A paternally imprinted DMD is found 
overlapping the Nesp promoter, a maternally imprinted DMD overlapping the Nespas and Gnas-
xl promoter, and a maternally imprinted DMD at Gnas exon1a (256-259). The DMD region 
overlapping the Nespas promoter is the primary germline DMD, the Gnas-xl promoter and Gnas 
exon 1a DMDs acquire methylation secondarily in the germline, and the Nesp promoter DMD is 
only imprinted during postimplantation development in certain somatic tissues (256). Paternal 
inheritance of a Nespas DMD deletion increases Gnas Exon 1a methylation and decreases Nesp 
DMD methylation, mimicking the maternal allele’s epigenetic state and resulting in increased 
transcription from the Nesp and Gnas exon 1 promoters (259). A compound mutation of 
maternally inherited Gnas loss-of-function and paternally inherited Nespas DMD deletion 
partially rescued neonatal edema observed in the former (259). The role of the Nespas non-
coding RNA (ncRNA) is important for the establishment of the Nesp DMD, as shown genetically 
by paternally inherited truncation of Nespas results in loss of Nesp DMD methylation and in 
increase in its transcription (260). Paternal inherited deletion of the Exon1a DMD results in 
derepression of Gnas exon 1 expression and can rescue the metabolic and neonatal growth 
defects of maternally inherited Gnas mutations in compound heterozygotes (257, 258). Because 
of the importance of Gnas to metabolic and endocrine regulation it is plausible, although 
previously unsubstantiated, that Gnas plays a role in placental hormone production and 
metabolism during prenatal development and is worthwhile to study the effects of loss of 
imprinting at this locus on placental development. 
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1.5.3  Mest 
The long arm of mouse chromosome 6 has multiple imprinted loci. Reciprocal translocations 
involving chromosome arm 6q from centromere to the 6G3 telomeric band are embryonic lethal 
in matUPD6q offspring but support viable development in patUPD6q offspring (10). The parent-
of-origin specific region was narrowed to the region between the centromere and a breakpoint in 
chromosomal 6qB3 and is now known to harbor the Peg10, Mest (also known as Peg1), and 
Nap1l5 imprinting clusters (261). Furthermore bimaternal inheritance of the region between the 
centromere and a proximal breakpoint at 6qA3.2 between the Mest and Peg10 loci is viable, 
demonstrating that the lethal matUPD6q phenotype cannot be attributed to the sub-proximal 
Mest and therefore is likely attributable to the Peg10 cluster (262). A fetal growth restriction 
phenotype is associated with matUPD of the sub-proximal region between 6qA3.2 and 6qC2 
including Mest and Nap1l5, whereas fetal overgrowth is associated with patUPD of the same 
region, suggesting the 6q sub-proximal imprinting region is a regulator of fetal growth (262, 
263). Placental weights were normal in both sub-proximal matUPD and patUPD offspring (262, 
263). In humans, matUPD7 and Mest DMD hypermethylation are causes of a minority of SRS 
cases (125, 264). 
 The Mest DMD is located at a 550bp CGI overlapping Mest exon 1 as well as 157bp of 5′ 
promoter and 120bp of 3′ intron 1 DNA sequence (265). The Mest DMD is maternally 
methylated on the inactive allele; therefore in this context DNA methylation is repressive (265, 
266). The full DMD extends in both 5′ and 3′ direction to cover 2.4kb in total in embryonic 
tissues (265). Imprinted methylation patterns at the Mest DMD control the monoallelic 
expression of a cluster of imprinted genes including the paternally expressed Mest, and the 
maternally expressed Copg2, Cpa4 and Klf14 (265-270). 
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 The Mest (mesoderm expressed transcript) gene is as a transcript enriched in fetal 
mesodermal tissues in both mouse and man (271, 272). It is located at mouse chromosomal band 
6qB1 and human chromosome band 7q32 (271-273). The MEST protein is a putative beta-
hydrolase with unknown substrates, although it is speculated to function as a lipid hydrolase 
(268). A targeted mutation of Mest, in which an IRES-βGeo cassette is inserted in place of exons 
3-8, maintains normal methylation patterns but reduces viability (274). Fetuses and placentas of 
paternal null conceptuses at E18.5 are growth restricted by approximately 15% (274). Maternal 
behavior of placentaphagia and nesting are decreased in paternal Mest null F1 female mothers 
(274). These growth restriction phenotypes are similar to the sub-proximal translocation mouse 
with loss of Mest expression, however no maternal behavioral changes were observed in that 
model (262). The placental growth restriction phenotype is particularly interesting given that 
Mest is expressed within extraembronic mesoderm lineages within the placenta including the 
chorionic plate, fetal vessels and hemangioblast precursors (275). In human placenta Mest is also 
expressed in cytrophoblasts (275). Mest isoform 2 (which encodes a protein shorter by 7 amino 
acids) transcribed from upstream exon 1a is the predominant form expressed in the human 
placenta and has a promoter CGI that is maternally methylated specifically in the placenta; a 
similar genetic structure suggests a homologous mechanism in mouse (276). Stochastic loss of 
Mest imprinting (biallelic expression) is correlated with increased body, spleen and kidney 
weight in interspecific hybrids of Mus musculus and M. spretus, suggesting not only that Mest is 
involved in somatic growth, but also that maintenance of imprints is not as robust in inter-species 
crosses (277). 
 Copg2 (nonclatharin coat protein  2) is paternally imprinted in adult and late gestation 
fetal brain (278). Its transcription is directionally opposed and abutting Mest. Neuronal 
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expression of Mest-xl, an alternatively polyadenylated Mest transcript that incorporates a 3′ UTR 
that runs through Copg2 intron 20, occludes paternal Copg2 expression via transcriptional 
interference (278). Additionally, Mest contains an intronic (between exon1a and exon1) 
paternally expressed antisense transcript emanating from the Mest DMD as well as harboring the 
microRNA (miRNA or Mir) gene Mir335 downstream of exon1. Upstream of Mest resides  a 
series of carboxypeptidase paralogs (Cpa1, 2, 4 and 5), of which only Cpa4 is imprinted 
(paternally) (267, 269). Roughly 21kb downstream from Mest resides the paternally imprinted 
Klf14 (Krüppel-like factor 14). Klf14 is a parent-of-origin specific expression quantitative triat 
loci (eQTL) that modulates diabetes mellitus and elevated HDL risk (279-281). A handful of 
single nucleotide polymorphsims (SNPs) upstream of the Klf14 promoter decrease Klf14 
expression and increase risk for the above metabolic diseases when maternally inherited (279-
281). The same SNPs also regulate a network of metabolic genes in trans (282, 283). These 
findings implicate the KLF14 transcription factor as a master regulator of metabolic pathways 
(282, 283). A more thorough introduction to Klf14 and results from a novel targeted deletion 
model are presented in Chapter 4. The evidence presented here indicates that the Mest cluster is 
involved in the regulation of fetal growth, and deserving of further study of its function in 
prenatal development with a particular focus on placental function. 
1.5.4  Nap1l5 
The maternally imprinted Nap1l5 resides 30Mb distal to Mest in mouse chromosomae band 
6qB3 (263, 284). It is located within the same sub-proximal breakpoint region as Mest that is 
associated with matUPD growth restriction and patUPD overgrowth (263). The Nap1l5 promoter 
is a maternally methylated DMD that represses Nap1l5 transcription, mechanistically resulting in 
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either double or zero dosage of Nap1l5 transcription in sub-proximal 6q matUPD and patUPD 
mice respectively (263, 285). Nap1l5 is an intronless retrotransposed copy of a gene encoding 
nucleosome assembly protein-1 (Nap1) (263). It is located within an intron of the Herc3 host 
gene. (284) While Herc3 is not imprinted per se, it does undergo allele specific polyadenylation 
through transcriptional interference (286). Herc3, which encodes a ubiquitin ligase, is transcribed 
into a non-functional truncated isoform (Herc3b) from the unmethylated paternal allele, and a 
full length isoform (Herc3a) from the methylated allele (286). A syntenic homologous region is 
found on human chromosome 7 near MEST. Mouse embryonic neuronal and heart tissues 
express Nap1l5, but its expression has  not been studied in placenta (263, 284). Due to its 
location in the sub-proximal breakpoint region the Nap1l5 imprinted locus must be considered a 
candidate for the regulation of placental and fetal growth. 
1.5.5  Peg10 
Mouse chromosome band 6qA1 and human chromosome 7q21.3 harbor the Peg10 imprinting 
cluster (287, 288). A maternally methylated imprinted DMD is found at this shared promoter and 
regulates monoallelic gene expression of Peg10, Sgce, as well as the downstream maternally 
expressed genes Pon2, Pon3, and Ppp1r9a (288).The gene order of the syntenic Peg10/PEG10 
regions in mouse and man is identical (288). Peg10 is a intronless endogenous retrovirus derived 
gene of the suchi-ichi family (289, 290). It encodes gag and pol retroviral derived transcripts 
from two distinct open reading frames (291). Transcription of Peg10 runs adjacent and in 
opposite orientation from a shared promoter of the paternally expressed sarcoglycan protein 
epsilon gene (Sgce) (288). Peg10 is expressed in trophoblast lineages early within the 
ectoplacental cone and chorion and later in both P-TGCs and S-TGCs (292). Paternally inherited 
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deletion of Peg10 is embryonic lethal at E9.5 due to failure of LZ and JZ layer development 
(293). The lethality of matUPD of proximal chromosome arm 6q may be attributed to loss of 
Peg10 expression (262, 293). The role of imprinted genes within the Peg10 cluster and the 
function of Peg10 DMD methylation in placental biology is worthwhile to study further. 
1.5.6  H19 
The subtelomeiric chromosomal band 7qF5 in mouse has parent-of-origin effects derived from 
both bimaternal and bipaternal inheritance. This region is homologous with 11p15.5 in humans 
that contains the H19 and Kcnq1 imprinting clusters. Bipaternal inheritance of distal 
chromosome arm 7q results in fetal overgrowth, whereas bimaternal inheritance in growth 
restriction (294). The H19 imprinting cluster consists primarily of maternally expressed ncRNA 
H19 and the paternally expressed insulin-like growth factor 2 (Igf2). Differential DNA 
methylation has been observed at the H19 gene body and promoter and at the Igf2 promoter, 
however it is paternally inherited methylation at the H19 5′ upstream flanking regions that is the 
primary genomic imprint (295, 296). Deletion of the H19 DMD within the 5′ flanking region 
relieves strict monoallelic expression (297). Paternal inheritance of the H19 DMD deletion 
activates H19 expression and attenuates Igf2 expression, whereas maternal inheritance has the 
reciprocal effect of decreasing H19 expression and increasing Igf2 expression (297). 
Adulteration of the CTCF binding site within the H19 DMD has a similar effect of Igf2 
activation when maternally inherited (298). Based on these genetic models a mechanistic 
explanation of the H19 imprinting cluster has been proposed by which DNA methylation at the 
H19 DMD blocks chromatin access of the insulator protein CTCF thereby protecting Igf2 from 
being spooled into a transcriptionally inactive chromatin loop (299). 
48 
 
 The H19 imprinting cluster has strong influences on prenatal growth. Paternally inherited 
targeted deletion of Igf2 causes severe postnatal growth restriction, and explains the growth 
restriction associated with bimaternal inheritance of distal chromosome arm 7q (300). Transgenic 
overexpression of Igf2 results in prenatal overgrowth and phenocopies many of the changes 
observed in BWS (301). Paternally inherited deletion of the placenta specific Igf2p0 isoform, 
normally expressed within the SynT, results in both fetal and placental growth restriction (302). 
The efficiency of placental transport is decreased in these placenta (302). A study of both the 
Igf2 and Igf2p0 paternal null placentas indicate that the Igf2 deletion has a disproportionate 
decrease of JZ volume whereas the Igf2p0 deletion decreases LZ and JZ volume proportionately 
(303). In contrast, only the Igf2p0 knockout altered placental diffusion transport (303). In a 
targeted model of H19 in which 5kb of the H19 gene body and 10kb of upstream region were 
deleted, IGF2 expression was increased and placentas were overgrown with an abundance of 
GCs (304, 305). The H19 ncRNA primary transcript is processed into Mir675 in late gestation 
placenta but not in embryonic tissues (306). A 3kb deletion of the Mir675 region induces 
placental overgrowth indicating that H19 itself is a negative regulator of growth mediated 
through repression of identified Mir675 targets including Igfr1 (306). In addition to H19 and 
Igf2, imprinted expression of Ins2 and the ncRNAs Igf2os and Mir483 (both antisense to Igf2) 
have been reported in extraembryonic tissues (307). Given the strong placental and fetal 
phenotypes of the various H19 and Igf2 genetic models it is valuable to study the direct effects of 
loss of imprinting at this cluster. 
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1.5.7  Kcnq1 
The Kcnq1 imprinting cluster is roughly 500Mb distal to H19 within subtelomeric band 7qF5 in 
mouse. It is one of the largest and most important imprinting clusters in mammalian 
development. The Kcnq1 cluster includes the paternally expressed Kcnq1ot and several 
maternally expressed genes including Aslc2, Cdkn1c, and Phlda2 (118, 120, 125, 308). The 
regulation of a greater number of imprinted genes has been reported as specific to placental and 
extraembryonic lineages including Th, Tspan32, Cd81, Tssc4, Nap1l4, and Osbpl5 (118, 309). 
The Kcnq1 DMD resides at the promoter of Kcnq1ot, an antisense ncRNA transcript emanating 
from within Kcnq1 intron 5 (308, 310). An allele in which the Kcnq1 DMD is deleted mimics the 
maternally methylated imprinted state (310). Paternal inherited deletion of the Kcnq1 DMD 
deletion results in fetal growth restriction and overexpression of Ascl2, Cdkn1c and Phlda2 
(310). These phenotypes are opposite of those observed in BWS cases where there is loss of 
Kcnq1 DMD methylation (310). 
 The importance of the Kcnq1 cluster in placenta biology is most evident in targeted single 
imprinted gene deletion mouse models. Maternally inherited targeted deletion of Ascl2 is 
embryonic lethal at E10.5 due to failure of placental formation (222). Trophoblast lineage 
differentiation is strikingly abnormal in these placenta with a vast proliferation of TGCs at the 
expense of JZ and LZ development (222). Embryonic Ascl2 maternal null lethality can be 
rescued by tetraploid complementation, indicating placental maldevelopment was independent of 
fetal development (222). A hypomorphic Ascl2 allele is viable but growth restrictive and results 
in expansion of TGCs at the expense of LZ development (311). Similar placental phenotypes to 
Ascl2 maternal null mice are observed in and Dnmt3l maternal effect offspring that lack all 
maternally imprinted DMD methylation (including at Kcnq1), suggesting that Ascl2 is an 
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imprinted gene at the focal point of placental development (94, 97, 99). Maternal inherited 
deletion of either the Phlda2 or Cdkn1c genes, which also reside in the Kcnq1 cluster, results in 
placental overgrowth (312, 313). In contrast, transgenic over-expression of either Phlda2 or 
Cdkn1c results in poor placental growth (314-316). Deletion of Phlda2 has recently been shown 
to increase placental glycogen cell abundance and glycogen content suggesting that Phlda2 may 
limit maternal resource allocation (317). Based on the aforementioned studies it would be of 
interest to determine if loss of Kcnq1 DMD methylation has similar effects on placental 
development. 
1.5.8  Snrpn 
The central region of mouse chromosome 7 (7qB5-7qC) has a parent-of-origin postnatal lethality 
phenotype when two maternal copies are inherited (318). This genetic locus is homologous to a 
syntenic region on human chromosome 15q11.2 implicated in the imprinting disorders PWS and 
AS (reviewed in section 1.2.3). The Snrpn cluster contains the maternally expressed Ube3a, and 
the paternally expressed Snrpn, Magel2, Mkrn3, Peg12 and a cluster of C/D snoRNAs genes 
(Snord64, 107, 114, and 116) (319). The imprinted genes within the Snrpn cluster are regulated 
by a maternally inherited imprinted methylation mark at the promoter and first exon of Snrpn 
(320). The Snrpn gene is a bicistronic transcript encoding the mRNA splicing factor SmN and a 
neuropeptide encoded by Snurf from an uprstream reading frame (321). Snrpn, the Snord cluster 
and Ipw are part of a contiguous transcriptional unit that runs from the Snrpn promoter through 
Ube3a in an anti-sense orientation (319). The components of the Snrpn cluster are involved in 
numerous cellular processes including alternative splicing, transcription and neurogenesis. A 
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cluster of Mir334 transcripts are also found within the cluster but have not been firmly 
established as imprinted. 
 An array of targeted genetic mouse models have been generated to study the Snrpn 
imprinting cluster with a focus on understanding PWS and AS (recently reviewed by (319)). 
Deletion of the Snrpn DMD replicates the growth restriction and hypotonia traits observed in 
PWS cases with imprinting mutations (320). Paternal inherited deletion of the Snrpn DMD 
results in loss of expression of the maternally imprinted Ndn, Ipw and Mkrn3 genes, indicating 
that Snrpn DMD deletion imitates the maternally methylated state, and that the paternally 
unmethylated Snrpn DMD acts as a bidirectional promoter (320). A 6.8MB paternal deletion of 
the Snprn region encompassing the totality of the imprinted cluster as well as some genes 
upstream of Ube3a results in fetal and neonatal growth restriction, and abnormal endocrine 
pancreatic structure and function that culminates in in neonatal lethality (322, 323). The loss of 
Snord products in this model alters alternative splicing patterns (324). Targeted deletion of the 
Snord116 cluster in mouse results in both growth restriction and hyperphagia, two hallmarks of 
PWS (325). Although no specific role has been ascribed for any member of the Snrpn cluster in 
placenta biology, it is plausible they are involved in placental function based on their ubiquitous 
expression, the prenatal phenotypes found in Snrpn deletion models, and the endocrine functions 
the placenta has during in utero development 
1.5.9  Peg3 
The Peg3 imprinting cluster resides on proximal mouse chromosome 7 in chromosomal band 
7qA1 (326). A homologous region is found on human chromosome 19q13.4 (327, 328). The 
Peg3 cluster consists of paternally expressed Peg3, Peg3os, Usp29 and Zfp264, and the 
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maternally expressed Zim1, Zim2 and Zim3 (329). Peg3 and Zim1-3 encode zinc finger 
transcription factors, whereas Usp29 encodes a ubiquitin-specific protease (328, 330, 331). The 
PEG3 protein is a transcriptional repressor containing an N-terminal KRAB domain and 12 C-
terminal C2H2 Krüppel-type zinc finger DNA binding motifs (329, 332). The germline Peg3 
DMD resides in the bidirectional promoter between Peg3 and Usp29. A secondary somatic DMD 
is established during preimplantation development at the bidirectional promoter of Zim3 and 
Zfp64 (333). Peg3 and the majority of imprinted genes in this cluster are highly expressed in 
human ovary, placenta, testis and hypothalamus (328). Based on gene expression patterns and 
the phenotypes described below, it is evident that this locus is involved in reproductive, 
metabolic and hormonal pathways and placental function. 
Multiple genetic models have been made to study the function of the Peg3 cluster in 
mouse (most recently reviewed by (329)). The first reports of targeted deletion of Peg3 showed 
that paternal inheritance of the null allele leads to growth retardation from E17.5 to adult, and 
that paternal null dams have poor maternal behavior that results in partial perinatal lethality 
(334). In addition, paternal null offspring have increased abdominal subcutaneous fat, 
hypophagia, elevated circulating leptin, resistance to leptin, reduced metabolic rate and 
resistance to cold. These changes are concomitant with alterations in hypothalamic gene 
expression, indicating the involvement of Peg3 in metabolic regulation (335). A second targeted 
Peg3 deletion model has slightly different phenotypes with perinatal lethality, reduced suckling 
and altered fetal brain gene expression (336). Intriguingly, the brain of paternal null fetuses have 
altered expression of metabolic genes (e.g. Clec2d, Cidea and Pparg), and express placenta-
specific genes of the prolactin (ie. Prl3b1, Prl2b1), cathepsin (ie. Ctsj and Ctsq) and ceacam (ie. 
Ceacam11 and Ceacam12) families (336). Based on the derepresion of many genes in the Peg3 
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null model concomitant with reduction in repressive H3K9me3 suggests that the PEG3 KRAB 
domain interacts with TRIM28 and SETDB1 and/or EHMT2 to modulate chromatin structure at 
target genes (329).  
A deletion of the Peg3 DMD, when paternally inherited, results in fetal growth restriction 
and partial embryonic lethality (337). Gene expression is altered in these mice with increased 
Zim1 and reduced Peg3 expression indicating the Peg3 DMD null recapitulates a maternal 
(methylated) allele (337). Based on these results, the effects of direct loss of Peg3 DMD 
methylation may have an opposite phenotype as the Peg3 DMD deletion, with fetal overgrowth 
rather than growth restriction. It would be interesting to examine placental phenotypes in the 
absence of the Peg3 imprint given the expected increase in Peg3 expression and its known 
involvement in placental gene regulation. 
1.5.10  Plagl1 
Plagl1, previously called Zac1, is an imprinted gene on mouse chromosome band 10qA2 and 
human chromosome 6q24 that is a single imprinted gene cluster (reviewed by(338)). A 
maternally imprinted DMD found 5′ of the Plagl1 gene body regulates the expression of the 
paternally expressed Plagl1 and Hymai transcripts (338). Plagl1 encodes a zinc finger 
transcription factor with multiple alternative splicing isoforms (338). Hymai is a ncRNA with 
possible epigenetic function transcribed in the same direction as Plagl1 and sharing the same 
first exon (338). The boundaries of the Plagl1 imprinted locus are defined by CTCF sites and 
exclude the neighboring genes Phactr2 and Stx11 (339). 
Loss of PLAGL1 imprinting via patUPD6, pat6q24 duplication or mat6q24 
hypomethylation causes TNDM1 with associated fetal pancreatic glucose insensitivity and IUGR 
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(152-154). Transgenic over-expression of Plagl1 in mouse captures many of the phenotypes of 
TNDM1 (340). Paternal inherited deletion of Plagl1 in mouse results in fetal but not placental 
growth restriction and reduced neonatal survival (341). Based on meta-analysis of co-expressed 
genes in micro-array data, PLAGL1 is part of a network of imprinted genes which regulate 
embryonic growth, including members of the H19, Peg3, Kcnq1, Mest, Gnas, and Dlk1 clusters 
(341). Neither PLAGL1 DMD methylation nor imprinted expression is altered in term placentas 
from IUGR pregnancies (155). However, overall expression levels of HYMAI is increased in 
IUGR placentas and PLAGL1 is decreased in female IUGR placentas (155). Chromatin immuno-
preicipitation has identified PLAGL1 binding to the H19 enhancer and DMD, as well as to the 
promoters of metabolic regulators GLUT4, TCF4 and PPARG1 in human term placentas (155). 
Given these finding it is important to determine the direct effects of loss of imprinting at the 
PLAGL1 locus on placental development. 
1.5.11  Grb10 
Robertsonian translocations involving proximal chromosome 11 have parent-of-origin specific 
effects. A homologous imprinted region on human chromosome 7q11.2-12 is a candidate SRS 
locus (342). Proximal chromosome 11 matUPD neonates are growth restricted whereas patUPD 
neonates are larger (10). These growth abnormalities occur prenatally in E12.5-E17.5 mid 
gestation  placentas and fetuses, and likely begin at E7.5 (343). The Grb10 gene at 11qA1 within 
this region is maternally expressed in fetuses and placentas, but is paternally expressed in adult 
brain tissues from an alternative promoter (344). The genes flanking Grb10, Ddc and Cobl, are 
imprinted in an isoform and tissue specific manner (309, 345). Ddc is preferentially paternally 
expressed from exon 1 in yolk and liver, and from exon 1a in whole embryo and neonate heart 
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(345). Cobl is preferentially maternally expressed in yolk (345). The GRB10 protein is an 
adaptor for receptor tyrosine kinases including the insulin and insulin-like growth factor 
receptors, and is an intermediate between receptor-ligand binding and downstream signaling 
(342). 
 Similar to the proximal UPD11 phenotypes, targeted deletion of the Grb10 gene results in 
altered embryonic growth. Maternal inheritance of the Grb10 null allele eliminates embryonic 
Grb10 expression in non-brain tissues, and results in both fetal and placental overgrowth (346). 
Placental overgrowth in Grb10 maternal null placentas is a direct result of LZ expansion (347). 
This phenotype is independent of the Igf2 pathways as evidenced by the partial rescue of the Igf2 
null growth restriction in compound heterozygotes (346). At maturity maternal Grb10 null mice 
are lean (reduced adiposity and greater muscle mass) and have enhanced insulin sensitivity and 
glucose responsiveness (348). These effects are likely mediated through increased insulin 
receptor signaling (348). These results indicate that in the mouse fetus, placenta and adult the 
maternal Grb10 allele has growth restricting functions mediated through its inhibition of insulin 
receptor signaling. 
The maternally methylated Grb10 DMD resides adjacent its brain specific promoter 
(Exon 1b) (349, 350). The brain specific promoter is downstream of the major promoter (Exon 
1a) and splices into conserved exons 2-17. Exons 1a and 1b encode unique 3′ UTRs. A mouse 
specific region overlapping the Grb10 DMD contains CTCF binding sites and may be 
responsible for an insulator mechanism of imprinting by regulating promoter access to 
downstream enhancers (350). Neuronal expression from the paternal Exon 1a promoter is driven 
by tissue specific epigenetic changes. The maternal Grb10 allele in neurons has an expanded 
DMD extending across exon 1b (349). On the paternal allele, bivalent chromatin (with activating 
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H3K4me2 and repressive H3K27me3) at the Grb10 1b promoter resolve into active chromatin 
during neuronal differentiation (351, 352). 
Genetic ablation of the Grb10 DMD effectively makes the allele analogous to the 
maternally methylated state (345). Paternal inheritance of the Grb10 DMD deletion allele results 
in biallelic expression of Grb10 from the major promoter, decreased Ddc expression and 
increased (biallelic) Cobl expression (345). These mice are fetal and placental growth restricted 
from E10.5 onwards (345). Adult paternal Grb10 DMD deletion mice are growth restricted and 
do not recover (345). The results from these studies show the maternal Grb10 imprint regulates 
expression of a small cluster of imprinted genes critical for prenatal development and warrants 
further study. 
1.5.12  Zrsr1 
Located at mouse chromosome 11qA3.2 the Zrsr1 gene contains a maternally methylated DMD 
at its promoter (353, 354). Zrsr1, formerly known as U2af1-rs1, is a retrotransposed copy of an 
auxiliary alternative splicing factor inserted in an antisense orientation within intron 1 of the 
Commd1 (Murr1) gene (353, 354). This transposition event is specific to rodents and is not 
found at the non-imprinted human COMMD1 locus at 2p15 (355). The maternally methylated 
Zrsr1 allele is transcriptionally silenced, whereas the unmethylated paternal allele is active in 
preimplantation embryos, embryonic and adult neuronal tissue and all other adult mouse tissues 
analyzed (353, 354). Commd1 is exclusively maternally expressed in adult neuronal tissue and 
preferentially maternally expressed in other adult tissues (356). In contrast, fetal tissues do not 
show Commd1 parental allelic expression bias (354, 356). It is speculated that the paternal 
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imprinting of Commd1 expression is due to anti-sense transcriptional interference from Zrsr1 
(356, 357). 
Imprinted expression of neither Zrsr1 nor Commd1 within the placental compartment has 
been confirmed. However, homozygous deletion of Commd1 in mouse is embryonic lethal at 
E9.5 in part due to failure of placental vasculogenesis and over activation of Hif1a (358). The 
COMMD1 protein is critical for copper metabolism and other cellular processes (359). Commd1 
is expressed in the mouse allantois and chorionic plate as well as in the human chorionic villi 
(358). The Commd1 null allele was generated by insertion of a neo cassette in place of exon 2, 
and has no effect on Zrsr1 expression (358). There are currently no genetic models targeting 
Zrsr1 or the Zrsr1 DMD specifically. It would be interesting to see if loss of Zrsr1 DMD 
methylation influences placental development. 
1.5.13  Dlk1 
Whole and distal chromosome 12 disomies have parent-of-origin effects on mouse development 
(360, 361). A syntenic imprinted region found at human 14q32-31 is thought to be responsible 
for clinical developmental phenotypes associated UPD14 (362-364). In mice, maternal UPD12 
offspring have fetal and placental growth restriction starting at E15.5, reduced skeletal muscle 
fiber thickness, and 50% neonatal lethality (360). Paternal UPD12 progeny have placental 
overgrowth at E18.5, increased skeletal muscle fiber thickness, 50% late gestation (E18.5) 
lethality, and 100% lethality at birth (360). The phenotypes of maternal and paternal distal 
UPD12, revealed from studies of reciprocal translocation T(4;12)47H, collaborate the whole 
chromosome UPD12 findings (361). Maternal distal UPD12 results in fetal and placental growth 
restriction at E15.5 onwards together with decreased fetal skeletal muscle fiber widths and 
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delayed bone ossification (361). Paternal distal UPD12 is non-viable past E15.5 and shows a 
gradual decline in fetal:placental ratio from E13.5 when it is higher than control littermates, to 
E15.5 where it substantially lower than control littermates (361). 
 Genetic studies have attributed the UPD12 parent-of-origin effects to the large Dlk1 
imprinted gene cluster at distal chromosomal band 12qF1 (365). This cluster contains the 
paternally expressed protein coding genes Dlk1, Rtl1 and Dio3 and numerous maternally 
expressed ncRNAs including Meg3 (also called Gtl2), Rtl1as, Meg8 (Rian) and Meg9 (Mirg) 
(366). The Dlk1 imprinting cluster is regulated by an intergenic DMD (IG-DMR; herein called 
Dlk1 DMD) between the Dlk1 and Meg3 promoters and secondarily by differentially methylated 
CGIs at the Meg3 and Dlk1 promoter (364, 365, 367). Imprinting of the Dlk1 cluster arose during 
eutherian evolution with the insertion of Rtl1, ncRNAs and intergenic DMD sequences between 
the ancestral Dlk1-Dio3 locus found in more primitive vertebrates (368). 
Dlk1 encodes a transmembrane protein with EGF like extracellular domains similar to the 
juxtacrine signaling Notch ligand Delta in Drosophila, but can also undergo proteolytic cleavage 
to produce a soluble extracellular ligand involved in intercellular signaling (369). Dlk1 is 
expressed at sites of branching morphogenesis during embryonic development (e.g. lungs, liver, 
and adrenal cortex) as well as connective tissues and skeletal muscle (370). Within 
extraembryonic lineages expression of Dlk1 is detected in the fetal endothelium of the placental 
labyrinth and yolk-sac blood pools (370). Genetic ablation of Dlk1 results in late gestation 
(E18.5) growth restriction and partial neonatal lethality in both homozygous and paternal null 
offspring (371). These mice also have postnatal growth retardation, increased adiposity and 
increased circulating lipid metabolites (371). Conditional deletion of Dlk1 within myoblasts 
reduces body mass, muscle fiber count and myocyte differentiation, whereas overexpression of 
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Dlk1 in myoblasts promotes differentiation indicating DLK1 has muscle-specific functions 
(372). 
Rtl1, like Peg10,  is a paternally expressed endogenous retrovirus of the suchi-ichi family 
(289, 290, 373). However it is encodes a larger protein complete with retroviral derived pol, gag 
and env domains that have been subverted to mammalian function (289, 290, 373). An antisense 
transcript, Rtl1as, is transcribed in opposite orientation to Rtl1 and encodes miRNAs Mir431, 
Mir434, Mir432 and Mir136 that directly overlap the Rtl1 coding region (374). Paternal inherited 
deletion of Rtl1 results in prenatal growth restriction and neonatal lethality (374). At E15.5 
placental morphological abnormalities are observed including fractured SynT basement 
membranes, lysosomes in SynT layer II, clogged fetal capillaries and phagocytic uptake of fetal 
endothelium by SynT leading to placental infarction (374). Maternal deletion on the other hand 
results in 150% placentomegaly with expanded fetal capillary spaces, and vacuoles in SynT layer 
II that are evidence of trophoblast starvation (374). These results display the opposing effects of 
Rtl1 and Rtl1as on placental development. 
 A plethora of maternally expressed ncRNAs arise from the 12qF1 imprinted region from 
a continuous transcript including, from 5′ to 3′, the Meg3, Rtl1as, Meg8 and Meg9 genes (375, 
376). No fewer than 65 Refseq miRNA genes are found within this region, as well as a series of 
snoRNAs that have not yet been annotated within Meg8 (376). A model in which Meg3 exons 1-
5 are deleted along with the Meg3 promoter CGI, reveals a strong developmental role for this 
cluster (377). The maternal knockout offspring die within 0-4 weeks due to lung and liver defects 
and have decreased Meg8 and Meg9 expression (and lower levels of the miRNA and snoRNAs 
they encode), but increased Rtl1 expression (377). No changes in Dlk1 or Dio3 expression are 
observed in Meg3 maternal null offspring (377). In contrast, paternal inheritance of the Meg3 
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null allele results in 50% perinatal lethality and 50% postnatal lethality, with one quarter 
surviving to a viable and fertile but growth restricted adulthood (377). Expression of Dlk1, Dio3 
and Rtl1 are decreased in the paternal null offspring. Surprisingly homozygous null offspring, 
generated from F1 hybrid crosses of viable paternal knockout offspring, survive but have lower 
birth weights (377). Because the Meg3 null mutation does not affect methylation at the Dlk1 
DMD it is unlikely that there is de facto loss of imprinting (377). It is hypothesized that maternal 
Meg3 promoter CGI deletion results in direct loss of ncRNA products and derepression of Rtl1 in 
trans (377). However, paternal inheritance of the Meg3 null allele is thought to lead to repression 
of Dlk1 and Dio3 in cis due to ablation of the secondary DMD (377). There is a need for finer 
mutations targeting individual miRNAs and snoRNAs to better understand the function of 
ncRNAs in this cluster. 
 Deletion of the Dlk1 DMD that resides between the 3′ end of Dlk1 and the Meg3 
promoter, results in developmental defects based on parental inheritance (367). Maternal Dlk1 
DMD null conceptuses have late gestation lethality (~E16) with increased expression of Dlk1, 
Rtl1 and Dio3, and decreased Meg3, snoRNA and miRNA expression (367). However, paternal 
inheritance results in normal transcriptional profiles and viable offspring (367). These results 
indicate that the Dlk1 DMD is the primary germline-DMD regulating the 12qF1 cluster, and that 
its deletion effectively creates a paternal (methylated) allele (367) 
 Additional research on the importance of the Dlk1 imprinting cluster in fetal and 
placental development is warranted. The Dlk1 cluster has been implicated in animal husbandry 
research as the genetic determinant of the calligpye allele in sheep, which has parent of origin 
effects that result in lean muscle hypertrophy (378). In humans, maternal and paternal UPD14 
cases can also be caused by Dlk1 DMD deletion and hypomethylation (362, 363). Intriguingly, 
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one of the phenotypes associated with UPD14 is placentomegaly (363). The fetal and placental 
phenotypes observed in the Dlk1, Rtl1, Meg3 and DMD deletions discussed above demonstrate 
that the Dlk1 cluster has a critical role in prenatal development. Lastly, there are only 2 paternal 
imprinted DMDs shared in mouse and human (H19 and Dlk1), and both are required for 
embryonic development from induced pluripotent stem cell and bimaternal embryonic 
development in mouse (379-381). These disparate but important phenomenon may be related to 
modulation of placental function by the Dlk1 imprinted loci. 
1.5.14  Igf2r 
The insulin receptor growth factor type 2, Igf2r, is maternally expressed and resides within the 
larger Tme locus that when deleted in maternal lineages is lethal at E15.5 (10, 382). Igf2r and its 
human homolog are found on chromosomal bands17qA1 and 6q25.3 respectively. The Igf2r 
DMD is maternally methylated in both species, however in humans and other primates Igf2r is 
biallelically expressed in the majority of individuals ((383) and references therein). A maternally 
methylated DMD sequence within intron 2 of Igf2r can confer imprinting of YAC transgenes in 
mice (384, 385). The Igf2r DMD is situated at the promoter of Airn (antisense Igf2r RNA), a 
long antisense ncRNA (385, 386). Transcription of Airn occurs on the unmethylated paternal 
allele that is associated with a silenced Igf2r (385, 386). Truncation of the Airn transcript by 
insertion of poly-adenylation sequences mitigates Igf2r silencing independent of DNA 
methylation (387, 388). It is therefore hypothesized that the act of Airn transcription is directly 
responsible for Igf2r maternal inactivation (387). However, it has also been noted that in the 
placenta full length but not truncated Airn ncRNA associates with the Slc22a3 promoter and 
recruits the H3K9 methyltransferase EHMT2 to invoke lineage-specific imprinting (389). 
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 In the majority of embryonic and adult tissues imprinting at the Igf2r locus is limited to 
the expression of Igf2r and Airn. However, in the placenta and extra embryonic visceral yolksac 
the downstream Slc22a2 and Slc22a3 transcripts, encoding molecular transporters of unknown 
function, are preferentially expressed from the maternal allele (307, 309, 390). The expansion of 
the imprinted locus in extraembryonic tissues is similar to that found at other loci including 
Kcnq1, Igf2, Peg10 and Grb10 (309). The IGF2R protein is a receptor for IGF2 expressed in 
SynT as both a plasma membrane and cleaved soluble form (391). IGF2R exerts negative inputs 
to IGF2 signaling by acting to bind and clear excess IGF2, but may also have signaling 
properties (391). Targeted deletion of Igf2r (deletion of exons 13-18) when maternally inherited 
results in fetal and placental overgrowth (392, 393). Maternal Igf2r null conceptuses have 
elevated levels of IGF2 and IGF2-binding proteins (392). Deletion of the Igf2R DMD generates 
an allele that effectively mimics the maternal methylated state, and when paternally inherited 
results in increased Igf2r expression and embryonic and neonatal growth restriction (394). Due to 
increased Igf2r expression, paternally inherited the Igf2r DMD deletion can rescue maternally 
inherited Tme mutations (394). Based on these studies Igf2r is a growth suppressor. Based on the 
importance of the Igf2r locus in growth and its expanded boundaries in extraembryonic tissues it 
is important to determine the effects of loss of imprinting at the Igf2r DMD in placental 
development  
1.5.15  Impact 
The Impact gene resides on chromosomal band 18qA1 and is equated with parent-of-origin 
specific embryonic developmental delays observed with patUPD in studies of Robertsonian 
translocations involving chromosome 18 (395, 396). The paternally imprinted and ubiquitously 
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expressed Impact contains 11exons, and has a maternally methylated DMD within its first intron 
(397). Impact is adjacent to the non-imprinted proximal Osbpl1 and the distal Hrh4 (398). In 
humans, IMPACT is found in the same genomic context on chromosome band 18q11.2-12.1 but 
is not imprinted and lacks an intronic DMD (397, 398). Intriguingly a similar arrangement of 
Osbpl2 and Hrh3 but lacking an Impact paralog is found between the tandem duplicated Lama3 
and Lama5 genes on mouse chromosome 2qH4 near the Nnat and Gnas clusters, and within a 
syntenic region on human chromosome 20q13.3 (398). Expression of Impact is much higher in 
rodent species where it is imprinted (e.g. mouse, rat and rabbit) than in pigs and primates where 
it is not (399). This suggests that the regulation of Impact gene dosage can explain the difference 
in imprinting status between mammalian clades (399). 
 The IMPACT protein is homologous to the ancestral yeast protein YIH1 involved in 
nutrient starvation responses (395, 397). In fact, IMPACT participates in the same translational 
regulation molecular pathways as its yeast homolog. IMPACT binds to GCN1 and inhibits the 
activity of GCN2 inactivating phosphorylation of Ser51 on the eukaryotic translational initiation 
factor 2 (eIF2) (400). Unphosphorylated eIF2 inhibits translation of many proteins and 
activates translation of a few stress response genes (400). High levels of IMPACT in the 
hypothalamus and low levels of phosphorylated eIF2 are thought to be involved in nutrient 
deprivation and feeding behavior stress responses (400). In addition, IMPACT associates with 
ribosomes in post-differentiation neurons to promote neuritogenesis (401). Given the expression 
of Impact within the placenta and its role in mediating nutrient stress response it is plausible this 
gene has important functions within this essential organ. 
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Figure 2.  15 Imprinted gene clusters. (A-O) 15 imprinted loci implicated in placental 
development are labeled by mouse chromosomal bands and refseq gene names. Each gene is 
represented by a filled rectangle and arrows give transcriptional direction. The color of each gene 
box indicates its imprinting status as maternally expressed (Pink), paternally expressed (Blue) or 
biallelic (Gray). DMDs are indicated as rectangle of lesser height outside above the gene 
diagram and are colored as to indicate their DNA methylation as maternal (purple) or paternal 
(green) in origin with secondary DMDs in lighter shades. Triangulated lines indicate alternative 
splicing, where relevant to genomic imprinting. This figure is the summation of the numerous 
works cited within section 1.5.1-15. Figure not drawn to scale. 
 My dissertation research tests the hypothesis that genomic imprints are essential during 
placental development and aims to define their importance in this fundamental mammalian 
organ. In my introduction I have described the importance of genomic imprinting in mammalian 
development and human disease. I have discussed the dynamics of methylation changes during 
germ cell and preimplantation development with a focus on imprinted DMD methylation. In 
addition, I have reviewed the function and development of the mouse placenta highlighting 
aspects relevant to modeling the human placenta. Herein, I have also described in detail fifrteen 
imprinted gene clusters with possible involvement in placental development. The placental 
function of imprinted gene clusters as an integrated unit, including both imprinted genes and the 
DMD methylation that controls their parent-of-origin specific expression, are incompletely 
understood. My thesis research builds off the knowledge presented within the introduction and 
seeks to identify the roles of genomic imprints in placental development by studying placental 
development in their absence. 
In Chapters 2 and 3 of my dissertation I address the first two aims of my dissertation 
which examine the effects of partial loss of genomic imprints on placental development using the 
1.6 SPECIFIC AIMS  
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Dnmt1Δ1o maternal effect model. The first aim of my dissertation research is to determine which 
placental processes are influenced by genomic imprinting. To these ends I described the range of 
placental morphological and molecular phenotypes of Dnmt1Δ1o maternal effect (DNMT1o-
deficient) placentas across murine gestation from E9.5 to E17.5. Considerable emphasis was 
placed on quantifying changes in the following attributes: cellular composition, fetal viability, 
labyrinth vascularity, glycogen and lipid deposition, and gene expression. This section reveals 
many aspects of placental development are dependent on normal genomic imprinting as a whole.  
The second aim of my thesis is to identify specifically which imprints are responsible are 
responsible for placental phenotypes associated with loss of imprinting. I started by describing 
the spectrum of mosaic loss of genomic imprinting in DNMT1o-deficient placentas by assaying 
imprinted gene expression and DMD methylation levels Then I tested for associations between 
placental phenotypes quantified in Chapter 2 and loss of imprints at specific DMDs using linear 
regression analysis. These results enabled the direct interpretation of functional significance of 
individual imprinted clusters in placental biology. 
My third, and final dissertation research aim is to generate and describe a novel targeted 
deletion of the imprinted Klf14 gene. This allele was designed and engineered using 
recombineering and was used to test the maternal-specific expression of Klf14 in the placenta, 
and to record any phenotypes associated with its loss of expression. These results aide in the 
understanding of the role of the Mest imprinting cluster in its entirety in placental biology. The 
sum of my thesis aims is to provide pillars of evidence that unequivocally demonstrate the 
importance of genomic imprinting in placental development and identify specific placental 
functional and developmental processes that genomic imprints regulate.  
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The Dnmt1Δ1o maternal effect model produces DNMT1o-deficient embryos with partial loss of 
genomic imprints and grossly abnormal morphology (60, 104, 105, 402). As a consequence, 
DNMT1o-deficient fetuses do not survive until birth except on rare occasion. It is suspected that 
the poor developmental outcome of DNMT1o-deficient embryos is in part due to the failure of 
normal placental development. In this chapter I show that DNMT1o-deficient placentas exhibit 
variable abnormal phenotypes throughout gestation. Early in gestation Dnmt1Δ1o maternal effect 
mutant placentas were found to have considerable loss of LZ development and an increased 
abundance of TGCs. In mid to late gestation DNMT1o-deficient placentas were found to have 
ectopic SpT extensions into the LZ, dilated fetal blood vessels, SynT lipid droplet accumulation 
and increased glycogen cell abundance. The balance of placental and fetal growth was 
dysregulated in late gestation Dnmt1Δ1o maternal effect placentas. In addition, placental gene 
expression patterns were altered revealing that the imprinted gene network regulates important 
transcriptional pathways including oxidative stress response, molecular transport, lipid transport, 
and lipid metabolism. This evidence that placental development is disrupted in the Dnmt1Δ1o 
maternal effect model is interpreted as support for the hypothesis that genomic imprints regulate 
key processes in trophoblast differentiation and placental development.  
2.0  PLACENTAL PHENOTYPES OBSERVED IN THE DNMT1Δ1o MOUSE MODEL  
2.1  SUMMARY 
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2.2.1  The Dnmt1Δ1o model 
The Dnmt1 oocyte-specific isoform deletion (Dnmt1Δ1o) model is a unique genetic system in 
which absence of the maternal effect DNMT1o protein in oocytes results in offspring with partial 
and mosaic loss of imprinted DMD methylation. It is unique in that its primary genetic mutation 
compromises the integrity of epigenetic inheritance of genomic imprints. This model is 
particularly useful because it yields a myriad of loss of imprinting epigenotypes unlike other 
available genetic models used to study genomic imprinting. Inactivating mutations of Dnmt1, 
which eliminate maintenance methyltransferase activity throughout development, are embryonic 
lethal and erase all imprinted DMD methylation as well as other genomic methylation (101-103). 
In addition, offspring of the Dnmt3l null maternal effect model are homogenous in their 
complete loss of maternal imprints and early embryonic lethality at E9.5 due to placental failure 
(94, 97, 99). Furthermore, nearly all DMD deletion models (reviewed in section 1.5) acquire the 
imprinted state of the methylated allele. The Dnmt1Δ1o model provides a means to directly study 
the effects of loss of DMD methylation on embryonic and placental development. 
2.2.2  Identification of Dnmt1o  
DNA methylation is perpetuated during each mitotic S-phase by the maintenance DNA 
methyltransferase DNMT1 at replication foci (403). The DNMT1 protein contains the modular 
2.2  INTRODUCTION 
73 
 
RFTS, CxxC Zn finger, BAH, and methyltransferase catalytic domains from N- to C-terminal as 
well as a disordered domain between amino acids 100 and 400 (27, 83-85, 110). DNMT1 is a 
component of multimeric complexes that dynamically modulate the epigenome through its 
interactions with other epigenetic regulators including DMAP, ZFP57, TRIM28, and DNMT3 
isoforms (75, 76, 107). At least three mRNA isoforms of Dnmt1 are produced from transcription 
of alternative promoters yielding different 5′ exons (62). The mouse somatic, Dnmt1s isoform is 
transcribed in the majority of tissues and encodes a 1620 amino acid protein (DNMT1s) with a 
molecular weight of 190kDa. Two sex-specific isoforms are generated from alternative 
promoters of Dnmt1 in germ cells (62). Spermatagonia at the pachytene stage transcribe Dnmt1p 
from a downstream promoter immediately adjacent to the Dnmt1 exon 1s 3′ splice juncture (62). 
The Dnmt1p exon 1p contains a much weaker translation initiation sequence and does not 
produce DNMT1 protein (62). The Dnmt1o promoter initiates approximately 7.5kb upstream 
from the Dnmt1s promoter and yields a protein product that is shortened by 118 amino acids at 
the N-terminus (62) 
The oocyte specific DNMT1o isoform was first identified by the discovery of a truncated 
DNMT1 protein isoform in oocytes and preimplantation embryos that had a molecular weight of 
approximately 175kDa (404). The truncated N-terminus of DNMT1o as compared with 
DNMT1s ablates the sequences required for interaction with DMAP but enables the interaction 
of the N-terminus with annexin V (ANXA5) (62). The importance of the interaction between 
DNMT1 and DMAP is particularly important based on the epistatic lethality of the Dnmt1v 
(constitutive Dnmt1o expression) and Dmap1 null alleles (107). ANXA5 is a phospholipid 
binding protein at the plasma membrane of mature oocytes, and has been shown to interact with 
DNMT1o but not DNMT1s, suggesting that the longer N-terminus of DNMT1s may block this 
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interaction (62, 405). The ANXA5-DNMT1o interaction is likely responsible for the 
sequestration of DNMT1o to the cytoplasm and plasma membrane in oocytes until it translocates 
to the nucleus at the 8-cell stage (see section 2.2.4) and may explain differences in maternally 
produced DNMT1s and DNTM1o stability and activity in preimplantation embryos (62, 63, 
104). The research presented in the remaining introduction ascribes the primary function of 
DNMT1o to maintain imprinted DMD methylation during the rapid preimplantation genomic 
demethylation event. 
2.2.3  Targeted deletion of Dnmt1o 
The Dnmt1Δ1o allele was generated using homologous recombination in ESCs to eliminate a 
260bp region spanning Dnmt1 exon 1o and part of the 5′ 1o promoter (104). The targeting 
construct contained a loxp-neo-TK-loxp cassete in place of the 260bp to be deleted. Homologous 
recombinant ESCs were positively selected using neomycin and then transfected with a CRE 
expressing plasmid to induce deletion and then negatively selected for using the thymidine 
kinase substrate ganciclovir. These ESCs were used to derive a line of chimeric males that 
passed the Dnmt1Δ1o allele through the germline to establish a colony that was backcrossed onto 
the 129Sv background. Heterozygous and homozygous offspring of crosses between 
heterozygous parents develop normally, however homozygous females had progeny that could 
not survive, indicating a maternal effect. 
 Howell et al.(2001) studied DNMT1o-deficient embryos, derived from the Dnmt1Δ1o 
maternal effect model, for changes in their DNA methylation patterns (104). Methylation 
sensitive Southern blot analysis showed that global methylation was unchanged. Furthermore, 
both γ-satellite and IAP repetitive elements were proven to be normally methylated by 
75 
 
methylation sensitive Southern blotting and bisulfite sequencing in DNMT1o-deficient embryos. 
Genomic imprints on the other hand were not normally methylated in the Dnmt1Δ1o maternal 
effect offspring. 
 A severe reduction in genomic imprinting was observed in DNMT1o-deficient embryos 
(104). A single nucleotide polymorphism extension assay using conceptuses derived from 
crosses between the C57/B6 mus musculus homozygous Dnmt1Δ1o females and mus castenous 
wild-type males provided evidence of biallelic H19 and Snrpn expression in an example 
DNMT1o deficient embryo. Using the same interspecific crosses an approximately fifty percent 
loss of methylation was observed at the H19, Snrpn and Peg3 DMDs by bisulfite genomic 
sequencing. Imprinting in oocytes was shown to be normal, indicating a failure to maintain 
imprints in the zygote rather than a defect in the establishment of maternal imprints. 
Transplantation of DNMT1o-deficient pro-nuclei into wild-type oocytes resulted in full rescue of 
the methylation defect. The majority of Dnmt1Δ1o maternal effect progeny die between E12.5 and 
term and very few survive through the neonatal period of development. 
2.2.4  Localization of DNMT1 in preimplantation embryos 
Early studies on DNMT1 using the PATH-52 anti-DNMT1 antibody found that oocytes and 
preimplantation embryos express a shorter form (later named DNMT1o) than somatic cells 
(404). Immunoflourescense of oocytes and preimplantation embryos using the PATH-52 
antibody showed that DNMT1 was concentrated in the subcortical cytosplasm in oocytes and 2-
cell embryos, in cytoplasmic granules at the 4-cell stage and nuclear at the 8-cell stage (62, 404). 
Further studies using C-terminal truncated Dnmt1-β-galactosidase fusion genes identified regions 
required for cytoplasmic sequestration C-terminal to the RFTS domain (406).  
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 Two new anti-DNMT1 antibodies, UPTC21 and UPT82, enabled a clearer picture of 
DNMT1 localization during preimplanation development (63). These antibodies have greater 
sensitivity than PATH52, and UPT82 can distinguish between full length somatic DNMT1 and 
the shorter DNMT1o. UPTC21 is an antiserum raised against DNMT1 amino acids 636-1108 
and recognizes all DNMT1 isoforms, whereas UPT82 is an antiserum raised against the DNMT1 
118 N-terminal amino acids and thus recognizes the longer somatic form of DNMT1 (DNMT1s) 
but not DNMT1o. The presence of a UPT-82 band in western blot analysis of oocytes showed 
that oocytes express DNMT1s in addition to the shorter DNMT1o isoform identified with the 
PATH-52 isoform. Immunofluorescence revealed UPT82 signal within ooplasm and 2-cell 
nuclei indicating maternal DNMT1s present and likely to be active early in zygotic development. 
UPTC21 immunoflourescene was detected in ooplasm and in the zygote cytoplasm up until the 
8-cell stage, results interpreted to mean that DNMT1o is sequestered within the cytoplasm during 
early cleavage events. The amount of maternal effect DNMT1o protein far exceeds maternal 
DNMT1s in oocytes and preimplantation embryos, and provides an explanation for observations 
of the apparent absence of DNMT1s in the nucleus of 2- and 4- cell embryos using pan DNMT1 
antibodies. Furthermore replacement of the 1o exon with the 1s coding sequence increased the 
amount of DNMT1s in 4-cell embryos. Reverse transcription PCR was also used to confirm 
expression of both Dnmt1s and Dnmt1o isoforms in the mouse oocyte (63). 
 The Dnmt1Δ1o and Dnmt1v models provided an excellent confirmation of the above 
immunofluorescence assays (60). Wildtype embryos from 2 to 8-cells had nuclear UPT82 
staining, whereas embryos from homozygous Dnmt1v dams showed no UPT82 staining at the 1-
cell stage and only gradually increased through the morula stage. Additionally, heterozygous 
Dnmt1v females crossed with homozygous Dnmt1v males all had nuclear UPT82 signal in the 1-
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cell embryo, but only half had maintained UPT82 signal beyond that point. These results indicate 
that maternally derived DNMT1s is a nuclear protein during early cleavage prior to zygotic 
Dnmt1s transcriptional activation. Furthermore, loss of DMD methylation at H19 and Snrpn 
DMDs could be prevented in Dnmt1Δ1o maternal effect offspring by transgenic overexpression of 
Dnmt1s in occytes driven by the zona pelucida Zp3 promoter. This result was interpreted as 
evidence that there may not necessarily be anything inherently different between maternally 
acquired DNMT1o and DNMT1s recognition of methylation targets. Rather, DNMT1o is more 
effectively stored in oocytes, thus ensuring accurate maintenance of imprints (DMDs) in 8-cell 
embryos.  
2.2.5  Preimplantation function of DNMT1o 
The role of DNMT1o during preimplantation development is to maintain the integrity of 
genomic imprints. The initial report of loss of DMD methylation in Dnmt1Δ1o maternal effect 
offspring showed a fifty percent loss at three different DMDs in the analysis of a handful of 
samples and speculated that loss of methyltransferase activity at the 8-cell stage and random 
chromosomal assortment at the 5th mitosis would result in mosaic partial loss of genomic 
imprinting (104). A more thorough analysis confirmed these findings and found a profound level 
of epigenetic mosaicisim in Dnmt1Δ1o maternal effect offspring (402). Loss of Snrpn and H19 
DMD methylation could be detected as early as the morula stage by allele-specific bisulfite 
genomic sequencing and ranged from 13% to 65% methylation on the normally fully methylated 
parental alleles. The TR2+3 /Igmyc maternally imprinted transgene was crossed onto Dnmt1Δ1o 
females and used to determine that loss of methylation occurs as early as the 8-cell embryo and 
resolves to approximately 51% methylation at the blastocyst stage (402). Combined bisulfite 
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sequencing and restriction analysis (COBRA) was used to further validate that different 
DNMT1o-deficient ESC derived lines had varying levels of H19 and Snrpn DMD methylation. 
At E9.5 loss of imprinted methylation at the H19 and Snrpn DMD in DNMT1o-deficient 
embryos and placentas was observed alongside loss of monoallelic imprinted gene expression 
patterns. These studies firmly established the role of DNMT1o in preventing epigenetic variation 
at imprinted loci during preimplantation development and provided the framework for our 
current understanding of the Dnmt1Δ1o maternal effect model (Figure 3). 
2.2.6  Fetal development of Dnmt1Δ1o maternal effect offspring 
It is not surprising that the epigenetic mosaic predicted in the maternal effect model results in 
profound and variable embryonic morphology. A study of DNMT1o-deficient embryos focusing 
on fetal development at E9.5 revealed that mutant fetuses scored lower in nearly all 
morphological developmental features as compared to wild-type (105). DNMT1o-deficient 
fetuses were developmentally delayed on average 12hrs, had shorter crown-rump lengths and 
decreased number of somites. Although there were DNMT1o deficient fetuses that were 
morphologically normal, others had features such as failure of axial rotation, failure of anterior 
neuropore closure, poor heart morphogenesis and some that were in states of disintegration and 
reasbsorption. This varied and mosaic nature of DNMT1o-deficient fetal defects were in line  
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Figure 3.  Inheritance of a maternal imprint in normal and Dnmt1Δ1o maternal effect 
embryos. During gametic development genomic imprints are erased in primordial germ cells and 
then reestablished in a sex-specific manner, such that in this example the maternal gamete 
contains a methylated imprint. In the wild-type zygote the combined action of maternally 
inherited DNMT1s, DNMT1o and zygotic DNMT1s account for maintenance of imprinted DMD 
methylation during preimplantation development. In DNMT1o-deficient conceptuses the lack of 
DNMT1o at the 4th mitotic event generates hemimethylated DNA that is then replicated, 
generating a mosaic of cells with half completely lacking the maternal imprint. Because this 
occurs at 24 different imprints scattered on various independently segregating autosomes, a great 
number of partial loss of imprinting permutation of can occur. Therefore, each DNMT1o-
deficient 32-cell morula contains 16-normal cells and a mosaic of 16 cells with unique loss of 
imprinting epigenotypes.  
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with the molecular model of partial and varied loss of genomic imprinting and suggest a 
numerous roles for imprinted loci in early fetal development. 
2.2.7  Placental development of Dnmt1Δ1o maternal effect offspring 
Initial reports also suggest that the placental compartment is affected by loss of imprinting in the 
Dnmt1Δ1o maternal effect model. DNMT1o-deficient fetal and placental epigenomes are not 
always congruent. In fact, in a small set of E9.5 DNMT1o-deficient embryos, neither H19 nor 
Snrpn DMD methylation was eqivalent in corresponding fetal and placental DNA samples (402). 
Preliminary research on placental morphology in E9.5 Dnmt1Δ1o maternal effect offspring 
revealed that many DNMT1o-deficient placentas had shell shaped placentas draped around the 
conceptuses suggestive of trophoblast hyperplasia (407). This phenotype was more common in 
female than male conceptuses. Further studies examining loss of X-chromosome imprinting in 
extraembryonic lineages and placental trophoblast hyperplasia and diminished LZ development 
were performed by McGraw and colleagues (2013) contemporaneously with my own dissertation 
work (408). 
2.2.8  Chapter 2 aims 
The aim of this section is to utilize the Dnmt1Δ1o maternal effect model of partial loss of 
imprinting to better understand the role of genomic imprints in placental biology. The Dnmt1Δ1o 
maternal effect model is based on a genetic mutation that manifests loss of DMD methylation as 
the primary defect. This model produces a mosaic of epigenetic mutants that provide an 
opportunity to study the effects of loss of imprinting as a whole on placental development. In this 
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chapter I have tested the functional significance of genomic imprints in placental biology and 
tried to determine what layers and cell lineages are affected by describing DNMT1o-deficient 
placentas across gestation from E9.5 to E17.5. To assess placental efficiency and the balance of 
fetal and placental growth wet weight measurements of DNMT1o-deficient placentas and fetuses 
were made. To examine placental layer and cell type composition DNMT1o-deficient placentas 
were histologically analyzed using an array of tissue staining techniques. Placental metabolism 
in DNMT1o-deficient placentas was studied by triglyceride quantification and qualitatively by 
lipid and glycogen histological staining. The description and analyses of DNMT1o deficient 
placentas has been performed to delineate which placental processes genomic imprints are 
involved in and to lay the foundation for further research and modeling of the role of genomic 
imprints in placental development. 
2.3.1  Animal husbandry 
All mice were maintained and used in accordance with guidelines from the Institutional Care and 
Use Committee (IACUC) at the University of Pittsburgh. The Dnmt1Δ1o allele was maintained on 
a 129Sv (Taconic) background by backcrossing heterozygous females to 129Sv males. Placentas 
from crosses between heterozygous Dnmt1Δ1o females and 129Sv males were used as wild-type 
(wt) controls. Crosses between homozygous Dnmt1Δ1o females and 129Sv males generated 
DNMT1o-deficient (Dnmt1Δ1o maternal effect) mutant (mt) conceptuses. 
2.3  MATERIALS AND METHODS 
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2.3.2  Genotyping 
Genotyping was carried out on DNA isolated by phenol-chloroform extraction and ethanol 
precipitation of tails snipped at weaning or during embryonic collection. In addition, the 
genotype of pregnant mouse dams that were dissected for placental analysis was confirmed using 
DNA isolated from tail and spleen extracted at the time of dissection. Dnmt1Δ1o genotyping PCR 
used 350ng of starting genomic DNA and used the following thermocylcer program with Taq 
polymerase (Invitrogen): 95°C 5′ denaturing followed by 35 cycles of 95°C 30″, 56°C 30″; 72°C 
45″, a 72°C 10′ final extension and indefinite hold at 4°C. PCR products were run on a 1 or 1.5% 
agarose gel to look for the presence of a wild-type (380bp) or mutant (120bp) band. Sex 
genotyping of embryos was performed using primers specific to the Zfy gene on the male sex 
chromosome. PCR conditions were as follows: 95°C 5′ denaturing followed by 35 cycles of 
95°C 30″, 56°C 30″; 72°C 30″, a 72°C 7′ final extension and indefinite hold at 4°C. PCR 
products from the Zfy reaction were run on a 2% agarose gel to look for the presence of a 200bp 
band indicating male identity. The PCR primer sequences used for genotyping are given in 
Appendix A. 
2.3.3  Collection of placentas 
Embryonic day 0.5 (E0.5) was established based on the presence of a post-copulatory vaginal 
plug. Fertilization was assumed to have occurred at 12am based on the nocturnal nature of 
mating in Mus species. Pregnant females were sacrificed by CO2 asphyxiation and conceptuses 
were collected at embryonic day 9.5, 12.5, 15.5 and 17.5 (E9.5, E12.5, E15.5 and E17.5). 
Dissections were carried out under low magnification (0.8X-2.5X) with a 350MZ dissection 
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microscope (Leica) using fine 8mm forceps. The whole uterus of sacrificed pregnant dams was 
isolated following cesarean section. Incision at the fat pad of each ovary and at the cervix 
facilitated removal of the uterus, which was placed in a 10cm petri dish of phosphate buffer 
saline (PBS) pH 7.5. 
 Each individual conceptus was removed from the uterine myometrium and placed in a 
60mm petri dish with PBS leaving the embryo, yolk sac, placenta and decidua and inner 
myometrium intact. Whole E9.5 conceptuses were immediately placed in 4% paraformaldehyde 
(4% PFA). E12.5, E15.5 and E17.5 placentas were collected by the below protocol. The inner 
myometrium was carefully removed leaving the embryonic tissues and decidua intact. The yolk 
sac was excised away from the base of the placenta leaving the embryo exposed. The umbilical 
cord was pinched for 20″ to stop blood flow and stimulate clotting to stem leakage from both the 
fetus and placenta. The umbilical cord was then cut at the base of the chorionic plate and fetal 
abdomen. Each placenta and fetus was then weighed to the nearest tenth of a milligram. A small 
tail piece was cut and used for embryonic sex genotyping. Placentas were immersed in PBS 
again, then paced on a glass microscope slide with labyrinth facing down and cut in half with a 
sterile razor blade. One half was then placed back in fresh PBS and the other in 4% PFA for 
fixation. The half immersed in PBS was then cleaned of the decidua cap and any remaining yolk-
sac and allantois. The E12.5 half samples were placed in RNA later, whereas the E15.5 and 
E17.5 samples were cut into two quarters, one placed in RNA later and the other snap frozen on 
dry ice for lipid extraction. Samples at each gestational age were labeled by litter (Letter A-G) 
and individual embryo (Number 1-8) for those used in DMD methylation analysis in Chapter 3. 
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2.3.4  Cryo-histology 
Following fixation in 4% PFA, placental halves were suspended through a sucrose gradient up to 
20% weight per volume, and then embedded in Tissue-Tek O.C.T compound (Sakura). Placental 
cryosections of 5μm and 10μm thickness were cut with a CM1850 cryostat (Leica) for 
histological analysis. Regressive hematoxylin and eosin (H&E; Sigma or Leica) staining was 
performed on a series of 5 micron meridian placental sections. In brief cryosections were fixed 
with O-Fix (Leica) for 30″, flushed with tap water for 30″, placed in hematoxylin for 45″ then 
washed for 1′ in water, placed in bluing reagent for 1′, water for 30″ and then 70% EtOH for 7-
dips, alcoholic eosin for 16″, 95% EtOH for 7-dips, two washes in 100% EtOH of 7-dips and two 
washes in xylene of 7-dips before being mounted in a xylene based mounting medium. Periodic 
Acid-Schiff (PAS; Sigma) staining was carried out on E15.5 samples using standard instructions 
with the addition of a 5′ methyl-green (0.5%) nuclear staining prior to dehydration steps. In brief, 
PAS staining was carried out in coplin jars by placing cryosections in O-Fix for 1′, washing with 
water for 1′, placing in periodic acid solution for 5′, washing with water for 1′,, placing in 
Schiff’s reagent for 15′, washing with water for 5′, placing in distilled deionized water for 1′, in 
5′ methyl-green (0.5%) for 5′, rinse in water for 1′, and then run through 95-100-100% EtOH 
dehydration steps of 7-dips and then cleared  in xylene for 7-dips twice and coverslipped in 
xylene based medium. All E9.5 and E12.5 histology was performed on cryosections, however 
some E15.5 and E17.5 H&E, PAS and immunocytochemistry was performed on paraffin 
embedded samples with the assistance of the MWRI histology core. 
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2.3.5  In situ hybridization 
A series of 10μm sections were stained by in situ hybridization (ISH) with Digoxigenin-11-
dUTP (Roche) labeled antisense RNA probes. ISH probes of the placental marker genes Tpbpa, 
Tfeb, LepR, Pchdh12, Mest, Prl2c2, Prl3b1 and Prl3d1 were in-vitro transcribed (Promega) from 
cDNA cloned into pBluescript, and used to identify the labyrinth (Tfeb), SpT (Tpbpa), SynT 
(LepR), GCs (Pchdh12), fetal vascular (Mest) and TGCs (Prl2c2, Prl3b1 and Prl3d1) 
respectively. ISH probes of the imprinted genes Ascl2, Phlda2 and Igf2 were similarly generated. 
RNA probes were purified using a G50 column (GE Healthcare) to remove unincorporated 
nucleotides, ammonium acetate ethanol precipitation, and dissolved in 30μl of water. RNA 
concentration was then determined by using a nanovue spectrometer (GE Healthcare) and diluted 
in ISH hybridization buffer (50% Formamide, 5X SSC, 5X Denhardt’s, 0.25mg/ml tRNA, 
0.5mg/ml herring sperm DNA) to a concentration of 200ng/μl. 
 Cryosections were stored at -70°C and warmed to 30°C to dry before starting ISH 
processing. Slides were fixed in 4% PFA for 10′, washed with PBS 3x for 3′ and digested with 
proteinase K for 5′. Following digestion slides were placed back into 4% PFA for 5′, washed 3x 
with PBS and then placed in an acetylation reaction (200ml aqueous solution of 0.1M 
triethanolamine and 0.2M HCl, initiated with 500μl of acetic anhydride immediately prior to use) 
for 10′. Slides were then washed with PBS 3x for 5′, tissue sections outlined with a pap-pen and 
were pre-incubated with ISH buffer for 2h at room temperature. At the end of 2h ISH probes 
were heated to 75-80°C for 5′ on hot beads, placed on ice for 3′ and spun down and then diluted 
(10μl probe +140μl ISH buffer per section). 125μl of diluted probe was added to each slide, a 
cover slip placed on top, the slides placed in a humidified slide box wrapped with paraffin tape 
and incubated overnight at 65°C. The following day slides were washed with 5x SSC to remove 
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coverslips, and incubated with 0.2X SSC for 2h at 70°C. After cooling down to room 
temperature samples were incubated with buffer B1 (0.1M Tris pH7.5 and 0.15M NaCl) for 5′ 
then incubated with B2 (B1 +5% Fetal Goat Serum) for 1 hour and then with B1 + anti-DIG 
alkaline phosphatase (AP) conjugated antibody (1:5000) overnight at 5°C. On the third day 
slides were washed three times with B1 and then equilibrated with B3 (0.1M Tris pH9.5, 0.1M 
NaCl and 50mM MgCl2) for 5′. Slides were then incubated in the dark with B4 (B3+levamisole 
and NBT/BCIP) for 3-24 hours depending on strength of probe. AP reactions were stopped using 
TE buffer, the slides air-dried, passed through an ethanol dehydration gradient and xylene 
clearing step and cover slipped with a xylene based media. 
2.3.6  Immunohistochemistry 
E17.5 10μm paraffin sections were stained by immunohistochemistry (IHC) using an anti-CD31 
antibody. Briefly, samples were processed according to IHC kit instructions (Pierce): Slides were 
deparaffinized and rehydrated using xylene and ethanol washes, then were washed with exposed 
3% hydrogen peroxide for 10′, washed with PBST (PBS + 1% Tween 20) blocked with horse 
serum, incubated overnight with 1:200 rabbit polyclonal anti-CD31 (Vector Labs) at 4°C, 
washed, incubated with biotinylated secondary, washed and then stained using the Vectastain 
ABC reagent (Pierce), and counter stained with hematoxylin. 
2.3.7  Immunofluorescence 
E17.5 cryosections were stained with a combination of DAPI, LipidTOX (Invitrogen) and anti-
CD31 fluorescent reagents. Briefly samples were washed with PBST, blocked with 5% goat 
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serum, incubated with primary anti-CD31 (Jackson ImmunoResearch Labs) overnight at 4°C, 
washed with PBST, incubated with 1:200 alexa-555 or -488 goat anti-rat IgG (BD) for 1h at 
room temperature, washed with PBST, stained with 1:250 LipidTOX for 30′ in the dark, washed 
with PBST and then coverslipped with DAPI containing medium. E12.5 samples were stained 
with DAPI and coverslipped to count TGCs. 
 
2.3.8  Stereology and morphometrics 
All images of placental tissue sections were taken using a DMI4000B inverted microscope 
(Leica) using 1.6x, 5x, 10x, 20x or 40x objectives and a 10x multiplier. Morphometric area 
measurements were made using the Image J (NIH) grid tool. The area of JZ and LZ layers were 
determined using random grid sampling within 2-3 central 50x or 16x fields of view of H&E 
stained sections for E12.5 and E15.5 placentas respectively. H&E images were overlaid with a 
random offset grid with 0.050 or 0.125mm2 per point respectively based on image magnification. 
The placental cell layer of each point (or upper left quadrant at boundary areas) was determined 
based on cell morphology of JZ (compact diploid SpT layer) or LZ (integrated SynT, fetal 
vasculature and maternal blood spaces). The chorionic plate was excluded from LZ 
measurements. Areas were integrated across the known distance (~250μm) between serial 
sections to generate a central LZ and JZ volume metric. Area and volume measurements were 
confirmed by analysis of adjacent slides stained by ISH of lineage markers. P-TGCcount 
measurements were obtained from 2-3 central 10μm DAPI stained sections. The polyploidy P-
TGC nuclei were readily distinguished from the diploid nuclei of the neighboring decidua and 
SpT cells at greater than 100x total magnification. The average cell count per 10μm section was 
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used as the reported metric. The identity of trophoblast giant cells was confirmed with ISH of 
adjacent sections. 
2.3.9  Lipid extraction  
Placenta samples cleaned of maternal decidua were stored at -70C for up to 3 months prior to 
lipid extraction. Samples were weighed and reduced to 25mg total weight. Samples were then 
placed in a dounce homogenizer with 250μl of deionized water with 5% NP40 and completely 
homogenized. Samples were then transferred with a Pasteur pipette to a clean glass test tube and 
cycled through a beaker of hot (80-100°C) water and room temperature two times to precipitate 
cell debris. The samples were then transferred to microcentrifuge tubes and centrifuged at 
13000rpm for 5′ to pellet debris. Supernatant was transferred to a clean glass test tube, covered 
with paraffin film and stored for up to 1 week at 5°C. A triglyceride assay kit (Biovision) was 
used to quantify lipid content using a colorimetric assay in 96 well flat bottom plates. Duplicate 
standard controls of 10, 20, 30, 40 and 50 ng/well were used to generate a standard curve. 
Samples were plated in triplicate using 10μl of placental triglyceride extract and 40μl of sample 
buffer per well. Samples and controls were incubated with 2μl of lipase for 20′ at room 
temperature and then incubated with a reaction mix containing 46μl of buffer, 2μl of triglyceride 
probe and 2μl of enzyme mix per well and incubated for 1 hour at RT with gentle shaking. 
Absorbance at 570nm was the colormetric readout. Sample concentrations were back calculated 
as nmol triglyceride per mg of tissue using the standard curve and known mg per volume of 
sample.  
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2.3.10  Biostatistics 
Mean mutant and wild-type phenotypic averages were calculated for all quantitative traits. The 
phenotypic data was also subdivided into dead/alive and male/female subgroups to determine the 
influence of fetal viability and sex on placental phenotypes. The distribution of each data set was 
tested for normality using the Kolmogorov-Smirnov, Shapiro-Wilk and Anderson-Darling tests 
of normality. When distributions approximated normality the students t-test was used to compare 
the distribution of mutant and wild-type phenotypes as well as the phenotypes observed in 
subgroups. Likewise, where the data was non-normally distributed the Mann-Whitney U (Rank-
sum) test was used to compare the sample averages. Phenotypic data is most often displayed in 
charts showing mean + SEM. 
2.3.11  Microarray analysis 
E17.5 placental halves cleaned of maternal decidua were used to analyze global gene expression. 
Four wild-type controls, four low E/P DNMT1o-deficient and four high E/P DNMT1o-deficient 
placentas were analyzed. An even number of males and females were included in each group to 
minimize sex-specific expression differences. RNA was extracted from placental samples using a 
DNA/RNA combined kit (Qiagen). Illumina mouse WG-6-V2.0 Expression bead chips were 
used for whole genome expression profiling of 45,200 transcripts. Data was normalized and then 
mean expression values were determined for each subgroup. Ingenuity pathway analysis (IPA) 
was used to determine which biological pathways had altered gene expression patterns in low 
and high E/P ratio DNMT1o-deficient placentas. 
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2.4.1  Dnmt1Δ1o maternal effect embryonic viability 
DNMT1o-deficient placentas exhibited a large spectrum of phenotypic abnormalities in the 
placental compartment across gestational development from E9.5 to E17.5. The number of live 
DNMT1o-deficient embryos decreased across gestation such that a greater number of litters was 
required late to collect the same number of placental samples for each gestational age (Table 2). 
These results revealed a strong selection event between E9.5 and E12.5 that reduced the number 
of viable embryos. The results reported here differ slightly from those I published in 
Developmental Biology (409) and PLoS One: Epigenetics (410) because of less stringent 
viability criteria at E9.5 used herein. 
A diverse array of placental phenotypes was observed in the Dnmt1Δ1o maternal effect 
across gestation from E9.5 to E17.5. Early in development I observed decreases in the central 
volume of JZ and LZ layers and expansion of trophoblast giant cells. While placentas were 
smaller than average at E12.5, those recovered at E17.5 were overgrown. At mid (E15.5) and late 
(E17.5) gestational time points DNMT1o-defiicent placentas had reduced fetal vascular surface 
area, labyrinth hemorraghing, increased GCs abundance, increased lipid content and a prevalence 
of SpT extensions within the LZ. In addition, the balance of fetal and placental growth was 
disrupted 
 
2.4  RESULTS 
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Gestational Age (dpc) # Litters # Placentas(a) #Live Embryos(b) 
E9.5 4 30 29 
E12.5 3 24 10 
E15.5 4 23 11 
E17.5 5 23 14 
Table 2.  Survival of DNMT1o-deficient embryos and placentas.  (a) Only intact placentas 
that were not necrotic, reabsorbing or hydatidiform moles were counted. (b) Based on structural 
integrity at E9.5 and presence of active circulation at E12.5 and later. 
2.4.2  E9.5 Phenotypes 
I performed histological analysis on E9.5 whole mount cryo-embedded conceptuses from 3 
Dnmt1Δ1o maternal effect litters. A single example of a DNMT1o-deficient litter with 7 
conceptuses (M1-M7) is shown in Figure 4 alongside an exemplary wild-type (wt) control. 
Abnormalities in placental layers were identified in central placental H&E stained sections. 
Central sections were determined based on presence of the maternal spiral artery, a triangular 
shaped maternal artery at the apex of trophoblast implantation. Maternal and fetal blood was 
distinguished by the presence of hematoxylin stained nuclei in fetal erythrocytes and absence in 
erythrocytes of maternal origin. In wild-type placenta a large maternal artery was observed for 
all samples and each placental layer was intact (wt; Figure 4). Not all mutant placentas observed 
had a dilated maternal artery, indicating a defect in implantation (DNMT1o-deficient mutants 
M2, M5 and M7; Figure 4). Poor structural integrity of the labyrinth and expansion of 
trophoblast giant cells was noticeable in many of the mutants. DNMT1o-deficient placentas M2, 
M3, M4, M5 and M7 had underdeveloped LZ. DNMT1o-deficient placentas M2 and M7 had an 
easily discernible overabundance of trophoblast giant cells. 
To confirm the cell identities and phenotypes interpreted from H&E histology I 
performed in situ hybridization with a set of trophoblast lineage markers (Figure 4). The 
prolactin family member Prl2c2 was used as a TGC marker. Expansion of the TGC layer from 1-
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3 cells thick to 5-6 cells was observed in DNMT1o-deficient mutants M2 and M7 (Figure 4). An 
antisense probe to the transcription factor Tfeb cDNA was used to identify EXE derived 
chorionic plate and SynT progenitors. DNMT1o-deficient mutant M2, M3, M4, M5 and M7 
showed decreased expression and less structural development of maternal blood spaces (Figure 
4). In wild type placenta Tfeb had a complex spatial expression pattern of raised and convoluted 
chorionic trophoblast, whereas the abnormal DNMT1o-deficient placentas displayed flattened 
labyrinth chorionic trophoblast. An antisense probe for the ectoplacental cone specific 
transcription factor Tpbpa was used to identify SpT and progenitors. In wild-type placentas 
Tpbpa marks an apex area around the maternal spiral artery. DNMT1o-deficient mutants M3 and 
M4 have a marked decrease in Tpbpa expression. 
In conjunction with ISH of placenta lineage markers I probed adjacent E9.5 whole-mount 
DNMT1o-deficient placenta with antisense probes to the imprinted genes Ascl2, Phlda2 and Igf2 
(Figure 4). We expected and observed a decrease in the spatial expression pattern for each 
imprinted genes. Ascl2 is expressed in the EPC in wild-type E9.5 placentas whereas Phlda2 is 
expressed primarily in the labyrinthine EXE derived lineages. Loss of methylation at the Kcnq1 
DMD should have the predicted effect of decreased Aslc2 and Phlda2. DNMT1o-deficient 
mutants M3 and M4 had severely restricted expression of both Aslc2 and Phlda2 (Figure 4). Igf2 
is ubiquitously expressed in placental and embryonic tissues. Loss of H19 DMD methylation is 
expected to result in diminished Igf2 expression. The majority of DNMT1o-deficient mutants 
had minimal Igf2 staining, with the exceptions being M6 and M7 (Figure 4). Discordant Igf2 
expression patterns were observed between placenta and fetus and also between EPC (SpT and 
TGC) and EXE (chorion and SynT) derived trophoblast lineages. These results indicate that the 
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DNMT1o-maternal effect model has early wide-ranging phenotypes in placental structure and 
imprinted gene expression. 
 
 
Figure 4.  E9.5 Histology of wild-type (wt) and DNMT1o-deficient placentas (M1-M7). A 
broad range of morphologic and gene expression abnormalities is present in an exemplary single 
litter of E9.5 DNMT1o-deficient placentas. H&E staining and ISH of adjacent central placental 
sections are shown. ISH probes are listed on the left bar include placenta lineage markers Prl2c2 
(TGCs), Tpbpa (EPC), Tfeb (Chorion) and imprinted genes Ascl2, Phlda2 and Igf2. Scale bar 
500um. 
2.4.3  E12.5 Phenotypes 
I performed histological analysis on 24 E12.5 whole mount cryo-embedded conceptuses from 3 
Dnmt1Δ1o maternal effect litters (E12.5 Litters A-C). Two wild-type litters, with a total of 16 
conceptuses were used as controls. H&E staining was used to observe overall abnormalities and 
wt M1 M2 M3 M4 M6 M7M5
H&E
Prl2c2
Tfeb
Tpbpa
Ascl2
Phlda2
Igf2
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in situ hybridization in order to confirm cell type identities. DNMT1o-deficient and wild-type 
placentas differed in many ways at E12.5, particularly in weight, central JZ volume, central LZ 
volume and number of TGCs (Figure 5). There was a trend toward decreased placental weight in 
DNMT1o-deficient placentas (P<0.05; Figure 5A). Additionally, there were significant decreases 
in measured central LZ volume (P<0.005; Figure 5B) and central JZ volume (P<0.005; Fig 5B) 
in the DNMT1o-deficient placentas compared to wild-type controls. A marked increase in the 
number of TGCs per central section was measured in the E12.5 DNMT1o-deficient placentas 
compared to wild-type controls (P<0.01; Figure 5C). These findings are in line with my previous 
findings of distorted placental layer development at E9.5 (Section 2.4.2; (409)). 
 
Figure 5.  Phenotypic comparison of wild-type (wt) and DNMT1o-deficient (mt) placentas 
at E12.5. (A) Measurements of wet placenta weight, (B) Spongiotrophoblast and Labyrinth 
central volume, and (C) the number of TGCs per slide of a cohort of wt and mt placentas are 
displayed as open and filled bars respectively. Data are plotted as mean +SEM. *(P<0.05)  and 
**(P<0.005) denote significant differences between wt and mt averages by the Rank-sum test, wt 
n=21 for placental weights and wt n=12 for layer volumes, mt n=24 for all.  
 
 To determine the effects of fetal viability and sex on placental phenotypes in the 
Dnmt1Δ1o maternal effect mouse model we compared live/dead and male/female mutant and 
wild-type cohorts (Figures 6 and 7). We compared the phenotypes of DNMT1o-deficient 
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placentas that harbored live and dead fetuses and found that those placentas that did not support a 
viable fetus had less labyrinth volume than those that did support a live fetus (Figure 6). In a sex 
comparison of DNMT1o-deficient placentas we discovered that female placentas on average had 
smaller central LZ volumes than mutant males (P<0.05; Figure 7). In addition, DNMT1o-
deficient females had significant differences from wild-type counterparts at all measured 
phenotypes whereas mutant males only differed from wild-type males in LZ central volume and 
TGC number (Figure 7). These results are in line with preliminary reports earlier placental 
phenotypes that are more prominent in female than male Dnmt1Δ1o maternal effect offspring 
(407). 
 
Figure 6.  Phenotypic comparison of wild-type (wt) and DNMT1o-deficient (mt) live and 
dead placentas at E12.5. (A) Measurements of wet placenta weight, (B) Spongiotrophoblast and 
Labyrinth central volume, and (C) the number of TGCs per slide of a cohort of wt and mt-Live 
and mt-Dead placentas are displayed as white, black and gray bars respectively. Data are plotted 
as mean + SEM. *(P<0.05) and **(P<0.005) denote significant differences between wt, mt-live 
and mt-dead averages by the Rank-sum test. wt n=21 for placental weights, n=12 for layer 
volumes, mt(live) n= 11, mt(dead) n=13. 
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Figure 7.  Phenotypic comparison of wild-type (wt) male and female, and DNMT1o-
deficient (mt) male and female placentas at E12.5. (A) Measurements of wet placenta weight, 
(B) Spongiotrophoblast and Labyrinth central volume, and (C) the number of TGCs per slide of a 
cohort of wt-male, mt-male, wt-female and mt-female placentas are displayed as white, black, 
light-gray and dark-gray bars respectively. Data are plotted as mean + SEM. *(P<0.05) and 
**(P<0.005) denotes significant differences between wt-male, wt-female, mt-male and mt-
female averages by the Rank-sum test. wt-male n=11 and wt-female n=10 for placental weights, 
wt-male n=6 and wt-female n=6 for layer volumes, mt-male n=12, mt-female n=12.  
 
Labyrinth morphology was noticeably abnormal with hemorrhaging of maternal blood 
pools and poor fetal vasculature development (see Figure 37 in section 3.4.5 for H&E staining of 
DNMT1o-deficient placentas associated with loss of Peg10 DMD methylation). To confirm the 
poor vascular development in DNMT1o-deficient samples ISH with an RNA probe antisense to 
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the Mest transcript was used to identify fetal vessels. Although Mest is an imprinted gene, its 
expression is expected to increase rather than decrease with loss of methylation at the Mest 
DMD. Therefore, any reduction in expression observed should be due to loss of fetal vasculature 
and not loss of imprinting at the Mest locus. In one maternal effect litter of eight (Figure 8 C1-
C8), four have normal fetal vessel branching (C1, C5, C6 and C7), two have stumped and 
underdeveloped vasculature (C2 and C3) and two completely lacked vasculature (C4 and C8). 
Not surprisingly the placentas with diminished or no vasculature did not support a viable fetus. 
Although these results indicate imprinting is important for placental fetal vasculature 
development it does not tell us whether it is imprinting within the fetal derived vascular 
endothelium or trophoblast components of the placenta that is critical. 
 The spongiotrophoblast layer was examined by ISH expression analysis of Tpbpa and 
Ascl2 (Figures 9 and 10). In wild type placentas a distinct JZ layer was present at the boundary 
of the LZ and maternal decidua consisting of SpT that stained strongly for Tpbpa (WT; Figure 
9). ISH staining for Tpbpa in DNMT1o-deficient placentas ranged from normal (C2 and C7; 
Figure 9) to abnormal, showing ectopic expression in the LZ or decidua (C1, C6, C7 and C8; 
Figure 9) and/or diminished and dispersed signal (C1, C3 and C4 and C8; Figure 9). Expression 
of Ascl2 marks SpT but does not stain as strongly in wild-type placentas at E12.5 than at E9.5 
(wt, Figures 4 and 10). However, at E12.5 Ascl2 is also detected in C-TGCs and S-TGCs and 
remaining TSC populations embedded in the LZ (WT; Figure 10). DNMT1o-deficient mutant 
placentas exhibited a wide spectrum of Ascl2 spatial expression patterns (C1-8; Figure 10). 
Dnmt1Δ1o maternal effect mutants showed near normal (C1), partial loss (C3, C6, C8) or 
complete loss (C4) of Ascl2 expression, consistent with varying degrees of partial loss of Kcnq1 
DMD methylation. Intriguingly, DNMT1o-deficient placenta C3 has partial loss of Ascl2 
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expression on the same junctional zone side that lacks Tpbpa expression, and has stunted 
vascular development; whereas DNMT1o-deficient placenta C4 with complete loss of Ascl2 has 
neither Tpbpa expression nor vascular development. Some DNMT1o-deficient placentas had 
stronger than normal Ascl2 staining with the LZ (C1, C5 and C7) suggesting that undifferentiated 
EPC progenitors, C-TGCs or S-TGCs may be accumulating. 
Excessive abundance of TGCs is shown in three examples of DNMT1o-deficient 
placentas by DAPI nuclear staining (Figure 11; also See Figure 38 in section 3.4.5) for H&E and 
in situ analysis of TGC accumulation in E12.5 placentas with loss of Kcnq1 DMD methylation). 
DAPI TGC nuclei were counted for 2-3 central sections and averaged for each placenta. Wild-
type and Dnmt1Δ1o maternal effect mutant cohort TGC count averages were compared with 
extended analysis of live/dead and male/female subgroubs (Figures 5C, 6C, and 7C). 
Accumulation of TGCs in DNMT1o-deficient placentas was most evident in placentas lacking a 
viable fetus, and was significant in both male and female conceptuses. DNMT1o-deficient 
placentas C1, C3 and C8 had elevated TGC counts and abnormal (although not absent) Ascl2 and 
Tpbpa expression. These results suggest that the maldevelopment of each layer is interdependent 
in DNMT1o-deficient placentas. 
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Figure 8.  E12.5 Mest ISH of a Wild-type (WT) and a litter of eight DNMT1o-deficient (C1-
C8) placentas. Mest expression marks fetal endothelium and chorionic plate. Note the normal 
fetal vessel branching patterns in WT and C1, C5, C6, and C7, stumped in C2 and C3, and lack 
of in C4 and C8. 4x objective Scale bar is 1000um. 
Mest WT C1 C2
C3 C4 C5
C6 C7 C8
100 
 
 
Figure 9.  E12.5 Tpbpa ISH of a Wild-type (WT) and a litter of eight DNMT1o-deficient 
(C1- C8) placentas. Tpbpa expression marks the spongiotrophoblast. Notice the strong staining 
and compact layer in WT and mutant C2. However, other DNMT1o-deficient placentas show 
Ectopic (C6) diffuse (C1, C3, C4 and C8) or ectopic (C5, C6 and C7) expression. 4x objective 
Scale bar is 1000um  
Tpbpa WT C1 C2
C3 C4 C5
C6 C7 C8
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Figure 10.  E12.5 Ascl2 ISH of a Wild-type (WT) and a litter of eight DNMT1o-deficient 
(A-H) placentas. Ascl2 marks primarily the spongiotrophoblast and scattered S-TGCs and C-
TGCs in the labyrinth Notice the compact SpT layer in WT and DNMT1o-deficient placentas 
C1, C2, 5 and C7; whereas placentas C3, C4, C6 and C8 have have a range of loss of Ascl2 
expression from partial to complete. 4X objective, scale is 1mm.   
Ascl2 WT C1 C2
C3 C4 C5
C6 C7 C8
102 
 
 
Figure 11.  DAPI nuclear staining of TGCs in a wild-type (WT) and three DNMT1o-
deficient E12.5 placentas. A yellow asterisk highlights the nucleus of each TGC. 20X objective, 
orange scale bar is 100μm. 
 
2.4.4  E15.5 phenotypes 
The variability in phenotypic metrics observed at E15.5 was smaller than that seen at E12.5. 
Specifically, at E15.5 neither JZ central volume nor LZ central volume phenotypic metrics 
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significantly differed between wild-type and mutant cohorts (Figure 12C). However, there was 
an increase in both placental and fetal weights in DNMT1o-deficient placentas compared to 
gestational age matched controls (Figures 12A and 12B). In the comparison of live and dead 
mutants, viable DNMT1o-deficient placentas and fetuses were overgrown (P<0.005; Figures 
13A and 13B). Mutant female placentas weighed more than wild-type females (P<0.05) but 
males did not differ from their wild-type counterparts (Figure 14A).  
Although there was no quantitative difference in JZ central volume between wild-type 
and DNMT1o-deficient placentas (Figure 12C), there were noticeable qualitative changes. Wild-
type Tpbpa ISH staining in E15.5 controls showed a single compact layer of JZ (WT; Figure 15). 
DNMT1o-deficient placentas ranged from having a thin JZ layer (C3; Figure 15), to having an 
increased JZ layer (C6 and D2; Figure 15). Many of the E15.5 Dnmt1Δ1o maternal effect 
placentas exhibited extensions of Tpbpa positive SpT within the LZ. Much of the SpT including 
the extensions were rich in GCs. Three examples of GC rich placentas are shown with PAS 
staining to highlight glycogen content (Figure 16). These findings suggest that volumetric 
estimates may not be indicative of the full phenotypic spectrum of placental layer development.  
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Figure 12.  Phenotypic comparison of wild-type (wt) and DNMT1o-deficient (mt) placentas 
and fetuses at E15.5. (A) Wet placental weight, (B) Wet fetal weight, (C) Spongiotrophoblast 
volume and labyrinth zone volume of a cohort of wt and mt samples are displayed as open and 
filled bars respectively. Data are displayed as mean + SEM.  * (P<0.05) and **(P<0.005) denote 
significant differences between wt and mt averages by the Rank-sum test. wt n=27 for placental 
and fetal weights, wt n=9 for layer fractions, and mt n=21 for all measurements 
 
 
Figure 13.  Phenotypic comparison of wild-type (wt) and DNMT1o-deficient (mt) live and 
dead placentas at E15.5. (A) Measurements of wet placenta weight, (B) Wet fetal weight and 
(C) Spongiotrophoblast and Labyrinth central volume of a cohort of wt and mt-live and mt-dead 
placentas are displayed as white, black and gray bars respectively. Data are plotted as mean + 
SEM. *(P<0.05) and **(P<0.005) denote significant differences between wt, mt-live and mt-
dead averages by the Rank-sum test. wt n=27, mt-live  n= 14 and mt-dead n=7. 
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 The concentration of triacylcglycerides (lipids) within E15.5 DNMT1o-deficient 
placentas was measured. This analysis compared four wild-type and twenty Dnmt1Δ1o maternal 
effect placentas. Wild-type E15.5 placentas had an average triacylglyceride concentration of 5.70 
nmol/mg compared to the DNMT1o-deficient placental average of 7.36 nmol/mg (P>0.05; 
Figure 17A). Additionally, neither fetal viability nor embryonic sex significantly differed from 
wild-type nor within mutant subgroups (P>0.05; Figures 17B and 17C). This data is interpreted 
as evidence that there may be changes to trophoblast lipid accumulation at E15.5 but that 
elevated levels may not occur to a great enough degree or in a sufficient fraction of samples to 
reach significance in a comparison of means. LipidTOX fluorescence of E15.5 DNMT1o-
deficient placenta shows that lipid droplets primarily accumulate in SynT rather than CD31 
positive fetal endothelium (Figure 18). 
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Figure 14.  Phenotypic comparison of wild-type (wt) male and female, and DNMT1o-
deficient (mt) male and female placentas at E15.5.  (A) Measurements of wet placenta weight, 
(B) wet fetal weight and (C) spongiotrophoblast and labyrinth central volume of a cohort of wt-
male, mt-male, wt-female and mt-female placentas are displayed as white, black, light-gray and 
dark-gray bars respectively. Data are plotted as mean + SEM. *(P<0.05) and **(P<0.005) 
denotes significant differences between wt-male, wt-female, mt-male and mt-female averages by 
the Rank-sum test. wt-male n=4 and wt-female n=17 for placental and fetal weights, wt-male 
n=2 and wt-female n=7 for layer fractions, mt-male n=9 and mt-female n=12 for all 
measurements. 
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Figure 15.  Tpbpa ISH of wild-type (WT) and DNMT1o-deficient E15.5 placentas. Tpbpa is 
a marker of spongiotropbhoblast, which is present as a compact layer in WT but ranges from a 
thin layer to thickened and having projections in to the labyritnth in DNMT1o-deficient mutant 
placentas. Scale bar is 2mm. 1.6X objective. 
 
Figure 16.  PAS in E15.5 DNMT1o-deficient placentas. Vacuolated and glycogen rich (purple) 
GCs indicated by Yellow arrows and zoomed in areas in orange boxes. Scale bars 1mm and 
100μm. 
C3WT
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Figure 17  E15.5 triacylglyceride Levels.  (A) Comparison of wild-type (wt) and DNMT1o-
deficient (mt) placental lipid concentrations. (B) Comparison of wt and mt-live and mt-dead 
placentas. (C) Comparion of wt and mt-male and mt-female placentas. Mean and SEM of each 
sample distribution are shown. All comparions were not siginificant (P>0.05) by rank sum test. 
wt n=4, mt n=20, mt-live n=13, mt-dead n=7, mt-male n=9, mt-female n=11 
 
 
Figure 18. Fluorescent imaging of E15.5 DNMT1o-deficient placentas. Nuclei are shown in 
blue (DAPI), lipid droplets in red (LipdTOX), fetal vasculature in green (CD31) and composite 
RBG merged image. Note that lipid droplets occur primarily in SynT that are negative for CD31 
staining. Images taken with 40X objective, orange scale bar is 100μm. 
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2.4.5  E17.5 placental phenotypes 
Placental and fetal weights at of DNMT1o-deficient placentas recovered at E17.5 were greater 
than wild-type controls (P<0.005; Figure 19A). Conceptuses supporting live fetuses harbored 
heavier placentas (P<0.005) and fetuses (P<0.005) than those that were not viable (Figures 20A 
and 20B). Both male and female mutant placentas were heavier than wild-type controls (P<0.005 
and P<0.05; Figure 21A). These results suggest that DNMT1o-deficient placentas that survive 
into late-gestation are overgrown. 
 The ratio of embryonic to placental weight (E/P) is a standard metric of placental 
efficiency as it directly measures the placental capacity to support fetal growth normalized to the 
amount of placenta present. An analysis of fetal and placental weights from 17 wild-type and 62 
DNMT1o-deficient placentas revealed that mutant placentas are widely variable in their 
placental efficiency. Wild-type placentas had an average an E/P ratio of 9.99 and when plotted 
cluster into a tight group (Figures 22A and 22B). DNMT1o-deficient placentas showed a wide 
range in E/P ratios with a significantly lower than wild-type average of 6.08 and when plotted 
show a scattered distribution (P<0.001; Figures 22A and 22B). Not surprisingly mutant placentas 
that did not support growth had a lower E/P ratio than those that could (E/P of 3.13 versus 8.36), 
and formed distinct groups when plotted (Figures 22A and 22B). 
To determine if the wild-type, mutant-live and mutant-dead samples formed distinct E/P groups 
the Kmeans clustering algorithm was applied to all E17 embryo and placenta data. The number 
of clusters (K) was set to 5, because the data as plotted in Figure 22B appeared to have one wild-
type placenta group and four DNMT1o-deficient groups: normal placenta with large embryo, 
large placenta with large embryo, normal placenta with small embryo, and small placenta with 
small embryo. Kmeans clustering returned these expected groups (Figure 22C). Cluster 2 
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included all wild-type samples, along with one live mutant and one dead mutant and had a 
centroid E/P ratio of 9.62, close to that of wild-type samples (Figure 22C). Cluster 1 contained 
18 live mutants and one dead mutant, and had a centroid E/P ratio of 8.78 with enhanced fetal 
growth (Figure 22C). Cluster 3 contained 14 live mutants with a centroid E/P ratio of 8.5 with 
large placentas and fetuses (Figure 22C). Cluster 4 had 7 dead mutants and a centroid E/P ratio 
of 2.9; these samples had extremely small placentas and fetuses (Figure 22C). Lastly, Cluster 5 
contained 18 deceased mutants and one live mutant with a centroid E/P ratio of 2.7; these 
samples had normal placental weights but small fetuses and therefore were very inefficient 
(Figure 22C). These results highlight that DNMT1o-maternal effect placentas without a viable 
fetus are very inefficient, whereas those that survive are slightly less efficient than normal but 
can be extremely overgrown. The range of fetal weights found in cluster 1 show that within the 
live-mutant population that have slightly above average placental weights some placentas are 
more efficient (supporting higher fetal weight) than others (supporting lower fetal weight). 
Placentas within cluster 1 with high and low E/P are compared in transcriptional analysis 
described at the end of this results section.  
 In a cohort of E17.5 DNMT1o-deficient placentas substantial phenotypic variance was 
unearthed. The volume fraction of JZ increased whereas the volume fraction of the LZ layer 
decreased (P<0.05; Figures 23B and 23C). Strong qualitative phenotypes were also noticed. The 
JZ layer of many placentas had ectopic extensions of SpT into the LZ visible on H&E and Tpbpa 
ISH histological sections (left column; Figure 24). Much of the excess SpT was positive for the 
glycogen cell marker Pcdh12 (data not shown) and contained glycogen vacuoles visible in PAS 
staining (right columns; Figure 24).  
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Figure 19.   Comparison of wild-type (wt) and DNMT1o-deficient placental and fetal 
weights at E17.5. (A) Wet placental weights and (B) wet fetal weights of wt and mt cohorts are 
shown as open and filled bars respectively. Data are displayed as mean +SEM. ** (P<0.001) by 
the Rank-Sum test, wt n=17, mt n=23. 
 
 
Figure 20.  Phenotypic comparison of wild-type (wt) and DNMT1o-deficient (mt) live and 
dead placentas at E17.5.  (A) Measurements of wet placenta weight and (B) Wet fetal weights 
of wt and mt cohorts are shown as open and filled bars respectively. Data are displayed as mean 
+SEM. ** (P<0.001) by the Rank-Sum test. wt n=17, mt-live n=14 and mt-dead n=9. 
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Figure 21.  Phenotypic comparison of wild-type (wt) male and female, and DNMT1o-
deficient (mt) male and female placentas at E17.5.  (A) Measurements of wet placenta weight 
and (B) Wet fetal weights of wt and mt cohorts are shown as open and filled bars respectively. 
Data are displayed as mean +SEM. ** (P<0.001) by the Rank-Sum test. wt-male n=12, wt-
female n=5, mt-male n=13 and mt-female n=10. 
 
 The labyrinth layer of E17.5 DNMT1o-deficient placentas was also abnormal. Expression 
of SynT marker Lepr was sporadic or diminish to varying degrees in mutant placentas (left 
column; Figure 25). IHC staining with antibodies against the fetal vascular endothelium marker 
CD31(VECAM) enabled detailed resolution of both fetal vessels and maternal blood pools (right 
column; Figure 25). This IHC analysis showed that many DNMT1o-deficient placentas have 
dilated maternal blood sinuses (asterisks; Figure 25). However, it was of note that unlike at 
E12.5 all placentas at E17.5 had intact fetal vasculature, indicating that those showing severe 
labyrinth defects at E12.5 cannot survive to E17.5. Taken together this evidence demonstrates 
that DNMT1o-deficient placentas exhibit variable abnormal labyrinth morphology. 
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Figure 22.  Analysis of E/P ratio in wild-type and DNMT1o-deficient E17.5 offspring. (A)  
Bar chart of E/P ratio in wild-type, mutant live and mutant dead samples. (B) Plot of E/P ratio for 
each subgroup: wt n=17, mt-live n=67, mt-dead n=34. (C) Kmeans clustering with K=5. 
**P<.001 with two tailed unequal variance T-test. 
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Histological analysis of E17.5 DNMT1o-deficient placentas by ORO staining revealed an 
abundance of lipids in the LZ (Figure 26A-D). There was a wide range in the staining from 
extremely abundant staining to similar levels as wild-type. Quantification of triaclyclgeride 
content revealed an overabundance of lipids in DNMT1o-deficient placentas that was 
statistically significant (P<0.0 Figure 26E). The robust lipid deposition combined with the 
overabundance of GCs is evidence that the metabolic states of late gestation DNMT1o-deficient 
placentas are altered. 
A microarray gene expression analysis was performed to determine what cellular 
pathways are altered in the Dnmt1Δ1o maternal effect model in E17.5 placentas with high and low 
E/P ratios (Figure 27). Hierarchical clustering analysis of all samples revealed a structured 
hierarchy in which wild-type samples were highly similar, and high and low E/P samples 
separated into distinct mutant sub-groups (Figure 27A). Of the genes down-regulated 1.3 fold or 
more there was significant overlap in the low and high E/P groups (Figure 27B); and these were 
enriched in genes involved in oxidative response (Figure 27C). On the other hand there was less 
overlap in genes up-regulated by both low and high E/P ratio DNMT1o-deficient placentas 
placentas (Figure 27B). Genes involved in lipid metabolism were up-regulated by both groups. 
In contrast, only high E/P ratio had up-regulated genes enriched for molecular transport and lipid 
metabolism pathways. Overall, my description of DNMT1o-deficient at E17.5 and throughout 
mid-gestation demonstrate a large gamut of placental developmental and structural defects. 
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Figure 23.  H&E Histology and volume fraction measurements of E17.5 DNMT1o-deficient 
placentas. (A) Histology of H&E stained paraffin embedded wild-type (WT) and DNMT1o-
deficient (M1-M4) placentas. (B) Box plots showing spongiotrophoblast and labyrinthine wild-
type and DNMT1o-deficient volume fractions medians and upper and lower quartiles. 
Abbreviations de decidua; sp spongiotrophoblast; lb labyrinthine.1.6X ojective, Scale is 400μm 
*P<0.05 Kruskal-Wallis 
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Figure 24.  Tpbpa ISH and PAS staining of a wild-type and three E17.5 DNMT1o-deficient 
placentas. (A-D) Tpbpa ISH of a wild-type and 3 representative DNMT1o-deficient placentas. 
(E-H) Adjacent sections from the same samples with PAS glycogen staining. Abbreviations: de 
decidua; sp spongiotrophoblast; lb labyrinthine. Left and center panels 5x objective, scale bar is 
400μm; Right panel 10X objective scale bar is 100μm. 
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Figure 25.  Lepr ISH and CD31 IHC histology of DNMT1o-deficient E17.5 placentas. (A-E) 
Lepr ISH staining of SynT in a wild-type and four representative DNMT1o-deficient placentas. 
(F-J) CD31 IHC staining of fetal vessels in a different set of representative DNMT1o-deficient 
placentas. Left panel 5X objective, scale bar is 400μm. Right panel 40X objective, scale bar is 
50μm. * dilated maternal blood pools. 
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Figure 26.  Lipid accumulation in E17.5 DNMT1o-deficient placentas. (A-D) Staining with 
Oil-Red-O in a single wild type and three DNMT1o-deficient placentas. (E) Quantification of 
triaclyglyceride concentrations. (F) Quantification of cholesterol concentrations. (G) Inverse 
relationship of triglyceride concentration and embryonic weight revealed by linear regression. 
Abbreviations: TGs Trigylcerides; wt Wild-type; de decidua; sp spongiotrophoblast; lb 
labyrinthine. Left panel 1.6X objective, scale is 400um. Right panel 40x objective, scale is 
100μm. * P-values from Kruskal-Wallis test. 
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Figure 27.  E17.5 microarray analysis of DNMT1o-deficient placentas. (A) Hierachical 
clustering derived dendrogram describing genome-wide expression patterns. The X-axis is 1 
minus the correlation coefficient. (B) Ven diagrams showing overlapping subsets of genes 
common to low and high E/P ratio DNMT1o-deficient placentas and (C) enriched gene ontology 
pathways determined by Ingenuity Pathway Analysis.  
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2.5.1  Fetal viability and growth 
Partial mosaic loss of imprinting in the Dnmt1Δ1o maternal effect model has a profound impact on 
placental development and fetal growth that progresses across gestation. The most prominent and 
obvious phenotype in DNMT1o-deficient placentas was the inability to support a viable fetus. At 
E9.5 the majority of embryos are alive, at E12.5 roughly half of each litter is deceased, and by 
E15.5 and E17.5 only a fraction of normal litter sizes are recovered (Table 2). This gradual mid-
gestation lethality points to a temporal juncture between E9.5 and E12.5 in genomic imprinting 
that is critical for proper development. While the embryonic lethality observed in the Dnmt1Δ1o 
maternal effect model is likely due to loss of imprinting in both the fetal and placental 
compartment, given the severe placental abnormalities and similar stage of gestational 
developmental arrest in known placental lethal mutants (e.g. Ascl2, Rtl1, Peg10, Pparδ and 
Pparγ) it is likely that placental development is the major factor. 
 At E12.5 Dnmt1Δ1o maternal effect litters were similar in size to wild-type litters in 
having 8 conceptuses. The partial embryonic lethality observed at E12.5 was an opportunity to 
observe placental abnormalities associated with loss of fetal viability. Two distinct groups of 
placentas were observed in a representative E12.5 DNMT1o-deficient litter that were either able 
to support a viable fetus (C1, C5, C6 and C7; Figures 8, 9 and 10) or were unable to (C2, C3, C4, 
C8; Figures 8, 9 and 10). Notably expression of the fetal endothelium marker Mest was normal to 
2.5  DISCUSSION 
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slightly expanded in placenta with viable fetuses but stunted or nearly absent placenta from non-
viable conceptuses (Figure 8). Likewise, three out of four non-viable placentas had diminished 
Ascl2 staining and abnormal Tpbpa spatial gene expression patterns (C3, C4, and C8; Figures 9 
and 10). I interpret these results to indicate that fetal vasculature in the labyrinth is an absolute 
requirement for fetal development. In addition, I interpret these results as evidence that that loss 
of placental Ascl2 imprinting resulting in lower expression may predispose embryonic lethality 
through abnormal JZ and LZ layer development. However, these results do not enable the 
determination as to whether the absence of fetal vasculature is the cause or effect of loss of 
imprinting in the fetus proper, extraembryonic mesoderm derived fetal vessels or trophoblast 
derived cellular subtypes. 
The parental conflict hypothesis, put forth by Haig and Moore suggests that genomic 
imprinting evolved to balance maternal health and fetal growth (411). The majority of 
mammalian species are not monogamous, therefore having multiple less taxing litters over a long 
lifetime increases maternal reproductive fitness by increasing the total number of offspring, 
whereas having vigorous fecund offspring with little regard to maternal resources and post-
nurturing maternal health increases male reproductive fitness by ensuring robust and viable 
offspring. Imprinted genes generally follow the canonical dogma of the parental conflict 
hypothesis with maternally expressed genes restricting placental and fetal growth (e.g. Phlda2, 
Igf2r) and paternally expressed genes enhancing placental and fetal growth (e.g. Igf2, Mest, 
Grb10). Based on this theory, a widespread disruption of genomic imprinting such as predicted 
in the Dnmt1Δ1o maternal effect model, should result in a broad range of placental and fetal 
weights. 
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In fact, this is exactly what was observed in DNMT1o-deficient placentas (Figures 22). 
At E12.5 DNMT1o-deficient placentas were on average growth restricted, particularly those 
associated with either non-viable or female conceptuses (Figures 5A, 6A and 7A). At E15.5 
DNMT1o-deficient placentas and fetuses were overgrown, particularly with those associated 
with either a viable or female conceptus (Figures 12A, 12B, 13A, 13B and 14A and 14B). 
However, at E17.5 only placental weight, but not fetal weight was significantly increased in 
DNMT1o-maternal effect placenta (Figures 19A, 19B, 20A, 20B, 21A and 21B). At E17.5 
placenta efficiency (E/P ratio) trended lower and showed great variation between samples 
(Figure 22). It was lowest in conceptuses associated with a non-viable fetus (Figure 22). The E/P 
ratio of wild-type samples was clustered in a tight group but in DNMT1o-deficient mutants 
formed expansive clusters segregated by fetal viability (Figures 22B and 22C). In addition, we 
found specific gene ontology pathways (i.e. oxidative stress response and lipid metabolism) that 
were altered in high and low E/P placentas and others that were specific to high E/P placenta 
(molecular transport and lipid metabolism) suggesting that loss of placental imprinting has major 
effects on placental metabolism (Figure 27). These findings were further corroborated in analysis 
of placental glycogen and lipid content in the JZ and LZ layers. A number of imprinted genes 
have been implicated in regulating placental efficiency including Igf2 (enhances efficiency) and 
Grb10 (represses efficiency) (347, 412, 413). Overall these results suggest that the balance of 
fetal and placental growth is disrupted in the Dnmt1Δ1o maternal effect partial loss of imprinting 
model. 
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2.5.2  Placental labyrinth phenotypes 
In early gestation DNMT1o-deficient placentas exhibit under development of the placenta LZ. 
At E9.5 the labyrinth marker Tfeb as well as the imprinted gene Phlda2 show a decreased and 
less convoluted labyrinth structure in the majority of DNMT1o-deficient samples (M2, M3, M4, 
M5 and M7; Figure 4). While the chorionic plate appears intact, there is poor integration of the 
EXE derived chorionic trophoblast and fetal derived vessels with the EPC, resulting in less 
definition of maternal blood spaces and diminished percolation of maternal blood. At E12.5 the 
phenotype is pronounced as evidence of the overall decrease in placental LZ central volume and 
decreased penetration and branching of fetal vessels (Figures 5B and Figure 8). The decrease in 
LZ central volume is most pronounced in female DNMT1o-deficient placentas (Figure 7B). 
These findings of an exacerbated phenotype in female DNMT1o-deficient placenta are similar to 
those made by a group led by Trasler (408). In their study a coarse scoring system was used to 
show that female placentas had reduced LZ development (408). In addition they found female 
placentas to have placental hyperplasia at E9.5 indicative of TGC proliferation (408). Many of 
the E9.5 and E12.5 DNMT1o-deficient placentas studied herein had a combination of diminished 
labyrinth development and expanded TGCs, indicating that these two phenotypes are connected. 
 Late in gestation DNMT1o-deficient placentas that lacked fetal vasculature were not 
recovered. In contrast E15.5 placentas had nearly normal LZ central volumes and E17.5 
placentas displayed a large range of LZ volume fractions that were on average slightly lower 
than wild-type. However strong qualitative differences were observed in the structure of the LZ. 
For instance, many DNMT1o-deficient placentas had engorged maternal blood spaces and 
dilated fetal vessels. Furthermore, ultrastructural SEM of DNMT1o deficient placentas, 
performed by colleagues, showed that SynT basement membrane was thickened (414). The 
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findings presented here demonstrate that loss of genomic imprinting is detrimental to both LZ 
structural development and suggest that the placental SynT development is more robust and less 
of an absolute requirement than fetal vessels in the partial absence of genomic imprints. 
In addition to the structural defects both E15.5 (not significant) and E17.5 (P<.001) had 
increased triacylglyceride content (Figures 18 and 26E). These triglycerides accumulated in 
SynT within lipid droplet organelles as seen in both LipidTOX and ORO staining (Figures 18 
and 26B-D). A broader metabolomics survey of DNMT1o-placental tissue performed by my 
colleague Katherine Himes, MD., revealed accumulation of mitochondrial metabolites (414). 
Excess carnitine derivatives in DNMT1o-deficient placentas indicated disrupted -oxidation of 
triacylglycerols. Reduced acontinase activity and accumulation of the TCA cycle intermediate 
citrate suggested mitochondrial oxidative stress. These results were interpreted as evidence that 
triacylglycerides accumulate in lipid droplets because their catabolism by -oxidation and the 
TCA cycle is blocked. In combination with ultrastructual findings that mitochondria were 
bloated, Dr. Himes has hypothesized that the mitochondria of DNMT1o-deficient placenta are 
dysfunctional. Furthermore, the transcriptional changes to molecular transport and lipid 
metabolism genes in high and low E/P placenta provide two additional lines of evidence that 
genomic imprints directly regulate fetal and placental growth through metabolic pathways 
(Figure 27). 
 The disorganized and abnormal labyrinth structure seen in DNMT1o-deficient placentas 
is similar to targeted deletions of both imprinted and non-imprinted genes. For example, Peg10, 
Ascl2 and Rtl1 genes are imprinted genes that when deleted have detrimental consequences on 
LZ placental development and embryonic survivorship. Peg10 is an imprinted gene within a 
cluster of imprinted genes on chromosome 6 (Section 1.5.5) that is expressed in many 
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trophoblast cell types. When Peg10 is paternally deleted the resulting phenotype is embryonic 
lethal at E9.5-E10.5 due to vastly diminished LZ development as well as a near complete 
absence of JZ (293). However, the connection with the DNMT1o-deficient phenotype is 
counterintuitive because loss of Peg10 DMD methylation on the maternal allele should result in 
an increase in Peg10 expression rather than a decrease. Ascl2 is a maternally expressed 
transcription factor within the Kcnq1 imprinting cluster (Section 1.4.7) that is expressed in the 
EPC, and when maternally deleted results in diminished LZ and JZ layers and an expanded TGC 
population (222). Rtl1 is a paternally expressed gene within the Dlk1 cluster (Section 1.4.13) that 
is expressed in the fetal endothelium (374). Paternal deletion of Rtl1 results in a trophoblast 
phagocytic response to invading fetal endothelium, placental infarction, and late-gestation 
growth restriction and lethality (374). Based on my results in combination with the information 
garnered from individual imprinted gene deletions it is evident that imprinted genes are 
important both for early SynT differentiation and LZ development as well as normal late 
gestation LZ integrity. 
 It is also of note that some DNMT1o-deficient placentas exhibited phenotypes similar to 
targeted deletion of Pparγ, Pparδ and Rxrα (Section 1.3.5). Deletion of Pparγ is embryonic 
lethal at E10.5 due to maternal blood space hemorrhaging and lack of fetal vasculature, two 
phenotypes commonly observed in E12.5 DNMT1o-deficient placentas (218). The Pparδ null 
model shows attenuated chorio-allantoic fusion, which is also observed in many E9.5 DNMT1o-
deficient placentas (220). Lastly, both Pparγ and Rxrα mutants display an accumulation of lipid 
droplets within the SynT (218, 221). I interpret these common phenotypes to indicate that loss of 
genomic imprinting may alter the genetic pathways vitally important for placental development 
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2.5.3  Placental junctional zone phenotypes 
Early in placental development at E9.5 and E12.5 Dnmt1Δ1o maternal effect placentas exhibited 
mosaic, patchy and sporadic SpT layers that often extended into the LZ. At E9.5 in situ 
hybridization with the SpT marker Tpbpa, and the imprinted EPC marker Ascl2 revealed that 
many placentas had decreased SpT with corresponding decreases of both markers (Figure 4). At 
E12.5 these phenotypes progressed into overt structural abnormalities. On average E12.5 
DNMT1o-deficient placentas had a diminished SpT central volume (Figure 6B). E12.5 placentas 
stained with Tpbpa showed very distinct patterns with some having minimal SpT development 
(C3 and C8; Figure 9), others having a sporadic staining patterns (C4; Figure 9), while others had 
expanded SpT with LZ extensions (C2, C6 and C7; Figure 9). The staining pattern for Tpbpa 
matched the pattern of sporadic Ascl2 (Figure 10). I interpret these results to indicate that 
reduction in Ascl2 expression, as modulated by loss of imprinting at the Kcnq1 cluster, has a 
direct impact on SpT development. However, it is also plausible that the changes in Ascl2 spatial 
expression patterns are passive secondary changes associated with abnormal SpT development 
due to loss of imprinting at other loci. 
 In mid- to late-gestation, DNMT1o-deficient placentas had either a thinner layer of SpT 
or an expanded layer of SpT with LZ extensions and accumulation of GCs (Figures 9, 15, 16 23, 
24). A transition from diminished JZ central volume at E12.5 to no difference at E15.5 to an 
increase in JZ volume fraction at E17.5 occurs in DNMT1o-deficient cohorts. This indicates that 
those DNMT1o-deficient placentas with severely diminished SpT layers either compensate 
during mid-gestation or do not survive. While some E12.5 DNMT1o-deficient placentas show 
SpT extensions into the LZ, it is much more pronounced at E15.5 and E17.5 (Figures 9, 15, 23A, 
24A-D). Both the junctional zone as well as the ectopic extensions are enriched in GCs and 
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glycogen content (Figures 16, 24E-H). There generally appears to be a correlation between GC 
enrichment and SpT volume, although this has not been quantified. These results, in combination 
with the previously discussed accumulation of lipid droplets, suggest that loss of genomic 
imprinting alters placental energy storage. 
 The diminished spongiotrophoblast observed herein is similar to phenotypes observed in  
Ascl2 and Peg10 targeted deletion models that disrupt both JZ and LZ development, indicating 
that early placental layer developent are dependent on each other (222, 293). Igf2 and Igf2p0 null 
placentas also have decreased SpT development (303). The mid- to late-gestation SpT and GC 
expansion phenotypes observed in DNMT1o-deficient placentas have similarities and differences 
with Phlda2 deletion and overexpression models (316, 317). Ablation of Phlda2 expression 
promotes placental and fetal overgrowth with excessive SpT and GCs (317). Given the endocrine 
role of spongiotrophoblast one interpretation is that expansion of this layer and increased 
glycogen stores due to loss of genomic imprinting enhances fetal growth. In contrast, 
overexpression of Phlda2 in mouse results in growth restriction with reduced SpT and GCs, 
however protrusion of SpT into the LZ, similar to that seen in the Dnmt1Δ1o maternal effect 
model does occur (316). It has been suggested by Tunster et al., that these ectopic SpT and GCs 
within the late gestation LZ are due to failure of these cells to migrate (316).  
2.5.4  Trophoblast giant cell phenotypes 
Early in development at E9.5 and E12.5 there was a marked increase in the number of P-TGCs 
found between the JZ and decidua (Figures 4 and 5C). The accumulation of P-TGCs was often 
accompanied by a lack of LZ development. However, at E15.5 and E17.5 none of the recovered 
placentas displayed an abundance of P-TGCs (data not shown). These findings suggest a 
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selection event against placentas with an overabundance of P-TGCs early in development. These 
results can also be interpreted to indicate that TGC accumulation is a common response to failing 
embryonic development and may facilitate reabsorption. The similarities to placental 
development in the absence or muted Ascl2 expression implies a direct role of this imprinted 
gene in the dysregulation of TGCs in DNMT1o-deficient placentas (222, 311). In addition, the 
accumulation of TGCs was the most prominent phenotype in Dnmt3l maternal effect placentas at 
E9.5, suggesting that this is the strongest early phenotype caused by loss of maternal imprints 
(95, 97, 99). 
2.5.5  Conclusion 
The wide range of placental phenotypes observed in DNMT1o-deficient placentas begs the 
question of what are the causative epigenetic changes that drive these abnormalities. Previous 
work in the Chaillet lab has shown that the Dnmt1Δ1o maternal effect model generates a mosaic of 
conceptuses with partial loss of genomic imprinting (60, 402), however no prior attempts to link 
these alterations with phenotypic measurements have been made. Herein I have quantified 
placental phenotypic metrics in across mid to late-gestation which will enable using quantitative 
measurement of imprinted gene expression and DMD methylation the association of specific 
phenotypes and epigenotypes. The array of distinct phenotypes ranging from early lethality to 
overgrowth, as well as specific placental layer disruptions fits in with the model in which each 
placenta of a litter has a unique set of DMDs with loss of imprinting. While it may be difficult to 
make 1:1 associations between loss of imprinted DMD methylation and placental metrics in 
order to better understand the role of genomic imprinting in placental biology. 
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My dissertation results in Chapter 2 revealed that the Dnmt1Δ1o maternal effect model produces 
varied and abnormal placentas. Previous studies, focusing primarily on the fetus, determined that 
the Dnmt1Δ1o maternal effect model generates a mosaic and partial loss of imprinting. In this 
section I have confirmed that DNMT1o-deficient placentas are also subjected to this mosaic 
partial loss of imprinting by measuring imprinted gene expression by quantititative RT-PCR, by 
allele specific DMD methylation analysis by bisulfite genomic sequencing, and by quantifying 
imprinted methylation at a broad array of DMDs using EpiTYPER-mass array technology. 
Imprinted gene expression was altered at many imprinted gene clusters examined but did not 
always fit the pattern expected to be associated with loss of DMD methylation late in gestation. 
Regression analysis revealed a direct association between Mest expression and E/P ratio, and an 
inverse association between Ascl2 expression and E/P ratio. Allele specific methylation analysis 
revealed partial loss of methylation on the normally methylated allele of the H19, Snrpn, Peg1, 
and Kcnq1 DMDs in some but not all DNMT1o-deficient placentas, and provided no evidence of 
compensatory methylation of the normally unmethylated allele. EpiTYPER DNA methylation 
analysis of 15 DMDs in E12.5, E15.5 and E17.5 DNMT1o-deficient placental cohorts revealed a 
3.0 LOSS OF GENOMIC IMPRINTING IN DNMT1o-DEFICIENT PLACENTAS IS 
ASSOCIATED WITH SPECIFIC PLACENTAL ABNORMALITIES 
3.1  SUMMARY 
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mosaic partial loss of genomic imprinting. Methylation of some imprinted DMDs, most notably 
Dlk1, was nearly normal in mid-gestation DNMT1o-deficient placentas, consistent with the 
notion that cells having lost methylation on these DMDs do not contribute significantly to 
placental development. Most imprinted DMDs however showed a wide range of methylation loss 
among DNMT1o-deficient placentas. Furthermore, I have revealed significant associations 
between strong placental phenotypes and loss of methylation at specific imprinted loci. At E12.5 
two striking associations were observed. First, loss of DNA methylation at the Peg10 imprinted 
DMD associated with decreased embryonic viability and decreased LZ volume. Second, loss of 
methylation at the Kcnq1 imprinted DMD was strongly associated with TGC expansion. I 
conclude that the Peg10 and Kcnq1 ICRs are key regulators of mid-gestation placental function. 
3.2.1  Loss of genomic imprinting in DNMT1o-deficient placentas 
The Dnmt1Δ1o maternal effect model generates offspring with a mosaic and partial loss of 
genomic imprinting due to the absence of DNMT1o maintenance methyltransferase activity 
during preimplantation development (Section 2.2 for full review). This has previously been 
confirmed at a small subset of DMDs in the embryonic (H19, Snrpn, Mest and Dlk1) and 
placental (H19 and Snrpn only) compartments. DNMT1o-deficient placentas have profoundly 
abnormal phenotypes (Section 2.3 for description). At E9.5 and E12.5 attenuated LZ 
development and TGC accumulation is common in DNMT1o-deficient placentas. Later in 
3.2  INTRODUCTION 
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gestation, at E15.5 and E17.5, SpT extensions, dilated fetal vessels, and triacylgylceride 
accumulation are prevalent features. It is of note that Dnmt1Δ1o maternal effect offspring have 
sporadic phenotypes with large variation within and between litters that is similar to the 
predicted mosaic nature of  imprinting in this model. In this chapter, I test the hypothesis that the 
wide-ranging phenotypes are associated with loss of imprinted methylation at specific DMDs in 
DNMT1o-deficient placentas. 
 Loss of genomic imprinting in the Dnmt1Δ1o maternal effect model has previously been 
validated by DNA methylation and gene expression analysis at a limited set of imprinted loci. 
Bisulfite genomic sequencing, bisulfite converted restriction analysis, and methylation Southern 
blots provided the original evidence that the Dnmt1Δ1o maternal effect model generates partial 
loss of methylation at DMDs but not other genomic loci (e.g. Iap and Line1 repetitive elements) 
(104, 402). Restriction fragment polymorphisim analysis of RT-PCR products of imprinted 
genes within the Kcnq1 cluster of Dnmt1Δ1o maternal effect trophoblast and embryo displayed 
biallelic maternally biased expression of the normally exclusively paternally expressed Kcnq1ot 
but had no effect on allelic bias of maternally expressed genes within the cluster (415). 
Quantitative RT-PCR gene expression analysis of Kcnq1ot and seven maternally expressed 
genes (Osbpl5, Phlda2, Cdkn1c, Kcnq1, Tssc4, Cd81 and Ascl2) within the Kcnq1 cluster 
revealed that in DNMT1o-deficient E10.5 trophoblast Kcnq1ot expression was increased, while 
the expression of the maternally expressed genes decreased (415). Intriguingly, despite this 
transcriptional repression, the H3K4me3 active chromatin mark levels at these maternally 
imprinted genes was not statistically altered in DNMT1o-deficient trophoblast (415). In addition, 
loss of H19, Igf2 and Snrpn imprinting has been observed in a handful of Dnmt1Δ1o maternal 
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effect placentas (402). However, transcriptional analysis of the majority of imprinted gene 
clusters has not been performed in either DNMT1o-deficient embryonic or placental lineages.  
3.2.2  Transcriptional analysis of imprinted genes 
Out of the 24 confirmed genomic imprints in mouse there are reasons to suspect at least 15 of 
them harbor imprinted genes that are integral to placental development (Section 1.5). There is 
particularly strong genetic evidence derived from targeted gene deletion mouse models for the 
involvement of imprinted genes in the Kcnq1, H19, Peg10, Mest, Grb10, Dlk1 and Igf2r clusters 
in placental developmental pathways (222, 274, 293, 302, 312, 313, 347, 374, 392). In this 
chapter, quantitative RT-PCR was used to test the hypothesis that Dnmt1Δ1o maternal effect 
placentas have loss of imprinted gene expression, with some transcripts increasing in expression 
(presumably biallelic), while others becoming fully repressed. Specifically, imprinted gene 
expression from the following clusters were analyzed: Peg10 (Peg10, Sgce and Pon2), Dlk1 
(Dlk1, Meg3, and Rtl1), H19 (H19 and Igf2), Igf2r (Igf2r and Slc22a2), Mest (Mest and Klf14), 
Kcnq1 (Phlda2 and Ascl2) and Grb10 (Grb10). 
3.2.3  Imprinted DMD methylation analysis 
The exact genomic coordinates of DMDs in oocyte and embryonic genomes are overlapping but 
significantly different, suggesting that the physical extent of differential methylation is dynamic 
during embryonic development (58). Both gametic and embryonic DMD boundaries are defined 
by biallelic methylated regions (58). It is unclear if the exact DMD coordinates in the genome of 
trophoblast lineages are closer to those in gametes or embryos. In my dissertation research I have 
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examined imprinted DNA methylation at sequences that are common to both germline and 
embryonic DMDs. Bisulfite genomic sequencing was used to confirm loss of imprinting in the 
placenta compartment. A survey of DNA methylation at 15 DMDs across gestation was 
performed using EpiTYPER technology to quantify DMD methylation at 15 different loci in 
cohorts of mid-gestation DNMT1o-deficient placentas and to correlate loss of methylation with 
placental phenotypic metrics. 
Imprinted DNA methylation patterns have been analyzed over the years using an array of 
techniques. Early studies performed methylation sensitive Southern blots that utilized 
isoschizomeric restriction enzyme pairs in which one enzyme is methylation-sensitive (e.g. 
HpaII) and the other is methylation-insensitive (e.g. MspI) and sequence specific genomic 
probes. This approach analyzes a handful of CpG dinucleotides at a time. The use of sodium 
bisulfite (NaSO4) based techniques enabled methods of DNA methylation analysis that can 
provide a readout of multiple CpGs at specific sequences (416). High sodium bisulfite 
concentrations at elevated (85°C) temperatures and low pH (5.0) deaminate unmethylated 
cytosine nucleosides to uracil (416). PCR amplification of bisulfite treated genomic DNA using 
targeted primers replicates the ribonucleoside uracil into the deoxy-ribonucleoside thymidine 
(416). These bisulfite treated DNA amplicons can be analyzed by DNA sequencing (BGS: 
bisulfite converted genomic sequencing) or by restriction analysis (COBRA: combined bisulfite 
restriction analysis) to infer the ratio of unmethylated to methylated CpG methylation by the 
amount of CT converted and unconverted product (416, 417). Both BGS and COBRA have 
their limitations: BGS requires the sequencing of many amplicons to obtain a good 
representation of the allelic population; and the COBRA assay, similar to methylation sensitive 
Southern blotting, only analyzes a handful of CpGs at a time (416, 417). 
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EpiTYPER analysis is a novel technique that provides a readout of many CpGs at a time 
from the whole allelic population of a sample (418). Ehrich and colleagues (2005) invented 
EpiTYPER DNA methylation analysis as a high-throughput bisulfite conversion based method to 
identify methylation differences of targeted sequences in normal and neoplastic lung tissue 
(418). In brief, EpiTYPER analysis is performed as follows: DNA is treated with bisulfite 
reagent; targeted genomic regions are PCR amplified using sequence specific primers with a T7 
polymerase promoter attached; ssRNA is in vitro transcribed from the bisulfite PCR amplicon 
templates; the ssRNA is then cut with a nucleotide specific RNase; and the digestion products 
are analyzed by mass spectrometry to determine the sizes of the products (which are different if 
they incorporated a C or a T) (418). This technique gives a readout of 8-25 informative mass 
spectrometry fragments containing 1-4 CpGs each across amplicons ranging from 200-800bp 
(418). 
Bisulfite converted DNA has also been used to measure genome wide methylation 
patterns using reduced representation bisulfite genomic sequencing (RRBS; a technique that cuts 
DNA with methylation insensitive MspI, and sequences 200-250bp fragments enriched in CpG 
islands) and by microarray analysis (e.g. Illumina 450k human array), however these approaches 
are not as cost efficient for detailed analysis of small sets of genomic sequences such as 
imprinted loci which represent a minute fraction of the genome (419, 420). 
3.2.4  Association of  loss of imprinting and placental phenotypes 
In the results of Chapter 2 (Section 2.3) I quantified phenotypic metrics in cohorts of mid-
gestation Dnmt1Δ1o maternal effect placentas. Herein, the DMD methylation profiles of 
individual placentas from the same DNMT1o-deficient cohorts were quantified by EpiTYPER 
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analysis. A separate cohort of E17.5 DNMT1o-deficient placentas had both phenotypic 
measurements and quantified imprinted gene expression. Linear regression was used to examine 
the relationship between E/P ratio and expression of imprinted genes in those E17.5 placentas. 
Having the phenotypic and DMD methylation data sets enabled me to test for meaningful 
phenotype-epigenotype associations. Logistic regression analysis was used to determine if fetal 
viability, a binary variable, was associated with methylation at any individual DMD. Likewise, 
linear regression analysis was used to test for meaningful associations between continuous 
placental metrics (e.g. weight, layer volumes, TGC counts and triacylglyceride content) and loss 
of methylation at specific DMDs. It was expected that only the strongest phenotype-epigenotype 
associations would emerge due to the complications of epigenetic pleiotropic and epistatic 
interactions associated with mosaic loss of DMD methylation in the Dnmt1Δ1o model. 
3.2.5  Chapter 3 aims 
In this chapter I have analyzed placental DMD methylation patterns in the Dnmt1Δ1o maternal 
effect model. This analysis aimed to confirm loss of imprinting in DNMT1o-deficient placentas 
consistent with prior observations in the embryo and limited preliminary extraembryonic 
analysis using a combination of quantitative RT-PCR and BGS. The extent of epigenetic 
mosaicism in DNMT1o-deficient placentas was probed using EpiTYPER analysis of 15 different 
DMDs. This enabled logistic regression analysis of which epigenotypes are viable and which are 
not. Ultimately, I attempted to connect loss of DNA methylation at specific DMDs to 
quantitative placental phenotypic metrics using linear regression analysis. The overarching goal 
of this section was to gain insight into the collective and individual role of genomic imprints in 
placental biology and identify those imprints most crucial for normal placental development.  
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3.3.1  DNA and RNA purification  
Genomic DNA was extracted from placenta tissues cleaned of maternal decidua contamination 
and with minimal umbilical cord and yolksac membranes. Samples were stored in RNA later 
(Sigma-Adlrich) prior to extraction. Whole (E9.5) half (E12.5), or quarter (E15.5 and E17.5) 
placenta samples weighing <30mg were minced with a razor on a glass microscope slide and 
placed in 600ml of RLT buffer pre mixed with 6ul of 2’mercaptoethanol in a 2ml 
microcentrifuge tube with homogenization microbeads, and then homogenized using two 
45second cycles with a mini-beadbeater (Biospec). Nucleic acids were then extracted using the 
DNA/RNA combined extraction mini kit (Qiagen) or the RNeasy kit (Qiagen) following the 
manufacturer’s protocols.  
3.3.2  Imprinted gene quantitative real-time RT-PCR 
Quantitative real-time reverse transcription PCR (qPCR) was carried out on purified RNA 
samples from E9.5, E12.5, E15.5 and E17.5 wild-type and DNMT1o-deficient placentas using 
the standard methods described below and gene specific primers (Appendix B). Contaminating 
DNA was digested either on column during purification (with the RNeasy kit) or using an RQ1 
RNase free DNase digest before cDNA preparation. cDNA was prepared from 1μg of RNA 
using the high capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was 
3.3  MATERIALS AND METHODS 
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performed in triplicate using SYBR Green PCR Master Mix (Applied Biosystems) in total 
reaction volume of 10μl on the 7900HT Fast Real-Time PCR machine. Dissociation curves were 
run on all reactions to ensure amplification of a single product. A control without RT (-RT) was 
run for each sample and a control without template (-template) was run for each primer set. 
Samples were analyzed using the ΔΔct method method relative to the Rpl32 housekeeping gene. 
Five wild-type placentas were analyzed at each gestational age (421).  
3.3.3  Bisulfite genomic sequencing 
Genomic bisulfite conversion was carried out using an EpiTect bisulfite conversion kit (Qiagen). 
500ng to 1μg of genomic DNA was converted based the amount extracted from each sample. 
The DNA was diluted with water to 20μl volume, and mixed with 85μl of bisulfite conversion 
mix and 35μl of DNA protect buffer. Conversion was carried out in 200μl PCR tubes using the 
following thermocycler program: 99°C 5′, 60°C 25′, 99°C 5′, 60°C 85′, 99°C 5′, 60°C 90′, 20°C 
hold. Columns and reagents provided by the EpiTect bisulfite kit were used per manufacturers 
instruction to purify converted DNA in 100μl of elution buffer. Nested bisulfite converted 
genomic PCR was used to amplify targeted DMDs (primers in Appendix C). The first round of 
nested PCR used 125ng of bisulfite converted DNA and in a 25 μl Taq Polymerase (Invitrogen) 
reaction with the following thermocycler program: Precycle: 94°C 4′, 55°C 2′ , 72°C 2′, 94°C 4′, 
55°C 2′, 72°C 2′; followed by 35 amplification cycles: 94°C 1′, 55°C 2′, 72°C 2′; and a short 
72°C 30″ extension and indefinite hold at 4°C. The second round of nested PCR was primed 
from 2.5 or 5μl of the first PCR and used a standard thermocycler program: 95°C 5′ denaturing 
followed by 35 cycles of 95°C 30″, 60°C 30″; 72°C 30″, a 72°C 7′ final extension and indefinite 
hold at 4°C. Bisulfite PCR reactions were run on 1.5% agarose gels at 80V and the appropriate 
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sized bands excised and gel purified using Qiaquick gel extraction kits (Qiagen). PCR amplicons 
were cloned using the TOPO-TA cloning kit (Invitrogen), transformed into competent E.coli 
cells, and plated onto LB + ampicillin agar plates coated with β-galactose and IPTG. 15-30 white 
opaque colonies were picked and sequenced in both directions using M3 and T7 promoter 
primers. Sequences were viewed and shortened to include only relevant genomic (and not 
plasmid) sequence and positioned in the same DNA strand orientation using CLC sequence 
viewer (CLC Bio). Bisulfite PCR amplicons from each placenta were aligned to fully converted 
DMD sequences with the Clustalomega multi-sequence alignment program and then exported to 
a text document where CG dinucleotides were underlined to easily identify converted and 
unconverted CpGs. Maternal and paternal DMD alleles were determine by use of SNPs between 
Mus musculus domesticus (maternal) and M.m castenous (paternal) strains. Results were 
transcribed into original figures in adobe illustrator. 
3.3.4  Epityper analysis 
EpiTYPER DNA methylation was used as a high-throughput bisulfite conversion based method 
to identify DMD methylation differences between wild-type and DNMT1o-deficient placentas 
(See section 3.1.3 for review). Genomic bisulfite conversion, bisulfite converted genomic PCR, 
and EpiTYPER (TM – Sequenom) mass-array DNA methylation analysis was performed at the 
Center for Genetics and Pharmacology at the Roswell Park Cancer Institute. Pre-validated 
bisulfite PCR primers for imprinted DMD genomic regions were used for the imprinted 
methylation analysis (Appendix D). All bisulfite amplcion sequences overlapped known primary 
imprinted DMDs ((26), and references therein). Bisulfite converted PCR amplification primers 
for all but H19 were chosen from a publicly available mouse imprinted panel (Sequenom). H19 
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primer sequences were originally published by McGraw et al. (2013) (408). Each EpiTYPER 
amplicon was further validated by internal control wild-type placenta DNA (50% imprinted 
DMD methylation), Dnmt1-null (Dnmt1c/c) ES cell DNA (0% imprinted DMD methylation) and 
1:2 (16.6% imprinted DMD methylation) and 2:1 (33.3% imprinted DMD methylation) mixtures 
of the two. Only amplicons that produced a linear relation between control genomic DNA 
expected and observed methylation fractions were selected for use in this study 
3.3.5  Biostatitics and bioinformatics 
EpiTYPER absolute methylation levels were calculated as the unweighted average CpG 
methylation fraction across each individual imprinted DMD amplicon. Overall imprinted DMD 
methylation was determined from 12 non-redundant DMD EpiTYPER amplicons (Appendix D) 
To determine if the wild-type and mutant sample methylation levels were normally distributed 
Kolmogorov-Smirnov, Shapiro-Wilk and Anderson-Darling tests of normality were applied to 
the data in Matlab (Mathworks). Because the mutant data were non-normally distributed we 
compared distributions using a Mann-Whitney U (Rank-Sum) test. In addition Fisher’s exact test 
was used to compare the number of low DMD methylation (less than 0.75 or 0.5 wild-type 
levels) placentas for each individual DMD across gestation. Bar graphs and scatter plots of 
overall and individual imprinted DMD methylation levels were originally generated with Matlab 
and then adapted into Adobe Illustrator. 
 To display the variability in DMD methylation intrinsic to the Dnmt1Δ1o maternal effect 
model we constructed heat maps. Mutant imprinted DMD methylation levels were normalized to 
wild-type by dividing each sample’s imprinted DMD absolute methylation fraction by the 
average wild-type methylation level for that imprinted DMD and gestational age. The relative 
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methylation levels were then log2 transformed and clustered using the clustergram function in 
Matlab. Each clustergram was adapted into a grayscale Adobe Illustrator file. 
 To associate individual placental DMD methylation defects with particular placental 
phenotypic abnormalities I performed regression analyses in Matlab. Logistic regression was 
performed to find associations between individual imprinted DMD methylation levels and the 
binary fetal viability variable. Bivariate linear regression analysis was used to associate 
imprinted DMDs with the continuous phenotypic metrics for LZ volume, JZ volume, trophoblast 
giant cell count and fetal/placental weights. Similarly, P/E ratio and aberrant imprinted gene 
expression was tested for meaningful associations using linear regression analysis. Stepwise 
forward linear regression modeling was performed to generate models that explain the Dnmt1Δ1o 
maternal effect phenotypic variation based on DNA methylation of the least number of 
significant DMDs. Phenotypes with strong associations (P<0.05) identified by bivariate 
regression were plotted against DMD methylation or imprinted gene expression. 
3.4.1  Loss of imprinted gene expression 
The epigenotypes of DNMT1o-deficient placentas showed a wide-range of loss of imprinting 
across gestation. Expression of genes from 7 imprinted loci (Peg10, Dlk1, H19, Igf2r, Mest, 
Kcnq1 and Grb10) were analyzed by qPCR with the expectation that loss of DMD methylation at 
any imprinted cluster would cause expression of some imprinted genes to increase and others to 
3.4  RESULTS 
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decrease. The observed average imprinted gene expression patterns of cohorts of DNMT1o-
deficient placentas are shown in Figure 28. The expected loss of imprinting gene expression 
patterns are displayed at the bottom of Figure 28. Abnormal imprinted gene expression patterns 
were observed by qPCR as early as E9.5 and continued through mid (E12.5 and E15.5) and late 
(E17.5) gestation. Early in gestation many imprinted genes behaved in the manner expected with 
loss of methylation at neighboring ICRs. For example, placental expression of Pon2, Igf2, Igf2r, 
Klf14 and Grb10 were down regulated in DNMT1o-deficient placentas relative to wild type at 
E9.5 (Figure 28). However, by E17.5 the expected loss of imprinted gene expression patterns 
was not as encompassing. At E17.5 DNMT1o-deficient placentas showed loss of imprinted gene 
expression within the Mest cluster congruent with expected results; with Mest expression up 
regulated and Klf14 down regulated. In contrast, within the Peg10 cluster, Sgce and Pon2 were 
up regulated in a manner incoherent with loss of Peg10 DMD methylation (Figure 28). 
Unexpected upregulation was also observed for Dlk1, Phlda2 and Ascl2 but did not reach 
significance compared to wild-type (Figure 28). This transcriptional analysis is evidence that the 
partial loss of imprinting observed in the Dnmt1Δ1o maternal effect model changes across 
gestation. 
 Linear regression was used to determine if the expression of any imprinted gene was 
associated with the E/P ratio placental efficiency metric in DNMT1o-deficient placentas. Both 
Ascl2 and Mest expression were significantly associated with E/P ratio (P<0.01; Figure 29). 
Expression of Ascl2 had an inverse association with with E/P ratio (Figure 29A), whereas 
expression of Mest had a direct association (Figure 29B). Furthermore, in multivariate linear 
regression modeling the expression of Ascl2 and Mest accounted for 82% of the variance in E/P 
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ratio. These relationships were maintained when controlling for gender (P<0.001; data not 
shown). 
3.4.2  Bisulfite genomic sequencing 
DMD methylation patterns were also disrupted in DNMT1o-deficient placentas. Allele specific 
loss of DMD methylation as measured by BGS was observed at E9.5 and E17.5 (Figures 30 and 
31). Strict parent-specific DMD methylation was observed for both paternally imprinted (H19) 
and maternally imprinted (Kcnq1, Snrpn, and Mest) DMDs in a wild-type placentas. In contrast, 
significant deviations from parent-specific methylation were observed in DMDs of all DNMT1o-
deficient placentas analyzed. For example, at E9.5 nearly complete loss of Mest DMD 
methylation was observed in all DNMT1o-deficient placentas (M1-M3; Figure 30). A large 
range of variation in the extent of methylation loss at individual DMDs was observed across 
placental samples. For example, whereas M1 showed a pattern of strict parent-specific 
methylation for the Snrpn DMD, M2 showed a near complete loss. In any individual E9.5 
placenta there was no correlation among the four different DMDs for the extent of methylation 
loss. For example, M1 showed nearly complete loss of DMD methylation of the H19 and Mest 
DMDs, yet normal methylation of the Snrpn DMD, whereas M2 showed nearly complete loss of 
DMD methylation 
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Figure 28.  Imprinted gene expression patterns in DNMT1o-deficient placentas across 
gestation. Bar graph columns show mean expression (+SEM) of 15 imprinted genes in 
DNMT1o-deficient placentas compared to wild-type (n=5). Normalization to the Rpl32 gene 
using the ΔΔct method. (n = the number of DNMT1o-deficient placentas studied). * Denotes 
significant (P<0.05) differences in expression between DNMT1o deficient and wild-type 
ascertained by Kruskal Wallis test. Expected expression changes with loss of DMD methylation 
for each imprinted gene cluster. Green up arrows indicates expected increase in expression; Red 
down arrows represent expected decreased expression. 
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Figure 29.  Linear regression of E/P Ratio and imprinted gene expression in E17.5 
DNMT1o-deficient placentas. (A) Negative association between Ascl2 expression and E/P 
ratio. (B) Positive association between Mest expression and E/P ratio. 
 
of the Mest, Kcnq1, and Snrpn DMDs, yet near normal methylation of the H19 DMD. Finally, 
there was no evidence in wild-type or in DNMT1o-deficient placentas of methylation on the 
normally unmethylated parental allele. In summation, these results indicate that DNMT1o-
deficient placentas develop as cellular epigenetic mosaics with loss of DMD methylation during 
the first half of gestation. 
 At E17.5, the type and extent of DMD methylation changes were distinct from those 
obtained from E9.5 DNMT1o-deficient placentas (Figure 31). Loss of methylation at the Snrpn 
DMD was observed at a single DNMT1o-deficient placenta (M1) whereas the Mest DMD was 
variable in all three mutants analyzed (M1-M3; Figure 31). The H19 and Kcnq1 DMDs did not 
significantly lose methylation in the 3 analyzed E17.5 DNMT1o-deficient placentas. This finding 
is notably different than the variation in loss of H19 and Kcnq1 DMD methylation observed in 
E9.5 DNMT1o-deficient placentas. There was no evidence for gain of methylation on the 
normally unmethylated allele at any of the four DMDs. Based on these results, I conclude that 
while DMD epigenetic mosaicism is found in late gestaional DNMT1o-deficent placentas, the 
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precise makeup of mosaics transforms during the second half of gestation such that it is 
uncommon to recover certain patterns of DMD methylation. 
 
 
Figure 30.  Variable loss of DMD methylation in E9.5 DNMT1o-deficient placentas. 
Bisulfite genomic sequencing of the H19, Kcnq1, Snrpn and Mest DMDs in a wild-type and 
three DNMT1o-deficient placentas. Abbreviations: M Maternal allele, P Paternal allele. Position 
of methylated CpGs are indicated as filled circles. Parantheses indicate intraquartile range. (*) 
significantly lower methylation than wild-type by Kruskal Wallis (P<0.05). 
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Figure 31.  Variable loss of DMD methylation in E17.5 DNMT1o-deficient placentas. 
Bisulfite genomic sequencing of the H19, Kcnq1, Snrpn and Mest DMDs in a wild-type and 
three DNMT1o-deficient placentas. Abbreviations: M Maternal allele, P Paternal allele. Position 
of methylated CpGs are indicated as filled circles. Parantheses indicate intraquartile range. (*) 
significantly lower methylation than wild-type by Kruskal Wallis (P<0.05). 
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3.4.3  EpiTYPER imprinted DMD methylation analysis 
 To understand the role of imprinted methylation on the wide-range of placental 
abnormalities seen in the Dnmt1Δ1o model, DNA methylation was measured at 14 imprinted 
DMDs at three times during the latter half of gestation. The average methylation fraction across 
12 non-redundant DMD EpiTYPER amplicons was calculated for both wild-type and DNMT1o-
deficient placental samples at each time point. Methylation was reduced in DNMT1o-deficient 
placentas at E12.5, E15.5 and E17.5 (Figure 32A). At E12.5 there was a significant decrease in 
the average methylation across all DMDs (P<0.001) from 0.388 for wild-type to 0.232 for 
mutant placentas.  In a collection of 23 E15.5 DNMT1o-deficient placentas, the average DMD 
methylation was 0.283, significantly lower than the wild-type average of 0.382 (P<0.001). 
Similarly in a collection of 24 E17.5 placentas average DMD methylation was 0.272, 
significantly lower than the wild-type average of 0.407 (P<0.001). There was a trend toward 
mutants approaching wild-type levels of imprinted DMD methylation levels as gestation 
progressed; average DMD methylation increased from E12.5 to E15.5 (P<0.01) and from E12.5 
to E17.5 (P<0.001) but not from E15.5 to E17.5 (not significant). These findings show that total 
DMD methylation levels in DNMT1o-deficient placentas do not remain constant across gestation 
but rather resolve to more normal levels, suggesting selection against low DMD methylation 
epigenotypes that do not support placental development and function. 
There was a large range in loss of DMD methylation at most, but not all, individual 
imprinted DMDs in DNMT1o-deficient placentas. The hypergeometric distribution was used to 
categorize DMDs as being enriched, depleted or within the expected range of loss of methylation 
(<0.75 wild-type levels) at E12.5 as compared to the total E12.5 DMD measurements. The 
Grb10, Plag1, Igf2r, Kcnq1, and H19 DMDs had a number of low methylation samples within 
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the expected range (Figures 32B-F). Other DMDs including Peg10, Peg1, Peg3, and Impact 
were hyper-variable and had a greater number of samples with low methylation values (Figures 
32G-K). A third group of DMDs was hypovariable and depleted for low methylation values, 
these included Dlk1, Nespas, and Snrpn (Figures 32L-P). Adjacent DMD amplicons were 
analyzed to confirm the hypervariable Impact and hypovariable Nespas and Dlk1 measurements. 
These findings are interpreted as evidence for early selection against loss of Nespas, Snrpn  and 
Dlk1 DMD methylation in trophoblast. 
Concomitant with the increasing average imprinted DMD methylation from E12.5 to 
E15.5 in DNMT1o-deficient placentas (Figure 32A), I observed a steady reduction in the range 
of methylation among the examined placentas for many but not all individual DMDs (Figures 
32B-P). Based on this, three distinct temporal patterns of methylation were defined by 
comparing median methylation levels across gestation for each DMD with the Rank-sum test. A 
group of five DMDs had higher average methylation at E15.5 than at E12.5 (Mest, Snrpn, 
Dlk1.A, Dlk1.B, and Nespas.B; P<0.025; Figures 32 G, L, O and P). Other DMDs had a more 
gradual increase in methylation from E12.5 to E17.5 (Peg10, H19 and Peg3; P<0.025; Figures 
32D, H and K). Five DMDs comprise a third DMD class that did not significantly change their 
average methylation across gestation in DNMT1o-deficient placentas (Igf2r, Kcnq1 Plagl1, 
Impact.A, Impact.B, Nespas.A, and Nespas.B; Figures 32B, C, F, I, J, M and N). Out of the three 
imprinted DMDS for which duplicate adjacent EpiTYPER amplicons were selected (Dlk1, 
Impact and Nespas), only Nespas showed a discordant trend with Nespas.A not differing 
between gestational cohorts and Nespas.B transitioning to higher average methylation between 
E12.5 and E15.5 (Figures 32M and N). Additionally the Grb10 DMD displayed opposing 
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changes from E12.5 to E15.5 and E15.5 to E17.5, and did not significantly differ between E12.5 
and E17.5 (Figure 32E). 
Fisher’s exact test was used to confirm these temporal patterns by comparing the number 
of low methylation placentas using a cutoff of <0.75 or <0.5 wild-type levels. These findings 
were slightly different. Using a low methylation cutoff of <0.5 wild-type the Fisher’s exact test 
revealed that Mest and Kcnq1 DMDs had significantly fewer low methylation samples at E15.5 
than at E12.5, and the Peg3 DMD had a significant gradual decrease in low methylation samples 
from E12.5 to E17.5. With a less stringent low methylation cutoff of <0.75 the Fisher’s exact test 
revealed that Nespas and Mest had a significant decrease in low methylation samples between 
E12.5 and E15.5, and Dlk1.B had a significant decrease in low methylation samples between 
E12.5 and E17.5. No significant changes were unearthed within the E15 to E17 transition using 
Fisher’s exact test with either cutoff. These results indicate selective pressure against loss of 
methylation of the Mest, Kcnq1, Nespas, Peg3 and Dlk1 DMDs during mid-gestation. 
Three additional imprinted DMDs were examined in E12.5 and E15.5 cohorts (Zrsr1, 
Nnat and Nap1l5), and only Zrsr1 had a significant difference between wild-type and the 
Dnmt1Δ1o mutant average methylation levels (Figures 32Q-S). Each of these DMDs is within a 
putative microimprinted domain (Section 1.5.1, 1.5.4 and 1.5.12; Figures 2A, D and L). In 
DNMT1o-deficient placentas Zrsr1 remained variable and did not differ between E12.5 and 
E15.5. Overall, the observed trends in DMD methylation during gestation suggest that there are 
strong biological influences blocking the loss of imprints at specific DMDs during mid-gestation. 
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Figure 32.  Imprinted DMD methylation levels in wild-type (wt) and DNMT1o-deficient 
(mt) placentas across mid gestation (E12.5, E15.5 and E17.5). (A) Bar graphs showing 
average mean and standard deviation of total imprinted DMD methylation of wt (open bars) and 
mt (filled bars) across mid-gestation. (B-S) Binned scatter plot showing individual wt and mt 
placentas across mid-gestation and the sample mean for the following imprinted DMDs: (B) 
Igf2r, (C) Kcnq1, (D) H19, (E) Grb10, (F) Plagl1, (G) Mest (H) Peg3 (I) Impact.A, (J) Impact.B, 
(K) Peg10, (L) Snrpn, (M) Nespas.A, (N) Nespas.B, (O) Dlk1.A, (P) Dlk1.B, (Q) Zrsr1, (R) 
Nnat, and (S) Nap1l5. Small brackets indicate significant differences between gestational age 
matched sample populations of wt and mt DMD methylation medians. Larger brackets indicate 
significant differences between mutant DMD methylation medians at different gestational ages. * 
(P<0.01), and **(P<0.001) denote significant differences of mutant median imprinted DMD 
methylation compared to wild type, or between gestational ages of mutant sample population by 
the Rank-sum test. DMDs are organized by hypergeometric distribution as having a number of 
low methylation samples falling within the expected range (B-F), greater than the expected range 
(G-K) or less than expected range (L-P). 
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 The spectrum of methylation among 12 DMDs for each individual E12.5 DNMT1o-
deficient placenta is displayed in the form of a heat map clustergram (Fig 33). Among the 24 
E12.5 placentas represented in this manner, the majority of placentas have a unique DMD 
methylation profile not found in other placentas, although there are a few cases of high 
similarity. For example placentas A8 and B2 have identical DMD methylation profiles. Placentas 
A4 and B5 differ only at Grb10, Kcnq1 and H19 DMDs, and placentas A3 and C1 are unique at 
only the Plagl1 DMD. Clustering of the DMDs at E12.5 indicate the genetically linked Peg10 
and Mest DMDs as well as the linked Kcnq1 and Snrpn DMDs vary in conjunction. Although 
there is a trend toward more normal DMD methylation levels at E15.5 and E17.5, each 
DNMT1o-deficient placenta at these stages still has a unique imprinted epigenotype (Figures 33 
and 34). These comparisons among placentas across the latter half of gestation point out the 
intrinsic power of the Dnmt1Δ1o maternal effect model to produce diverse and abnormal patterns 
of imprinted DMD methylation. 
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Figure 33.  Hierarchical clustering of 24 E12.5 DNMT1o-deficient placentas based on DMD 
methylation. Data is shown as the log2 transformed ratio of mt:wt DMD methylation. The heat 
map displays normally methylated DMDs as dark boxes whereas loss of methylation is indicated 
by lighter shades. The upper and side dendrograms display linkage between imprinted DMDs 
and DNMT1o-deficient samples respectively. Imprinted DMDs are labeled across the bottom 
axis. DNMT1o-deficient samples are labeled down the right hand side by cohort litter (Letters A-
C) and conceptus (Numbers 1-8).  
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Figure 34.  Hierarchical clustering of 23 E15.5 DNMT1o-deficient placentas based on DMD 
methylation. Data is shown as the log2 transformed ratio of mt:wt DMD methylation. The heat 
map displays normally methylated DMDs as dark boxes whereas loss of methylation is indicated 
by lighter shades. The upper and side dendrograms display linkage between imprinted DMDs 
and DNMT1o-deficient samples respectively. Imprinted DMDs are labeled across the bottom 
axis. DNMT1o-deficient samples are labeled down the right hand side by cohort litter (Letters A-
D) and conceptus (Numbers 1-8). 
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Figure 35.  Hierarchical clustering of 23 E17.5 DNMT1o-deficient placentas based on DMD 
methylation. Data is shown as the log2 transformed ratio of mt:wt DMD methylation. The heat 
map displays normally methylated DMDs as dark boxes whereas loss of methylation is indicated 
by lighter shades. The upper and side dendrograms display linkage between imprinted DMDs 
and DNMT1o-deficient samples respectively. Imprinted DMDs are labeled across the bottom 
axis. DNMT1o-deficient samples are labeled down the right hand side by cohort litter (Letters A-
G) and conceptus (Numbers 1-8). 
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3.4.4  Decreased fetal viability is associated with loss of Peg10 DMD methylation 
Logistic regression was used to identify those imprinted DMDs that exerted the greatest 
influence on fetal viability at E12.5 through placental imprinting (Table 3). The logistic 
regression coefficient (logit) is reported as a measure of the effect of DMD methylation levels on 
the odds ratio of fetal survival. A positive association was discovered between Peg10 DMD 
methylation and fetal viability at E12.5 (P<0.05) indicating that placentas with loss of the Peg10 
methylation imprint are less likely to support a viable fetus. A negative association between Nnat 
DMD methylation and fetal viability was observed (P<0.05). The only significant association 
identified between imprinted DMD methylation and fetal viability at either E15.5 or E17.5 was a 
negative association between Nespas.B DMD methylation and viability at E15.5 (P<0.05; Table 
3). These findings suggest that in the context of the Dnmt1Δ1o maternal effect mouse model, 
nearly normal Nnat and Nespas imprinting may decrease viability. 
 
Gestational Age DMD Logit P-Value 
E12.5 (n=24) Peg10 +2.17 3.25E-02 
 Nnat -2.49 4.12E-02 
E15.5 (n=23) Nespas.B -1.05 3.69E-02 
E17.5a (n=23)    
Table 3.  Logistic regression of E12.5, E15.5 and E17.5 DNMT1o-deficient placentas based 
on DMD methylation and fetal viability. Only significant (P<0.05) associations established by 
logistic regression analysis between dependent fetal viability and independent imprinted DMD 
methylation values are shown. The log odds ratio(logit) is the coefficient indicating the direction 
and strencth of the relationship. (a) no significant associations were found at E17.5. 
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3.4.5  Placental abnormalities are associated with loss of DMD methylation 
Because of the broader range of abnormal DMD methylation, histomorphological 
abnormalities and effects on fetal viability at E12.5 I focused primarily on phenotype-
epigenotype regression analysis at the E12.5 time point. Bivariate linear regression analysis was 
used to determine which imprinted DMDs underlie the observed E12.5 placental abnormalities. 
The most significant (P<0.05) DMD associations for each phenotype are displayed in Table 3 
and Figure 36. The regression coefficient (β) is reported as the change in phenotype associated 
with modulation of the DMD methylation fraction (0 to 1.0). Placenta weight is negatively 
associated with DMD methylation at Nespas.A (Table 4 and Figure 36A) although not at 
Nespas.B. For each 1% decrease in Nespas.A DMD methylation (0.01 methylation fraction) 
placental weight increased by a corresponding 1.275 milligrams (95% CI: 0.648, 1.902). 
Spongiotrophoblast volume was negatively associated with both analyzed Nespas regions as well 
as the H19 DMD (Table 4 and Figures 36B-D). Each 1% decrease in DMD methylation at 
Nespas.A, Nespas.B and H19 increased JZ volume by 0.0399 (95% CI: 0.0258, 0.054), 0.0266 
(95% CI: 0.035, 0.0497) and 0.0170 (95% CI: 0.0017, 0.0323) mm3 respectively. 
Linear regression analysis revealed a strong association between Peg10 DMD 
methylation and LZ volume (Table 4 and Figure 36E). Diminishment of Peg10 DMD 
methylation by 1% corresponds to a 0.0217 (95% CI: 0.002, 0.066) mm3 decrease in LZ central 
volume. Labyrinth structures in three DNMT1o-deficient placentas with low Peg10 DMD 
methylation are shown in Fig 4. Labyrinths in these samples are noticeably smaller, disorganized 
and hemorrhagic. Notably, methylation of the Nnat DMD is negatively associated with LZ 
volume (Table 4 and Figure 36F), counter to the observed trend of decreased LZ in DNMT1o-
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deficient placentas; a 1% decrease in Nnat DMD methylation resulting in a 0.0249 (95% CI: 
0.043, 0.111) mm3 increase in LZ central volume. 
 
Placental Phenotype DMD β P-Value 
Placental Weight (mg) Nespas.A -127.5 6.21E-04 
Spongiotrophoblast Central Volume (mm3) Nespas.A -3.99 1.41E-05 
 Nespas.B -2.65 3.54E-02 
 H19 -1.7 4.08E-02 
Labyrinth Central Volume (mm3) Peg10 +3.58 3.12E-02 
 Nnat -7.72 2.82E-04 
Trophoblast Giant Cell Count (#/section) Kcnq1 -508 1.87E-05 
 Snrpn -674 2.31E-04 
 Plagl1 -438 1.97E-02 
 Nespas.B -575 4.38E-02 
Table 4.  Bivariate regression analysis of 24 E12.5 DNMT1o-deficient placentas based on 
DMD methylation and placental phenotypes. Only significant (P<0.05) associations 
established by bivariate regression analysis between dependent placental phenotypes and 
independent imprinted DMD methylation values are shown. β is the linear regression coefficient.  
 
 Bivariate regression analysis revealed a significant negative association between Kcnq1 
DMD methylation and accumulation of TGCs (Table 3 and Figure 36G). A 1% decrease in 
Kcnq1 DMD methylation corresponds to an increase of 5.08 (95% CI: 3.25, 6.91) TGCs per 
histological section. Representative H&E and ISH stained histological sections of wild-type and 
DNMT1o-deficient placentas with very low Kcnq1 DMD methylation and pronounced expansion 
of parietal TGCs bordering the JZ are displayed in Figure 5. Positive ISH staining for the pan-
TGC transcripts Prl2c2 and Prl3b1 was observed in both parietal TGCs and JZ layers (Figure 5). 
Intriguingly, the early TGC marker Prolactin-1 (Prl3d1) was ectopically expressed in the parietal 
TGCs of DNMT1o deficient placentas with low Kcnq1 DMD methylation, where as it should be 
restricted to TGCs embedded within maternal spiral arteries by E12.5. 
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Figure 36.  Linear regression plots of imprinted DMD methylation versus placental 
phenotypic metrics in a cohort of E12.5 DNMT1o-deficient placentas. (A) Negative 
association between Nespas.A DMD methylation and placental weight. (B) Negative association 
between Nespas.A DMD methylation and spongiotrophoblast volume. (C) Negative association 
between Nespas.B DMD methylation and spongiotrophoblast volume. (D) Negative association 
between H19 DMD methylation and spongiotrophoblast volume. (E) Positive association 
between Peg10 DMD methylation and labyrinth volume. (F) Negative association between Nnat 
DMD methylation and labyrinth volume. (G) Negative association between Kcnq1 DMD 
methylation and TGC counts. (H) Negative association between Snrpn DMD methylation and 
TGC counts. (I) Negative association between Plagl1 DMD methylation and TGC counts. (J) 
Negative association between Nespas.B DMD methylation and TGC counts. R2 is unadjusted R-
square value. 
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Figure 37.  Histology of hematoxylin and eosin (H&E) stained labyrinth of one wild-type 
(wt) and three DNMT1o-deficient low-Peg10 DMD methylation placentas. The scale bars for 
50X, 100X and 200X magnification are 500, 200 and 100 μm respectively. Yellow lines in 50x 
and 100x magnification images outline the labyrinthine zone (LZ). 
 
 DNA methylation at the genetically linked Snrpn DMD (both Kcnq1 and Snrpn DMDs 
are on mouse chromosome 7) also inversely associated with TGC accumulation (Table 3 and 
Figure 36H). For every 1% decrease in Snrpn DMD methylation there is a corresponding 
increase of 6.74 (95% CI: 3.73, 9.75) TGCs per section. A weaker inverse association between 
both Plagl1 and Nespas.B DMD methylation and TGC number was also identified (Table 3 and 
Figures 36I and 36J). Decreases of 1% methylation at Plagl1 and Nespas.B modulate an increase 
in TGCs per section of 4.38(95% CI: 0.970, 7.79) and 5.75(95% CI: 0.500, 11.0) respectively.  
Imprinted DNA methylation at the Peg3 DMD, which like Kcnq1 and Snrpn is a maternally 
derived methylation imprint on mouse chromosome 7, was not significantly associated with TGC 
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accumulation (P=0.40). Linear regression model building confirmed the major DMD methylation 
influence of TGC accumulation to that of just the Kcnq1 and Snrpn DMDs (S2 Table). 
 
 
Figure 38.  In situ hybridization analysis of TGCs in E12.5 wild-type and DNMT1o-
deficient placentas with low Kcnq1 DMD methylation. All images were taken at 100X 
magnification. The scale bar is 100μm. Yellow lines delineate the layer containing trophoblast 
giant cells (TGCs) in the top row displays histology of hematoxylin and eosin (H&E) stained 
sections. ISH for the prolactin gene family members Prl3d1, Prl3b1 and Prl2c2 on adjacent 
sections to H&E are shown in the lower three rows. 
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Parameter Estimate SE P-Value 
Intercept +310 36.8 3.54E-08 
Kcnq1 Regression Coefficient (β) -364 109 3.11E-03 
Snrpn Regression Coefficient (β) -350 160 4.01E-02 
Table 5.  Stepwise forward linear regression analysis of associations between imprinted 
DMD methylation and TGC accumulation in E12.5 DNMT1o-deficient placentas. N=24, 
df=21, model P-value=1.54x10-5 
 
I performed bivariate linear regression to determine if there were any phenotype-
epigenotype associations at E15.5 and E17.5. Spongiotrophoblast central volume inversely 
associated with Impact.B and Mest methylation at E15.5  (P<0.05; Table 6). Each 1% decrease in 
Impact.B and Mest methylation increased JZ central volume by 0.0717 (95% CI: 0.043, 0.1004) 
and 0.0449 (95% CI: 0.0275, 0.0623) mm3 respectively. Using a relaxed significance threshold 
only three meaningful phenotype-epigenotype associations were found at E17.5 (P<0.075; Table 
7). Placental weight was positively associated with Dlk1.A methylation: each 1% decrease in 
Dlk1.A methylation corresponded to a 1.166 (95% CI: 0.591, 1.741) milligram decrease in 
placental weight. Fetal weight was associated with placental methylation at the Igf2r and Mest 
DMDs: for each 1% decrease in Igf2r and Mest methylation fetal weight decreased by 20.40 
(95% CI: 11.17, 29.63) and 16.81 (95% CI: 8.05, 25.57) milligrams respectively. 
 
Placental Phenotype DMD β P-Value 
Spongiotrophoblast Central Volume (mm3) Impact.B -7.72 1.45E-02 
 Mest -4.49 1.87E-02 
Table 6.  Bivariate Regression analysis of 21 E15.5 DNMT1o-deficient placentas based on 
DMD methylation and placental phenotypes. Only significant (P<0.05) associations 
established by bivariate regression analysis between dependent placental phenotypes and 
independent imprinted DMD methylation values are shown. β is the linear regression coefficient. 
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Placental Phenotype DMD β P-Value 
Placental Weight (mg) Dlk1.A +116 5.52E-02 
Fetal Weight (mg) Igf2r +2041 3.82E-02 
 Mest +1668 7.07E-02 
Table 7.  Bivariate regression analysis of 23 E17.5 DNMT1o-deficient placentas based on 
DMD methylation and placental phenotypes. Only significant (P<0.075) associations 
established by bivariate regression analysis between dependent placental phenotypes and 
independent imprinted DMD methylation values are shown. β is the linear regression coefficient. 
 
Linear regression analysis revealed an association between loss of Mest DMD 
methylation and triacylglyceride accumulation in E17.5 DNMT1o-deficient placentas (Figure 
29B). Mest was the only DMD that associated with lipid accumulation. In contrast to the prior 
regression analysis the methylation variable used in this regression analysis was normalized as 
the ratio of mutant:wild-type. In section 3.3.1 I showed that imprinted gene expression within the 
Mest imprinting cluster is altered at E17.5 in a manner indicative of loss of imprinting. Both 
Mest and Klf14 encode factors with functions in lipid metabolism as a putative lipid hydrolase 
and as a key metabolic transcription factor respectively. However, these results leave open the 
possibilities that loss of Mest DMD methylation causes placental lipid accumulation in a direct 
fashion through abnormal Mest and Klf14 imprinted gene expression or via an indirect 
developmental defect (e.g. poor SynT or fetal vessel development). 
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Figure 39.  Linear regression plot of Mest DMD methylation and placental triglycerides at 
E17.5. Loss of methylation at Mest is associated with elevated placental triacylglycerol 
concentrations. 
3.5.1  A broad spectrum of loss of imprinting is revealed in DNMT1o-deficient placentas 
 In the results of Chapter 3 I expected and found a large range of loss of imprinting 
between DNMT1o-placentas and individual DMDs underscoring the mosaicism of this model. 
Analysis of imprinted gene expression from 7 different imprinted loci revealed many of the 
expected patterns of loss of imprinting that yielded increased (biallelelic) or reduced (diminished 
monoallelic) expression at E12.5 (Figure 28). However, at E15.5 and to a greater extent at E17.5, 
imprinted gene expression was not as expected with certain genes behaving in unexpected and 
opposite ways (Figure 28). I reconcile these results to indicate that the primary effects of loss of 
DMD methylation in the Dnmt1Δ1o maternal effect model are manifested directly on gene 
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expression early in development, but become increasingly influenced by secondary factors such 
as trophoblast layer distribution and undefined compensatory mechanisms. In addition, novel 
associations were revealed between the expression of the Mest and Ascl2 genes with E/P ratio 
(Figure 29). DMD methylation was also highly variable but not static between gestation ages. 
My initial BGS results show variable methylation levels at all DMDs analyzed in at least some 
DNMT1o-deficient placentas at E12.5 but not for every DMD at E17.5, suggestive of an 
changing population of surviving DNMT1o-deficient placentas in late gestation in terms of both 
imprinted gene expression and DMD methylation (Figure 30 and 31). These results are further 
corroborated by EpiTYPER analysis of 14 DMDs in larger cohorts of DNMT1o-deficient mid- 
and late- placentas. 
Quantitative EpiTYPER DNA methylation analysis was used to ascribe placental 
functions for DMDs in two ways: by identifying nearly normal DMD methylation in DNMT1o-
deficient placentas; and by correlating highly variable DMD methylation with placental 
phenotypes. We expected total wild-type placental DMD methylation to be approximately 50%, 
but found the wild-type average to be just under 40% at each time point. These results are 
consistent with the slightly lower levels of DMD methylation found in control placentas than 
embryos in prior studies (408). E12.5 Wild-type placentas showed a large range of methylation 
across individual DMDs with Peg3 (32.7%) on the low end and Dlk1.A (57.7%) on the high. 
Based on the current understanding of DNMT1o action it is predicted that on average a 50% loss 
of methylation at each DMD should be observed in cohorts of DNMT1o-deficient placentas (60, 
104, 402). However, using the hyper-geometric distribution, I found that the Dlk1, Nespas and 
Snrpn DMDs were hypovariable and near normal in their methylation levels in E12.5 DNMT1o-
deficient placentas (Figures 32G-K). These findings suggest that many epigenotypes with these 
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DMDs poorly methylated may be incompatible with early trophoblast survival and/or 
proliferation resulting in selection against specific epigenotypes at the cellular and organismal 
level. 
Interrogation of the association of DMD methylation and placental phenotypes by 
regression analysis confirmed the importance of DMD methylation in placental development and 
function. Significant associations were observed between diminished imprinted methylation of 
the DMDs Peg10, Kcnq1, H19 and Nespas, and specific placental phenotypes in DNMT1o-
deficient E12.5 placentas (Tables 3, 4 and 7; Figure 36). Additional associations were found 
between the Impact.B, Mest, Dlk1, and Igf2r DMDs and placental phenotypes at E15.5 and 
E17.5 (Tables 6 and 7; Figure 39). Importantly, this approach using the Dnmt1Δ1o maternal effect 
model to gain insight into the role of imprinted genes in placental development and function is 
fundamentally different in two significant ways from genetic approaches that either inactivate 
single imprinted genes or remove ICRs. First, the Dnmt1Δ1o maternal effect model produces 
epigenetic mutant offspring with loss of DMD methylation, while retaining the genetic sequence 
of ICRs and imprinted genes. Second, the Dnmt1Δ1o maternal effect model produces broadly 
variable methylation effects across many DMDs. This permits DMD methylation to be treated as 
a continuous variable in a quantitative trait analysis, thus revealing strong associations between 
loss of methylation at particular DMDs and histo-morphological placental phenotypes. The 
recognition of these associations offers new insights into the integral role of genomic imprints on 
placenta development. 
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3.5.2  Association between Ascl2 and Mest gene expression with E/P ratio 
Overall my findings of wide-ranging E/P ratios in DNMT1o-deficient conceptuses supports the 
idea that a subset of imprinted genes is vitally important in placental function. Expression of 
Ascl2 and Mest accounts for a significant proportion of the observed variation in E/P ratio 
observed in DNMT1o-deficient offspring. There was a direct correlation between Mest 
expression and E/P ratio, and an inverse correlation between Ascl2expression and E/P ratio. 
Furthermore, Mest expression is predicted to increase with loss of methylation at the Mest DMD. 
In mouse placentas, Mest expression is limited to the fetal derived extraembryonic mesoderm 
and is most prominent in mid to late gestation placentas in the capillary endothelial cells of the 
LZ. Investigations suggest that Mest is involved in angiogenic sprouting in the LZ (275). An 
insertional disruption of the Mest gene when paternally inherited is associated with fetal and 
placental growth restriction at E18.5 of 86.4% and 87.5% respectively compared to wild-type 
(274). However, Mest null mutant placentas contained congruent LZ and JZ layers indicative a 
general growth defect rather than a disruption of a single layer. Loss of Mest DMD methylation, 
and concomitant upregulation of Mest, may thus be expected to increase the size of both embryo 
and placenta, and perhaps increase the placenta efficiency resulting an out-sized effect on fetal 
growth. It is also possible that Mest expression is a proxy for loss of imprinting of other genes 
within the Mest cluster (e.g. Cpa4, Copg2 or Klf14) that are actually the main effectors. 
Although expression of Klf14 is reduced in E17.5 placentas, no association was made between its 
expression and E/P ratio. 
 The inverse association between Ascl2 expression and E/P ratio is more difficult to 
rationalize due to the unexpected increase in average methylation levels. Taken at face value the 
expected decrease in Ascl2 expression associated with loss of Kcnq1 DMD methylation should 
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be most similar to either the Ascl2 null or hypomorphic alleles depending on how uniform the 
loss of imprinting is (222, 311). Maternally inherited deletion of Ascl2 is embryonic lethal at 
E10.5 due to excessive TGC accumulation and a lack of LZ and JZ layer development (222). 
Ascl2 hypomorphs on the other hand are viable but growth restricted with a lesser degree TGC 
expansion and diminished LZ (311). One explanation for the inverse relationship would be that 
decreased Ascl2 expression restricts placental growth disproportionately compared to fetal 
growth. However, there is also a cluster of four placental samples that have elevated Ascl2 
expression and lower E/P ratio, suggesting elevated Ascl2 expression may be indicative or 
causative of inefficient placentas. It is also plausible that Ascl2 expression is a proxy for other 
maternally expressed genes in the Kcnq1 cluster (e.g. Cdkn1c and Phlda2). Although expression 
of Phlda2 was also unexpectedly upregulated, its expression did not associate with E/P ratio. 
Intriguingly, transgenic over-expression of either Phlda2 or Cdkn1c results in placental growth 
restriction (314-316). Lastly, it is important to note that the unexpected increase in the maternally 
expressed members of the Kcnq1 cluster at E17.5 may be due to compensatory changes in 
placental layer contribution, selection for particular epigenotypes or gene expression patterns. 
3.5.3  Peg10 viability and labyrinth phenotypes 
A strong association was observed between loss of Peg10 DMD methylation and decreased fetal 
viability and LZ volume at E12.5 (Tables 3 and 4; Figure 36). Most placentas with loss of Peg10 
DMD methylation and decreased LZ volume were unable to support fetal development. I 
interpret these associations, and the gradual trend toward normal Peg10 DMD methylation levels 
from E12.5 to E17.5 (Figure 32K), as a progressive requirement for Peg10 methylation to sustain 
fetal viability during later gestation. The decreasing Peg10 DMD methylation variability and 
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lack of phenotypic association at E15.5 and E17.5 could be explained by selection against certain 
low Peg10 DMD methylation epigenotypes. The DMD methylation epigenotype of placentas 
with low Peg10 methylation at E12.5 is different than the epigenotype of placentas with low 
Peg10 DMD methylation recovered at E15.5 and E17.5 (Figures 33, 34 and 35). The 
combination of low Peg10 DMD methylation (<50% wild-type level) plus low Dlk1, Kcnq1, 
Nespas or Snrpn DMD methylation (<50% wild-type) was observed at E12.5 (samples A5, A7, 
B1 and C3; Fig 33) but does not occur in any DNMT1o-deficient placentas at either E15.5 or 
E17.5 (Figures 34 and 35). In summary, my analysis of DNMT1o-deficient placentas reveals a 
novel link between placentas with low Peg10 DMD methylation, poor LZ development and the 
inability to sustain fetal development. 
A strong linkage between Mest and Peg10 DMD methylation was found at E12.5 and 
E17.5 (Figures 34 and 35). This was expected given the proximity of the two DMDs on mouse 
chromosome 6, however Mest did not show significant associations with early placental 
phenotypes in this study. This observation does not preclude a role for Mest later in gestation, 
and in fact several associations were made between Mest DMD methylation and placental 
phenotypes at E15.5 and E17.5. An inverse association between Mest DMD methylation and 
spongiotrophoblast volume at E15.5, and a positive association between Mest and fetal weight at 
E17.5 were uncovered (Tables 6 and 7). Furthermore, regression analysis revealed a link 
between loss of Mest DMD methylation and placental lipid accumulation at E17.5 (Figure 39). I 
suggest that Mest and Peg10 DMDs may exert their influence on placental development in a 
serial manner; loss of Peg10 DMD methylation impairs LZ development early in gestation, 
which predisposes these placentas to metabolic abnormalities associated with lost Mest DMD 
methylation later in gestation. 
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The lethality and labyrinth failure in DNMT1o-deficient placentas with low Peg10 DMD 
methylation is similar to the phenotype observed in chromosome 6 translocations and Peg10 null 
mice (10, 261, 262, 293). Although the expected result of loss of Peg10 DMD methylation is 
increased Peg10 expression, I failed to detect significant changes in Peg10 expression in 
DNMT1o-deficient placentas at any time point between E9.5 and E17.5 (Figure 28). However, I 
did observe a significant increase in Sgce and Pon2 expression in late gestation DNMT1o-
deficient placentas (Figure 28). It is difficult to correlate DMD methylation with imprinted gene 
expression in Dnmt1Δ1o maternal effect placentas because of the confounding factors of a mosaic 
model, cell-type expression biases and differential effects of loss of DMD methylation. Based on 
my direct observation that partial loss of a maternally methylated Peg10 imprint is detrimental to 
placental development, I suggest that strict monoallelic dosage of Peg10, and/or other imprinted 
genes within the Peg10 imprinted cluster is critical for placental development. 
3.5.4  Loss of Kcnq1 DMD methylation and TGC expansion 
Mouse chromosome arm 7q contains three maternally methylated DMDs from proximal to distal: 
Kcnq1, Snrpn and Peg3. Not surprisingly, we found that the methylation status of the Kcnq1 and 
Snrpn DMDs was linked at E12.5 in DNMT1o-deficient placentas (Figure 33). However, Peg3 is 
situated closer to Snrpn than Kcnq1 but does not show linkage to the other two at any time point 
and is hypomethylated in DNMT1o-deficient placentas (Figure 32H and Figures 33-35). I found 
A strong association between DNA methylation at both the Kcnq1 and Snrpn DMDs and 
accumulation of TGCs (Tables 4; Figure 36). Based on our forward step-wise regression model 
the combination of DMD methylation levels of Kcnq1 and Snrpn is the best predictor of TGC 
abundance (Table 5). I speculate that the association between Snrpn methylation and TGC 
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accumulation is a passive effect due to close linkage with the Kcnq1 cluster and consistent with 
lack of known placental function for Snrpn (422), although the possibility of the involvement of 
the Snrpn in TGC development cannot be ruled out completely. The in situ staining of TGCs for 
Prl3d1 in DNMT1o-deficient placentas, an early TGC marker, indicates that not only is 
proliferation altered but also TGC differentiation (Figure 38). The morphology of DNMT1o-
deficient placentas with low Kcnq1 DMD methylation is similar to those described in null and 
hypomorphic Ascl2 mouse models in which expansion of TGCs was observed (222, 311). These 
findings are substantiated by the diminished expression of Ascl2 in DNMT1o-deficient E9.5 and 
E12.5 placentas (Figure 28).  
The accumulation of TGCs observed in the Dnmt1Δ1o maternal effect model shown herein 
is remarkably similar to placentas derived from Dnmt3L null mothers, which lack all maternal 
imprinted DMD methylation (97, 99). One mechanistic explanation of the TGC expansion that is 
common between the Dnmt1Δ1o, Dnmt3L and Ascl2 models is that a decrease in Ascl2 expression 
(by gene deletion or loss of Kcnq1 DMD methylation) results in derepression of Hand1, a 
transcription factor that promotes differentiation of the EPC, and terminal differentiation of SpT 
into TGCs (188, 231, 234). Loss of Kcnq1 DMD methylation in DNMT1o-deficient placentas 
has a distinct phenotype from paternal deletion of the Kcnq1 ICR, which mimics a maternal 
(methylated) state with resulting increased maternal expression of Ascl2, Phlda2, and Cdkn1c, 
and growth restriction (310). Regression analysis did not reveal meaningful associations between 
loss of Kcnq1 DMD methylation and placental overgrowth at E15.5 or E17.5 that might be 
expected based on targeted deletion mouse models of Phlda2 and Cdkn1c, which exhibit 
pronounced placental overgrowth (312, 313). These findings taken together with prior research 
suggest that the imprinted gene Ascl2 is a focal point for early placental development. 
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3.5.5  Loss of Nespas and H19 DMD and junctional zone development  
In addition to the effects of reduced Peg10 and Kcnq1 DMD methylation discussed above, 
regression analysis revealed weaker, but nonetheless significant, associations between loss of 
imprinted Nespas and H19 DMD methylation and increased JZ volume (Table 4, and Figures 
36B-D). Although both Nespas DMD amplicons assayed associated significantly with JZ 
expansion at E12.5 (Table 4 and Figures 36B and C), an association was not observed at E15.5 
(Table 6), indicating this phenotype may resolve to a more normal one during development. 
The observed association between loss of H19 DMD methylation and JZ expansion 
bordered the significant cutoff (P=0.048, Table 4 and Figure 36D). H19 DMD methylation 
gradually increased from E12.5 to E17.5 in DNMT1o-deficient placentas, indicating selection 
against loss of imprinting at this cluster (Figure 32D). Loss of methylation at the H19 DMD is 
expected to depress transcription of the growth factor Igf2. Expression of of Igf2 in DNMT1o-
deficient placentas was reduced at E9.5 and E12.5 but was near normal levels at E15.5 and E17.5 
(Figure 28). It is known that Igf2 is paternally expressed throughout the placenta, and that the 
placenta specific isoform (Igf2P0) is expressed exclusively in SynT (302, 303). Paternal 
inheritance of either the Igf2 null or Igf2P0 null allele results in placenta with reduced JZ volume 
(303) . Based on this knowledge one explanation for the observed trend is that 
spongiotrophoblast is less dependent on IGF2 signaling than labyrinthine cell types, and may 
increase as an early compensatory mechanism to low placental Igf2 expression. The association 
between H19 DMD methylation and JZ volume is not found at E15.5 reflecting the resolving of 
both H19 methylation levels and JZ volume toward normal levels. 
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3.5.6  No placental phenotypes associated with Dlk1, Igf2r or Grb10 DMD methylation 
At the onset of performing regression analysis I expected to find associations between imprinted 
DNA methylation at the Dlk1 DMD and LZ development, and between both the Grb10 and Igf2r 
DMDs and placental growth based on evidence from genetic models (347, 374, 393). In 
DNMT1o-deficient placentas imprinted DNA methylation at the Dlk1 DMD did not significantly 
differ from wild-type although it did increase across gestation (Figures 32O and 32P). This 
pattern is perhaps indicative of early selection against cellular epigenotypes with loss of Dlk1 
DMD methylation during trophoblast differentiation and proliferation. No associations were 
found between Dlk1 DMD methylation and placental phenotypes at E12.5 nor at E15.5, but a 
positive association between Dlk1.A methylation and placental weight at E17.5 was revealed 
(Table 7), indicating loss of Dlk1 methylation restricts placental growth. Although there was 
substantial variation in DMD methylation at the Igf2r and Grb10 DMDs (Figures 36B and 36E), 
associations between placental weight and DMD methylation were not significant for either loci 
at E12.5 and at E15. However, I discovered a positive relationship between Igf2r DMD 
methylation and fetal weight at E17.5 (Table 7), a counter intuitive finding given that loss of 
Igf2r methylation should repress expression of this growth suppressor. Regression analysis failed 
to identify DMDs responsible for the overgrowth of late gestation placentas and embryos but 
rather identified ones that promoted growth restriction. I interpret these results as evidence that 
in the context of the Dnmt1Δ1o mosaic loss of imprinting model, the mid to late gestation growth 
effects of the Grb10 and Igf2r DMDs may be obscured by epigenetic epistatic interactions with 
loss of imprinting at other prominent DMDs within both placental and embryonic compartments. 
The clinically relevant dysregulation of placental and fetal growth associated with loss of 
imprinting previously highlighted in Chapter 2 is likely due to these complex interactions 
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between imprinted regions. In contrast, the stronger associations between both Peg10 and Kcnq1 
and E12.5 placental phenotypes were not occluded by confounding epistatic effects. 
3.5.7  Zrsr1 is an imprinted DMD in placenta but Nnat and Nap1l5 are not 
We measured the DNA methylation levels of three additional imprinted DMDs (Zrsr1, Nnat and 
Nap1l5) in wild-type and DNMT1o-deficient E12.5 and E15.5 placentas (Figures 36Q-S). The 
mouse genomic coordinates for these three DMDs were previously established (26), but were not 
examined in placenta. EpiTYPER analysis showed that the Commd1 DMD was methylated at a 
level consistent with imprinting in wild-type placenta, which was then lost in DNMT1o-deficient 
placentas (Figure 36Q). Both the Nnat and Nap1l5 DMDs showed a methylation pattern that was 
not indicative of imprinted DMDs (Figure 36R and 36S). Both DMDs also had higher 
methylation levels in wild-type placentas than other imprinted DMDs tested (DMD methylation 
fraction >0.7), and furthermore, neither DMD lost methylation in DNMT1o-deficient placentas. 
We conclude that Nnat and Nap1l5 are not imprinted DMDs that are perpetuated from gametes 
to mature trophoblast lineages, and that although the Zrsr1 DMD is imprinted in the placenta, 
loss of imprinting at this locus is tolerated. Recent genome methylation studies have provided 
evidence that the Nap1l5 but not the Nnat DMD retains its imprinted status in the human 
placenta (423, 424). 
3.5.8  Conclusion 
In summary, I have validated the placental epigenetic variability inherent in the Dnmt1Δ1o 
maternal effect model using a broad survey of imprinted gene expression and DMD methylation. 
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I revealed that the expression of both Mest and Ascl2 are associated with E/P ratio at E17.5. I 
also discovered a novel association between loss of imprinting at the Peg10 loci with fetal 
viability and placental labyrinth maldevelopment. In addition, I found a strong association 
between loss of imprinting at the Kcnq1 cluster and TGC accumulation, validating prior genetic 
models. I conclude from the lack of Dlk1 DMD methylation variability at E12.5 that Dlk1 has an 
essential early trophoblast function. This chapter highlights the direct epigenetic effects of loss of 
imprinting on placenta development. My findings provide additional rationale to further dissect 
the Peg10 and Kcnq1 imprinting clusters for their roles in placental development. 
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In the previous chapter I revealed two strong associations between loss of imprinting at the Mest 
locus and placental phenotypes. First, Mest gene expression was directly associated with the 
placental efficiency metric E/P ratio. Second, Mest DMD methylation was inversely associated 
with placental triacylglyceride levels. In this chapter I sought to interrogate the role of Klf14, a 
maternally expressed gene within the Mest imprinted locus, to determine if loss of its expression 
recapitulated any of the phenotypes observed in DNMT1o-deficient placentas. To these ends I 
generated a novel targeted deletion of Klf14 in mouse. Using this new model, I confirmed that 
Klf14 is an imprinted gene expressed from the maternal allele in the placenta. Although the Klf14 
gene appears to be non-essential based on the near Mendelian inheritance observed in 
heterozygous intercrosses, there were some placental differences. Homozygous late gestation 
placentas were larger than either heterozygous or wild-type littermates, suggesting a role for 
Klf14 in limiting placental growth. No differences in placental layer fractions were observed 
between genotypes indicating that the placental overgrowth was symmetrical and not localized to 
one trophoblast cell type. In addition, placental triacylglyceride levels were unchanged in 
heterozygous intercrosses, however increased levels were observed in maternal null offspring 
4.0  KLF14 IS AN IMPRINTED GENE REGULATING PLACENTAL GROWTH  
4.1  SUMMARY 
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from homozygous null mothers fed a high fat diet. These results leave open the possibility that 
Klf14 may regulate placental growth and mediate metabolic responses to dietary inputs.  
4.2.1  Klf14 is part of the Mest imprinting cluster 
Klf14 is a paternally imprinted (maternally expressed) gene within the Mest imprinted loci at 
mouse 6qB3 (See section 1.5.3; Figure 2C). Bimaternal inheritance of Robertsonian 6q 
translocations is embryonic lethal [10]. The proximal 6q Peg10 imprinting cluster is most likely 
responsible for the lethal phenotype, whereas a more subtle intrauterine growth retardation 
phenotype is observed in embryos with bimaternal inheritance of the subproximal 6q region 
encompassing Mest (262). Epigenetic analysis of this region revealed that the Mest DMD is 
located in the promoter and exon 1 of the Mest gene and is maternally methylated (265). 
Multiple imprinted genes are regulated by the Mest DMD within a 400MB region including the 
paternally expressed Mest and the maternally expressed Copg2, Cpa4, and Klf14 (265-270). 
The Klf14 gene was first identified as a maternally expressed transcript in mouse using 
RT-PCR restriction length polymorphism analysis of offspring of JF1 and BL6 inter-strain 
crosses (270). Maternal-specific expression of Klf14 is dependent on Mest DMD methylation and 
is lost in Dnmt3anull/+ maternal effect offspring (270). Additionally, I have shown that DNMT1o-
deficient placentas show a strong reduction in Klf14 expression throughout mid-gestation (Figure 
28). Maternal-specific Klf14 expression has also been confirmed in humans by sequence 
4.2  INTRODUCTION 
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comparison of maternal and fetal Klf14 cDNAs using informative SNPs (270). Furthermore, 
human monochromosomal somatic cell hybrids with exclusively maternal or paternal 
chromosome 7 show either elevated or absent Klf14 expression respectively (270). These results 
in mouse and man demonstrate a conserved Klf14 imprinting mechanism and maternal-specific 
expression. 
4.2.2  The Mest imprinting cluster is implicated in placenta development 
In the previous chapter I uncovered four novel associations between loss of imprinting at the 
Mest locus and mid to late gestation placental phenotypes. At E15.5 Mest DMD methylation 
inversely associated with JZ central volume (Table 6). At E17.5 the placental efficiency metric 
E/P ratio is directly associated with Mest expression (Figure 29B). In addition, I found that 
methylation at the Mest DMD is positively associated with fetal weight (Table 7) and inversely 
associated with placental triacylglyceride levels (Figure 39). These results, using the Dnmt1Δ1o 
maternal effect model, suggest a role of the Mest imprinting cluster in regulating placental 
growth and metabolism. 
 The Mest gene itself is well studied, although the exact function of its encoded putative 
/ hydrolase protein is unclear (119, 266, 268, 271-276). The Mest gene is expressed in the 
vascular endothelium of the mouse placenta where it is thought to influence branching 
morphogenesis (275). When paternally inherited insertional mutagenesis of the Mest gene 
completely eliminates its expression, and results in placental growth restriction (274). These 
prior studies, corroborated by my findings in Chapter 3, suggest that Mest expression modulates 
placental and fetal growth. However, they do not fully explain the phenotypic findings of fetal 
growth restriction and labyrinth lipid accumulation in DNMT1o-deficient offspring. 
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4.2.3  KLF14 is a transcription factor regulating metabolism  
There are 17 mammalian genes encoding Krüppel-like factors (KLFs) including Klf14 (425, 
426). KLF proteins share a conserved C-terminal DNA-binding domain composed of a triad of 
C2H2 type zinc fingers. Each zinc finger is a 23-25 amino acid  peptide fold that coordinates 
a Zn2+ cation in a tetrahedral arrangement. The conserved KLF DNA-binding domains recognize 
similar CACCC or CGCCC sequence motifs and therefore may compete for DNA-binding sites 
(425). KLFs are classified into clades based on their N-terminal peptide sequences. The N-
termini of KLFs are known sites of interactions with DNA-binding cofactors. Many KLFs harbor 
CTBP binding sites whereas others have SIN3A binding motifs. KLF14 falls into the latter group 
with a putative, although biochemically unconfirmed SIN3A interacting motif (an -helical 
AA/VXXL peptide). SIN3a is a histone deacetylase repressive cofactor that acts as a multi-
domain scaffold for HDAC1/2, NCOR, SMRT, IKAROS MAD, UMA6 and other chromatin 
modulators. KLF14 is most closely related to KLF16 based on peptide sequence homology. 
Moreover, because Klf14 is an intronless gene, it has been suggested that it arose through 
retrotransposition during early protoeutherian evolution, whereby it acquired imprinting due to 
proximity of the Mest DMD (270). Intriguingly, Klf14 has undergone recent human specific 
evolution with genetic changes predominantly in the N-terminal coding region (270). 
 The Cabut KLF-like family member in Drosophila is a TGF responsive developmental 
regulator and evolutionary precursor to mammalian KLFs 9, 10, 11, 13, 14 and 16 (427, 428). 
These proteins contain a similar tripartite transcriptional regulatory domain (TRD) (428). The N-
terminal TRD1 contains SIN3A and HDAC interacting motifs whereas the more centrally 
located C-terminal contains proline rich domains that interact with WW and WD40 domain 
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containing proteins including numerous GTPases (428). The zinc finger domain, or TRD2, 
interacts with both DNA and histone acetyltransferases (428). The mammalian Cabut-related 
genes are divided into TGF inducible early growth response genes (Klf10 and Klf11) and basic 
transcription factors (Klf9, 13,14 and 16) (428). The conservation of metabolic regulation is 
exemplified by Klf11 which is mutated in maturity onset diabetes of the young (MODY7; OMIM 
610508) and neonatal diabetes (428). 
 Although Klf14 is not thought to be a TGF inducible early growth response gene it is 
involved in TGF signaling (429). In a human pancreatic epithelial cancer cell line (Panc-1) 
KLF14 and TGFRII are upregulated by exposure to TGF ligand (429). However, rapid 
upregulation of TGFRII is tempered by the delayed transcription of Klf14 in an inhibitory 
feedback circuit. Within TGF stimulated Panc-1 cells expression of a luciferase reporter driven 
by the TGFRII promoter is repressed by KLF14 bound at CG rich sequences (429). 
Furthermore, TGF stimulation increases the presence of the repressive histone modification 
H3K20me3 and decreases the amount of the active histone marks H3K9ac and H4ac at the 
endogenous TGFRII promoter (429). It was also revealed in vitro that FLAG-tagged KLF14 in 
Panc-1 cells pulls down SIN3A and HDAC2 (429). In addition, co-stimulation of Leydig cells 
with TGF and progesterone increases Klf14 expression and leads to increased KLF14 based 
activation of the endoglin gene promoter (430). The endoglin protein is a co-receptor for ALK1 a 
component of larger TGF receptor complexes (430). These two studies show that KLF14 is a 
non-canonical (i.e. non-SMAD) protein effector of TGF that has both positive and negative 
feedback on TGF signaling. They also provide direct evidence that KLF14 can function as 
either an activator or repressor of transcription. 
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 The mammalian family of KLFs have diverse physiological functions in cardiovascular, 
respiratory, digestive, hematological, and immune organ systems as well as in stem cells and 
tumor biology (425). It has recently been suggested that KLF14 is a master transcriptional 
regulator of adipose metabolism based on genome wide association studies (GWAS). Two 
separate microarray based studies utilizing human SNPs revealed strong parent-of-origin effects 
for allelic variants at rs4731702 and rs972283, roughly 14kb upstream of the KLF14 promoter, 
that are associated with increased risk of type 2 diabetes when maternally inherited (279, 281). In 
the case of rs4731702, correlations were also made to elevated HDL levels (280). Furthermore, it 
has been shown that both of these risk alleles are associated with decreased adipose expression 
of Klf14 in cis, when maternally, but not paternally inherited; thereby confirming that these 
alleles are parent-specific expressed quantitative trait loci (eQTLs) (279, 281). 
 To determine the mechanism by which the KLF14 eQTL modulates metabolic activity 
researchers looked for trans changes in gene expressions associated with rs 4731702 (282, 283). 
This approach was justified based on the assumption that KLF14 encodes a transcription factor 
that modulates expression of a network of genes. This approach identified 10 genome wide 
significant trans (GWST) parent-of-origin specific associations between rs4731702 and the 
following genes in adipose tissue: TPMT, ARSD, PRMT2, SLC7A10, C8ORF82, APH1B, NINJ2, 
KLF13, GNB1 and MYL5. Nearly all these genes were up-regulated (with SLC7A10 the lone 
exception) in conjunction with the rs4731702 risk allele suggesting that KLF14 is in fact a 
repressor at this set of genomic loci. Furthermore, amongst these 10 genes, the majority were 
independently associated with other metabolic syndrome traits in GWAS studies. The promoters 
associated with a set of 50 GWST associations with a relaxed significance threshold, were 
enriched with CACCC KLF binding motifs. These results taken together suggest that Klf14 
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expression is imprinted and that it regulates a network of genes that modulate insulin response in 
adipose tissue. With this in mind it is important to understand whether Klf14 has a similar role in 
regulating metabolism in mouse placental physiology given its high expression within the tissue, 
and to ascertain what targets it may regulate there. 
4.2.4  Recombineering is a genetic engineering technique 
I employed recombineering technology to construct a targeting vector and generate Klf14flox and 
Klf14null alleles. Recombineering utilizes bacterial strains that induce gap-repair recombination 
enzymes under certain conditions (i.e. temperature) that catalyze recombination between 
homologous 200-500bp sequences (homology boxes) enabling efficient exchange of sequences 
from one vector to another (for reviews see (431, 432)). A 13.5kb region encompassing Klf14 
and surrounding sequences was retrieved from a bacterial artificial chromosome (BAC) onto a 
plasmid adjacent to a diphtheria toxin gene (Dta). I then engineered plasmids to insert LNL and 
LFNTF cassettes to generate a targeting allele. Standard methods of ES cell transfection, 
homologous recombination, Flp electroporation, Neomycin/Ganciclovir positive/negative 
selection and blastocyst injection were used to generate a novel transgenic Klf14flox mouse line. 
This line was then crossed with Sox2:CRE transgenic females to generate a constitutive null 
allele (Klf14null). I then used this novel mouse line to study the imprinted expression profile and 
functional role of Klf14 in placental biology. Further details on the generation of this mouse line 
are provided in the material and methods (Sections 4.3.1-4.3.4). 
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4.2.5  Aims of chapter 4 
I genetically engineered a novel targeted deletion to determine if Klf14 downregulation was 
responsible for any of the placental phenotypes associated with loss of imprinting at the Mest 
loci in the Dnmt1Δ1o maternal effect model. This model was used to address important open 
questions including whether Klf14 is an essential gene that when deleted results in a lethal 
phenotype. I also examined litters of heterozygous Klf14null intercrosses at E16.5 for abnormal 
placental growth, layer development and lipid content. In addition, I attempted to provide 
absolute genetic proof of the maternal-specific expression of Klf14 in mouse placentas. These 
efforts explored the functional role of Klf14 in placenta biology. 
4.3.1  Recombineering 
Primers were designed to amplify homology boxes (HB1-6) containing unique nonrepetitive 
DNA sequences with 5′ extensions that added restriction endonuclease sites and GCGC clamps 
(Appendix E). HB1-6 were amplified from a murine 129Sv BAC containing an 80KB genomic 
contig including Klf14 (bMQ6044J02; Source Bioscience Lifesciences). HB1 primers were 
designed to amplify a region 5.5kb downstream of the Klf14 3′ UTR and added 3′ BglII and 5′ 
MluI restriction sites. HB2 primers amplified a region 4.4kb upstream of the Klf14 TSS and 
added 5′ HindIII and 3′ MluI restriction sites. Both HB1 and HB2 were cloned into the HindIII 
and BglII restriction sites in place of the PGKneo and adjacent to the PGKdta cassettes in 
4.3  MATERIALS AND METHODS 
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plasmid vector PGKneolox2DTA.2 (addgene plasmid #13449). The resulting 
PGKHB2HB1DTA.2 was linearized with MluI and used as a Klf14 retrieval plasmid. Prior to 
retrieval, E.coli strain SW106 was transfected with bMQ6044J02, selected for by 
chloramphenicol, and verified by PCR. On the day of retrieval, the bMQ6044J02 transfected 
SW106 was heat induced at 42°C and then directly co-transfected with the linearized Klf14 
retrieval plasmid. Positive recombinants were selected for by ampicillin resistance, then cloned 
and verified to contain PGKDta2 with a 13kb retrieved Klf14 region by restriction digest and 
DNA sequencing. 
Primers to generate HB3 and HB4 amplified adjacent 400bp regions centered less than 
300bp downstream from the Klf14 3′UTR and incorporated 5′BamHI and 3′ internal KpnI and 
external BssHII restriction sites for HB3, and 5′SalI and 3′HindIII restriction sites for HB4. 
Restriction digested HB3 and HB4 amplicons, derived from PCRs using BMQ6044J02 as a 
substrate, were cloned together with a BssHII and XhoI digested loxp-frt-neomycin-TK-frt-loxp 
(LFNTF) cassette and a BamHI and HindIII linearized pBluscript backbone in a quadruple 
ligation reaction. 
Primers to generate HB5 and HB6 amplified adjacent 400bp regions roughly 3kb from 
the TSS and incorporated 5′BglII and 3′KpnI restriction sites for HB3, and 5′SalI and 3′HindIII 
restriction sites for HB6. In addition, an endogenous BglII restriction site was removed from the 
3′ end of HB3. Restriction digested HB3 and HB4 amplicons derived from PCRs using 
BMQ6044J02 as a substrate were cloned together with a loxp-neomycin-loxp (LNL) cassette 
(isolated by restriction digest of by KpnI and XhoI ) and a BamHI and HindIII linearized 
pBluscript backbone in a quadruple ligation reaction. 
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 HB5-LNL-HB6 was excised from pBS with NotI and XhoI, transfected into heat induced 
SW106 cultures pre-transfected with the Klf14 positive retrieval plasmid and then plated onto 
Kanamycin/Ampicillin agar plates. Colony PCR was used to select clones with LNL inserted 
into the correct region upstream of Klf14 within the retrieval plasmid, and then subcloned to 
ensure a single Klf14 positive retrieval plasmid with a LNL cassette. The neomycin cassette of 
the LNL was then removed by transfection into SW106 arabinose inducible strain followed by 
ampicillin selection, and confirmation by HB5/6 PCR and lack of Kanamycin resistant colonies. 
Electrocompetent heat induced PGK-Klf14-5′loxp-Dta.2 transformed SW106 were transfected 
with linearized HB3LFNTFHB4 and plated onto dual Kanamycin/Ampicillin agar plates and 
subcloned to individual single vector colonies harboring the primary Klf14 targeting plasmid. 
The Klf14 targeting construct was confirmed by restriction digest analysis and full sequence 
coverage of the plasmid. To confirm the LFNTF cassette and Klf14 gene could be deleted, the 
targeting construct was transfected into SW106 with arabinose induced FLP and SW105 with 
arabinose induced CRE respectively. Recombineering plasmid maps are shown in Figure 40 for 
clarity. 
4.3.2  Transfection and selection of ESCs 
30μg of the Klf14 targeting construct was linearized by NotI and electroporated into murine J1 
ESCs using standard protocols (30μg of pDNA) and plated at various dilutions on irradiated 
murine fibroblasts. After 48 hours, positive selection with G418 was initiated to eliminate non 
recombinant ESCs. Within 7-10 days individual colonies were picked and plated onto 96-well 
plates which were then passaged into 24-well plates after 70% confluence was observed. 
Homologous recombinants were screened by Southern blot using 5′ and 3′ probes external to the 
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targeting construct in conjunction with BglII and KpnI digests (Section 4.3.4). The LFNTF 
cassette was deleted (leaving behind a loxp site and ~100bp of additional sequence) by transient 
transfection of a Flp recombinase plasmid. Colonies surviving ganciclovir negative selection 
were determined to have deletion of the Neo-TK selectable marker, which was confirmed by 
PCR and ScaI based Southern digest.  
4.3.3  Mouse colony establishment and CRE induced deletion 
All mice were humanely cared for in adherence to IACUC guidelines at the University of 
Pittsburgh. Mouse 129Sv ESCs heterozygous for the Klf14flox allele were injected into wild-type 
B6 blastocysts. Male chimeric offspring were bred with B6 females to test whether recombinant 
ESCs had been incorporated in the germline which manifests as yielding agouti offspring in 
those crosses. Agouti offspring were then genotyped for the presence of the Klf14flox allele. Male 
heterozygous Klf14flox offspring were mated to Sox2:CRE transgene positive females and the 
resultant offspring were screened for the combined presence of Sox2:CRE (via PCR), and null 
alleles (via ScaI Southern and PCR). The Klf14flox and Klf14null alleles, once established in mice, 
were backcrossed as heterozgotes for greater than five generations to both 129Sv and C57BL/6 
(Taconic) strains prior to use in experiments. 
4.3.4  Klf14 genotyping 
Southern blot genotyping was carried out using standard protocols utilizing agarose gel 
electrophoresis, capillary based transfer in alkaline buffer to charged nylon membranes, and 
hybridization with P32 radiolableled DNA probes.  Primers that amplified probe templates from 
189 
 
bMQ6044J02 are shown in Appendix E. Probes were generated using random hexamer primed 
Klenow fragment polymerase based PCR with a nucleotide mixture with radiolableled cytosine 
(Perkin Elmer). Southern blots were exposed to X-ray film from 2hrs to 2 weeks depending on 
signal strength. Homologous recombinant ESCs were identified by Southern blotting using 10μg 
of genomic DNA digested with BglII, run on a 0.7%gel and probed with an external 5′ probe 
(Klf14wt band of 4kb and Klf14targ of 9.4kb). Incorporation of the 3′ targeting region was 
confirmed with a KpnI digest and 3′ external probe (Klf14wt band of 16.1kb and Klf14targ of 
13.3kb). ScaI digestion and 5′ probes showed deletion of the PGKneo-tk marker (Klf14wt and 
Klf14flox bands of 11kb and Klf14targ band of 12.7kb). Floxed alleles were confirmed by Southern 
blotting of BglII digests with an external 5′ probe (Klf14wt band of 4kb and Klf14flox band of 
9.2kb). Null alleles were distinguished from wild-type and floxed alleles by Southern blot of 
ScaI digested genomic DNA with an external 5′ probe (Klf14wt and Klf14flox bands of 11kb and 
Klf14null band of 6kb).  
Klf14 floxed, null and wild-type alleles were also genotyped by semi-nested PCR using 
primers abutting homology boxes 4, 5 and 6 (Appendix A) using 350ng of genomic DNA and 
the following thermocycler program: 95°C 5′ denaturing followed by 35 cycles of 95°C 30″, 
60°C 30″, 72°C 30″, a 72°C 7′ final extension and an indefinite hold at 4°C. PCR products were 
run on a 1.5% agarose gel to look for the presence of 200bp (Klf14wt), 300bp (Klf14flox) and 
400bp (Klf14null) alleles. Sox2:CRE transgenes were also genotyped by PCR using primers 
provided by the Barak lab (Appendix E) 
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4.3.5  RT-PCR 
Nucleic acids were isolated using All-Prep or RNeasy kits (Qiagen) as previously described from 
fresh placental tissues, and other embryonic and adult tissues isolated by microdissection. Prior 
to reverse transcription, RNA was treated with RQ1 DNase for 1h to remove genomic 
contaminants. Reverse transcription was carried out using MMLV-RT (Promega) from 
approximately 500ng to 1ug of RNA template oligo dT primers. RT-PCR of Klf14 was 
performed using Taq polymerase, approximately 200ng, and primers previously reporter by 
Parker-Katiraee et al. ((270) ; Appendix B )). The housekeeping gene Gapdh was used as a 
positive control.  The RT-PCR themocycle was the following: 95°C 5′ denaturing followed by 30 
cycles of 95°C 30″, 60°C 30″, 72°C 60″, a 72°C 7′ final extension and an indefinite hold at 4°C. 
PCR products were run on a 2.0% agarose gel and examined for the presence of an 800bp Klf14 
band. 
4.3.6  Mest DMD methylation analysis 
The methylation status of the Mest DMD in wild-type and null placentas was examined by BGS 
and COBRA assays. Bisulfite genome conversion and PCR of wild-type and Klf14null placental 
DNA was carried out as previously described using the same reagents and nested primers 
(Section 3.3.3, Appendix C). The BstBI restriction enzyme was utilized to cut 1ug of bisulfite 
converted Mest PCR amplicon in order to examine for the presence of unconverted (methylated) 
sites within the Mest DMD. Bisulfite genomic sequencing of the same populations of alleles and 
generation of dot-pot figures was performed as previously described (Section 3.3.3). 
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4.3.7  Embyronic and placental analysis 
Placental analysis focused on the offspring of heterozygous Klf14null intercrosses. Dissections 
were performed at E17.5 in the same manner as previously described (Section 2.3.3). Placenta 
and embryonic wet weights were recorded. Half of each placenta was preserved for cryo-
histology as described earlier (Section 2.3.4). Portions of the remaining half were taken for 
genotyping, gene expression or lipid content analysis. Placental triacylglyeride content was 
measured as previously described (Section 2.3.6). Placental layer fractions were determined 
using the ratio of the average JZ and LZ area determined by random grid sampling of a single 
central placental section for each sample. Comparisons were made between wild-type, 
heterozygous and null placentas using students t-test and/or Rank-sum tests.   
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Figure 40.  Recombineering plasmids.  (A) Plasmid used to retrieve 13.5Kb region around 
Klf14 from bMQ6044J02. (B) Plasmid used to place 3′ LFNTF selectable marker on the targeting 
construct. (C) Plasmid used to place a 5′ LNL selectable marker on the targeting construct.′   
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4.4.1  Confirmation of Klf14 null allele 
I engineered a novel targeting construct using recombineering to produce a targeted deletion of 
Klf14 in mice (Figure 41A). Chimeric floxed allele mice were initially generated by blastocyst 
injection of 129Sv strain homologous recombinant ESCs into wild-type B6 blastocysts. Chimeric 
male offspring were crossed with B6 females and screened for passage of the agouti fur color 
trait indicating germline passage of the recombinant J1 ESCs. Offspring were then screened for 
the presence of a Klf14flox allele by Southern blot consisting of a BglII restriction digest and an 
external 5′ probe (Figure 41B). The wild-type BglII band is 4.9kb whereas the floxed allele is 
9.2kb (Figure 41B). Full incorporation of the targeting construct was confirmed by Southern blot 
with KpnI digestion and an external 3′ probe to differentiate the 16.1kb wild-type allele and 
the13.2 kb floxed allele (Data not shown). Confirmed heterozygous Klf14flox males were mated 
to Sox2:CRE transgenic females to generate Klf14null heterozygous offspring (Figure 41A). The 
presence of a Klf14null allele was confirmed by Southern blot with ScaI restriction digest and the 
same external 5′ probe. The wild-type ScaI band is 11kb whereas the null allele is 6kb (Figure 
41C). Semi-nested genomic PCR was used to assess genotyping of offspring as both the floxed 
and null alleles were backcrossed onto inbred 129Sv and B6 mouse strains. Using this strategy, 
the wild-type allele amplified a 200bp band from primer pairs b and c, whereas the floxed allele 
generated a 300bp doublet from primer pairs b and c, and the null allele generated a 400bp 
4.4  RESULTS 
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fragment from primers a and c (Figure 41D). These genotyping results clearly show the 
generation and stable inheritance of floxed and null Klf14 alleles. 
 
 
Figure 41.  Targeted deletion of Klf14 in mice. (A) Design and targeting of Klf14. (B) 
Southern blot confirming floxed allele in mice. (C) Southern blot confirming null allele in mice. 
(D) Genotyping PCR confirming flox and null alleles in mouse. Key: rectangles represent gene 
elements Klf14 gene, PGK-neomycin-thymidine kinase cassette, PGK-diptheria toxin cassette; 
triangles represent loxp sites Abbreviations: S-ScalI, B-BglII, K-KpnI, N-NotI; a,b and c- semi-
nested PCR primers. Scale bar is 1kb.  
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4.4.2  Klf14 is an imprinted gene expressed in the placenta 
I measured Klf14 expression in an array of fetal and adult tissues by RT-PCR and found that 
expression levels were highest in yolk sac, fetal intestine and placenta and to a lesser degree in 
fetal brain, fetal liver, adult kidney and adult heart. However, Klf14 expression was not detected 
in adult spleen, adult liver and homozygous null placenta (Figure 42A). Next, I sought to 
genetically confirm reports that Klf14 expression is exclusively from the maternal allele in the 
mouse placenta. To these ends I compared expression of Klf14 in wild-type (Klf14+/+), maternal 
null (Klf14null/+,), paternal null (Klf14+/null), and homozygous null (Klf14null/null) placentas using 
RT-PCR. Half of the offspring from heterozygous null dams crossed to wild-type males were 
Klf14null/+ and had no detectable expression of Kl1f14 after 35 RT-PCR cycles, and were 
queivalent in placental Klf14 gene expression to that of Klf14null/null placentas derived from 
offspring of interbred heterozygotes (Figure 42A). Expression of Klf14 in Klf14+/null placentas on 
the other hand were observed to be at or near Klf14+/+ levels. These results provide definitive 
proof that Klf14 is a maternally expressed gene within the mouse placenta. 
 To determine whether imprinting at the Mest DMD was altered in Klf14null/null placentas I 
assayed DNA methylation by COBRA and BGS. Bisulfite conversion and PCR amplification of 
a 550bp region of the Mest DMD yields two BstBI restriction sites, however if CT conversion 
is blocked by DNA methylation these sites will not be generated. Approximately half of the 
bisulfite PCR product in Klf14+/+ samples was undigested by BstBI, indicating roughly 50% 
methylation. Similar results were found in Klf14null/null placentas suggesting no changes in Mest 
DMD methylation in Klf14null transgenic placenta. However nearly all amplicons recovered from 
Dnmt1c/c ESCs were undigested by BstBI, indicative of the low methylation state of these cells. 
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Figure 42.  Klf14 is expressed in the mouse placenta and is an imprinted gene. (A) RT-PCR 
based expression assay for Klf14 in an array of fetal (Fe) and adult (Ad) tissues as well as 
extraembryonic tissue including homozygous null placenta. (B) Expression of Klf14 in wild-
type, heterozygous null and homozygous null E16.6 placentas. NTC-no template control. 
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 I confirmed the COBRA assays by sequencing 16 cloned bisulfite converted PCR 
amplicons of the Mest DMD from Klf14+/+ and Klf14null/null placentas (Figure 43A). Wild-type 
samples revealed the expected pattern of containing both fully methylated and fully 
unmethylated alleles. The average wild-type methylation value was 57.6%. Homozygous null 
placentas showed a similar pattern of Mest DMD methylation with both fully methylated and 
completely unmethylated alleles. The average Mest DMD CpG methylation in Klf14null/null 
placentas was 54.6%. These results further confirm that Mest DMD methylation is not altered by 
deletion of Klf14 
Due to the tissue specific expression patterns of Klf14 and the location of a CGI 
overlapping the Klf14 transcriptional start site and 5′-end of the gene I hypothesized that there 
may be tissue specific methylation at this region. The EagI and MluI CpG methylation sensitive 
restriction enzymes have unique restriction sites within the Klf14 coding region (Figure 43C). 
The EagI site falls within the CGI whereas the MluI site falls 3′ of it. Genomic DNA from an 
array of wild-type tissues was digested with ScaI in combination with either MluI or EagI, and 
probed with a 5′ internal radioprobe. The fetal liver was the only tissue in which partial digestion 
was observed in the ScaI-EagI double digest indicating partial methylation of the CGGCCG EagI 
CGI site (Figure 43C). Partial digestion was observed in genomic DNA derived from placental 
and adult liver samples suggesting partial methylation of the ACGCGT restriction sequence 
within the Klf14 gene body (Figure 43C). I interpret these results as evidence that the Klf14 CGI 
and gene body are generally hypomethylated but may have some tissue specific DNA 
methylation patterns  
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Figure 43.  DNA methylation at the Mest DMD is normal in homozygous Klf14 null 
placentas. (A) Mest DMD COBRA assay. (B) Mest DMD bisulfite genomice sequencing of 16 
wild-type and Klf14null/null alleles. (C) Methylation-sensitive Southern blotting of the Klf14 CGI 
and gene body. Abbreviations B-BstBI, S-ScaI, E-EagI, M-MluI.  
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4.4.3  Klf14 null mice are viable and fertile 
Heterozygous null mice were both viable and fertile regardless of sex, strain background or 
parent-of-origin of the Klf14 null allele. The offspring of heterozygous intercrosses were found 
to contain wild-type, heterozygous null and homozygous null genotypes at near mendelian 1:2:1 
frequency (Tables 8 and 9, Chi-square test P>0.05). Moreover, homozygous null mice of both 
sexes were viable and fertile on 129Sv and B6 strains. No differences were observed in the 
growth curves of wild-type, heterozygous and homozygous null littermates from weaning 
through postnatal day 90 (Data not shown). These results suggest that Klf14 is not essential for 
murine development or reproduction, but do not rule out more sublte developmental or metabolic 
defects in null mice. Therefore, it was still important to determine if any abnormalities were 
present in developing Klf14 null placentas. 
 
Genotype Obs Exp  Genotype Obs Exp 
Wild-type 37 27  Female Wild-type 18 13.5 
Heterozygous Null 50 54  Female Heterozygous Null 26 27 
Homozygous Null 21 27  Female Homozygous Null 11 13.5 
Total 108 108  Male Wild-type 19 13.5 
Chi-Square (df = 2) 5.33 (P>0.05)  Male Heterozygous Null 24 27 
    Male Homozygous Null 10 13.5 
    Total 108 108 
    Chi-Square (df = 5) 5.48 (P>0.05) 
Table 8.  Near Mendelian inheritance of the Klf14 null allele in 129Sv strain heterozygous 
intercrosses. (Left) Chi-square analysis without gender influence. (Right) Chi-square analysis 
including gender. Abbreviations: Obs, Observed; Exp, Expected; df, degrees freedom; P, P-
value. 
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Genotype Obs Exp  Genotype Obs Exp 
Wild-type 20 16.5  Female Wild-type 8 8.25 
Heterozygous Null 29 33  Female Heterozygous Null 18 16.5 
Homozygous Null 18 16.5  Female Homozygous Null 9 8.25 
Total 66 66  Male Wild-type 13 8.25 
Chi-Square (df = 2) 1.36 (P>0.05)  Male Heterozygous Null 11 16.5 
    Male Homozygous Null 8 8.25 
    Total 66 66 
    Chi-Square (df = 5) 4.79 (P>0.05) 
Table 9.  Near Mendelian inheritance of the Klf14 null allele in B6 strain heterozygous 
intercrosses. (Left) Chi-square analysis without gender influence. (Right) Chi-square analysis 
including gender. Abbreviations: Obs, Observed; Exp, Expected; df, degrees freedom; P, P-
value. 
 
4.4.4  Overgrowth in homozygous Klf14 null placentas 
Even though homozygous Klf14 null animals were viable and fertile we examine E17.5 litters to 
determine if there were any growth effects on either heterozygous or homozygous null embryos 
and placentas. Average placental and fetal weights from wild-type and mutant offspring from 
litters of heterozygous Klf14 null intercrosses are displayed in Figure 44. Homozygous null 
placentas were approximately 10% heavier than wild-type littermates (P<0.05; Figure 44A). The 
intermediate phenotype observed in heterozygous Klf14 null placenta is most likely due to equal 
distributions of Klf14+/null and Klf14null/+ that either had a functional or non-functional Klf14. 
Although the standard error of the mean (SEM) placenta weight is lower in heterozygotes than 
either wild-type or homozygous null littermates the standard error (uncorrected for sample size) 
is larger in heterozygotes. No difference in fetal weights was observed between genotypes from 
these crosses (Figure 44). 
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 To determine whether there was an imprinting effect on placental development in 
heterozygous offspring I analyzed E17.5 litters of Klf14null/+ mated to wild-type 129Sv males. 
Average placental and fetal weights from wild-type and Klf14-/+ offspring are shown in Figure 
45. The maternal null placentas were significantly heavier than wild-type littermates (P<0.05; 
Figure 45A). These results are interpreted as evidence rejecting a role for Klf14 within the 
mother from influencing placental size. Rather the data suggest loss of active maternal Klf14 in 
offspring autonomously enhances fetal growth. Similar to the offspring of heterozygous 
intercrosses no significant difference in fetal weights was detected in the offspring of Klf14null/+ 
dams (Figure 45B). 
 
 
Figure 44.  E17.5 Placental and fetal weights in offspring of heterozygous Klf14 null 
intercrosses. (A) Wet placental weight of wild-type (wt, n=17), heterozygous (het, n=43) and 
homozygous null (hom, n=12) littermates (B) Corresponding fetal weights (C) Placental layer 
fractions *P<0.05 2-way Students T-Test.  
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Figure 45.  E17.5 Placental and fetal weights in offspring of maternal Klf14 null dams. (A) 
Wet placental weight of wild-type (wt, n=9), and maternal null heterozygous (het, n=10) 
littermates (B) Corresponding fetal weights (C) Placental layer fractions *P<0.05 2-way Students 
T-Test. 
 
4.4.5  Placenta layer structure in Klf14 null placentas 
I chose to further investigate the placental overgrowth phenotype using histological methods in 
order to determine if there were any structural abnormalities. The LZ and JZ layer fractions of 
homozygous and heterozygous Klf14 null placentas from heterozygous intercrosses were not 
significantly different from wild-type littermates (44C). These results indicate that the observed 
placental overgrowth is evenly distributed between layers rather than attributable to expansion of 
either JZ or LZ. 
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4.4.6  Placental lipid content increased by high fat diet in Klf14 null placentas 
In the prior chapter loss of imprinting at the Mest cluster was determined to be associated with 
increased lipid content in the Dnmt1Δ1o maternal effect model. Therefore, it was important to 
determine if the increased placenta weight in the Klf14 null model was due to lipid accumulation. 
However, I observed no difference in placental triacylglyceride concentrations in wild-type and 
Klf14-/- placentas (Figure 46). I challenged wild-type and Klf14-/- females with a high fat diet 
(HFD) for 6-weeks prior to and then during pregnancy to determine if placental lipid content was 
contingent on diet. Placentas recovered from pregnant Klf14-/- females challenged with HFD 
were significantly higher than those from wild-type dams fed with normal chow (Figure 46). 
However, no difference was found in wild-type litters fed with HFD nor was there a significant 
difference between offspring of Klf14-/- females compared with wild-type HFD offspring. These 
preliminary data suggest Klf14 may regulate placental lipids in the context of HFD. 
 
Figure 46.  Lipid Accumulation in Klf14 null offspring. Comparison of litters from wild-type 
and homozygous null females fed either normal or high fat diet (HFD) chow. *P<0.05 2-tailed 
Students T-Test  
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4.5.1  Opposing effects of Klf14 and Mest on placental growth 
The results presented in this section that show Klf14 influences placental growth suggest that its 
loss of expression in the DNMT1o-deficient model may be in part responsible for the 
associations between loss of imprinting at the Mest cluster and placental phenotypes. In 
DNMT1o-deficient placentas the expression of Klf14 is decreased more than 2-fold at E9.5, 
E15.5 and E17.5 whereas Mest expression is increased significantly only at the two later time 
points (Figure 28). Although the reciprocal changes in Klf14 and Mest were concomitant, only 
Mest was identified by linear regression as associated with DNMT1o-deficient placental 
efficiency suggesting that Mest is either a marker of highly vascularized efficient placentas or 
that loss of imprinting of Mest influences the ratio of fetal and placental weight. Although fetal 
growth was unaffected in Klf14 null mice, the E/P placental efficiency ratio was not significantly 
decreased despite the moderate placenta overgrowth (data not shown). Congruent placental and 
fetal growth restriction is observed in mice with a paternally inherited Mest null allele (274). 
Therefore, it is expected, although unconfirmed, that Mest overexpression would increase 
placental and fetal growth evenly. Based on my results regarding the Klf14 null and the 
aforementioned Mest null model it is likely that the collective loss of imprinting at the Mest 
cluster integrates disparately towards fetal overgrowth. My results also show that Klf14 and Mest 
have opposing influences on placental growth.   
4.5  DISCUSSION 
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 In Chapter 3 I revealed novel associations between loss of Mest DMD methylation and 
accumulation of spongiotrophoblast at E15.5, and accumulation of placental triacylglycerides at 
E17.5. The latter phenotype is particularly relevant given my findings in this section that 
placental lipid accumulation occurred in offspring of homozygous null Klf14 females maintained 
on HFD during and six weeks prior to pregnancy. However, the lipid accumulation in DNMT1o-
deficient placentas was more pronounced and occurred without HFD administration. I interpret 
these results to indicate that mosaic loss of DMD methylation in the context of Mest DMD 
hypomethylation and HFD in the context of maternal Klf14null development are insults to 
placental metabolism that result in excess lipid deposition. Based on my research herein, a 
further investigation into the role of genes within the Mest imprinting cluster with a focus on 
Klf14 and Mest in fetal endothelial, syncytiotrophoblast and adipose lipid metabolism is 
warranted. 
 Klf14 null mice did not recapitulate the altered layer development observed in DNMT1o-
deficient placentas. Despite the increase in spongiotrophoblast associated with loss of Mest 
DMD methylation in DNMT1o-deficient placentas I did not observe any changes in SpT layer 
fraction in E16.5 homozygous null placentas compared to littermates. Similarly, no difference in 
placental structure was observed in the growth restricted Mest null placentas. This suggests that 
either another gene within the Mest cluster was responsible for this phenotype or that epistatic 
interactions within the Mest loci or between the Mest loci and other clusters. Previously it has 
been pointed out that the components of the H19, Grb10, Kcnq1 and Plagl1 clusters are involved 
in SpT development and are part of a larger integrated network of imprinted genes to which 
Klf14 and Mest may belong. 
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4.5.2  Placental and maternal influence on metabolism 
Placental function and maternal environment during prenatal development has strong influences 
on the lifelong health of individuals. The association between adult metabolic disease and SNPs 
upstream of Klf14 could be mediated by long lasting effects due to either maternal Klf14 
susceptibility alleles in either mother or placenta. Therefore, it was particularly of interest that 
homozygous null Klf14 females when fed HFD had offspring with placentas enriched in 
triacylglycerides. These results show that Klf14 may modulate lipid metabolism in pregnant 
females in a way that alters placental lipid deposition. This is exemplary of environmental 
influences being integrated through a genetic pathway. Further studies should be performed to 
validate my findings using a greater sample number of wild-type and homozygous Klf14 null 
females. In addition, it would be interesting to determine if heterozygous maternal null or 
paternal null (i.e. Klf14null/+ or Klf14+/null) dams mated to wild-type males and fed HFD also yield 
increased placenta triacylglycerides in either wild-type or heterozygous offspring. Such a study 
would confirm that placental triacylglyceride accumulation is the result of HFD plus maternal 
Klf14 deletion or provide evidence that the phenotype is caused by HFD plus placental Klf14 
deletion. Lastly, it might be interesting to perform a uterine transfer of wild-type embryos into 
homozygous Klf14 null females to verify that lipid accumulation occurs independent of offspring 
genotype. 
4.5.3  Comparison with other targeted Klf14 models 
During the time I was investigating the role of Klf14 in placenta biology three different groups 
published reports on the effects of Klf14 deletion in mouse (433-435). However, none of these 
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studies examined in utero fetal or placental development. These three groups utilized different 
targeted deletion models and examined diverse facets of mouse biology influenced by Klf14 
ranging from sphingosine-1-phosphate signaling in the liver, hepatic cholesterol metabolism, and 
centromere amplification (433-435). The fact that each of these groups published findings on 
homozygous Klf14 null mice confirms my finding that Klf14 is not an essential gene. 
 A group from the Mayo clinic utilized a neomycin insertion-deletion mouse available 
from the KOMP repository at UC Davis in their study of hepatic sphingosine kinase-1 (Sk1) 
transcriptional regulation (435). Using a luciferase assay this group observed that FGF2/FGFR1 
induced Sk1 promoter activity is dependent on GC rich sequences overlying KLF14 binding sites 
(435). They found that in HUVEC cells that Klf14 siRNA reduces FGF2 stimulated Sk1 
expression, whereas Klf14 overexpression increases basal and FGF2 stimulated Sk1 expression 
(435). They also showed that KLF14 dependent FGF2 stimulation resulted in accumulation of 
activating histone marks (increased H4K8ac and H3K14ac) and a decrease in repressive marks 
(decreased H3k9me3 and H3K27me) at the Sk1 promoter (435). Furthermore, they showed that 
epitope tagged KLF14 binds the endogenous Sk1 promoter and interacts directly with the histone 
acetyltransferase p300 (435). This study provides firm genetic proof that KLF14 is a 
transcriptional regulator that can interact with more than just SIN3A, and is a mediator of FGF2 
signaling.  
 Following up on the role of Klf14 in liver a second group generated a liver-specific 
conditional null by mating a floxed Klf14 allele with an Albumin:CRE mouse (433). They 
initially became interested in Klf14 due to the GWAS studies linking it to T2D and HDL levels 
and their preliminary findings that Klf14 expression is decreased in HFD fed wild-type mice, 
Apoe null coronary heart disease mouse model and in the leptin deficient (ob/ob) murine obesity 
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model (433). Overexpression of Klf14 by adenoviral infection in vivo resulted in increased HDL-
C and APO-A1 (433). Hepatocyte in vitro adenoviral induced Klf14 overexpression showed a 
clear increase in ApoA1 transcription that was dependent on two CACCC boxes bound by Klf14 
within the ApoA1 promoter (433). Furthermore, Klf14 expression was increased in perhexaline 
treated Apoe homozygous null mice and partially rescued the cardiac plaque phenotype in a 
manner independent of carnitine palmitoyltransferase1 inhibition by perhexaline (433). These 
results are particularly interesting given my findings that placentas derived from homozygous 
null Klf14 dams are more susceptible to lipid accumulation. In addition, it was noted in 
DNMT1o-deficient placentas that mitochondrial carnitine efflux was highly distorted (414).  
A third Klf14 null model was developed using TALON zinc finger nucleases (434). This 
group became interested in Klf14 when they discovered that it encodes a transcription factor that 
binds to and represses polo-like kinase-4 (Plk4) (434). It has previously been established that 
overexpression of Plk4 induces centrosome amplification (434). They found that 13-14 month 
old homozygous Klf14 null mice had more frequent tumors of the lung, lymph and spleen than 
wild-type (434). Homozygous Klf14 null mice were also more susceptible to azoxymethane 
chemically induced colon tumors (434). They established homozygous Klf14 null murine 
embryonic fibroblast cultures and found that roughly 12% of cells were polyploid. Additionally, 
they found that siRNA knockdown of Klf14 in HeLa cells resulted in increased Plk4 expression, 
centrosome amplification and misaligned metaphase plates, whereas Klf14 overexpression 
provoked mitotic catastrophe (434). These results may in part explain why imprinting of Klf14 is 
beneficial due to hazards of overexpression While I did not find any evidence of tumors in my 
Klf14 null colony, I did not observe them beyond 9 months. 
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In Chapter 2 I described an array of abnormal placental phenotypes present in the Dnmt1Δ1o 
maternal effect offspring. Early in development trophoblast differentiation was severely 
disrupted leading to diminished LZ development and increased TGC abundance. Many of the 
abnormal placentas found at E12.5 could not support a viable fetus and lacked fetal vasculature 
in the placental labyrinth. The phenotypes in late gestation DNMT1o-placentas were very 
different. Although at E15.5 placental layers were not significantly different than wt, by E17.5 
the fraction of JZ relative to LZ was increased. I observed extensions of SpT into the LZ in many 
E15.5 and E17.5 DNMT1o-deficient placentas. I also found that DNMT1o-deficient placentas 
recovered at E15.5 and E17.5 were enriched in glycogen deposits and lipid droplets. At E17.5 
the ratio of fetal and placenta growth was highly dysregulated and revealed that both high and 
low E/P ratio placentas had unique gene expression profiles. Taken together these results 
demonstrate the strong effects on placenta development that occur in the the Dnmt1Δ1o maternal 
effect model. 
 In Chapter 3 I described the breadth of loss of imprinting in DNMT1o-deficient placentas 
and correlated these molecular changes with placental abnormalities. In DNMT1o-deficient 
placenta imprinted gene expression was disrupted across gestation. At later gestational ages the 
5.0  OVERALL DISCUSSION 
5.1  SUMMARY AND SIGNIFICANCE 
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directionality of imprinted gene expression changes was not always congruent with the changes 
expected with loss of DMD methylation. Novel associations between Mest and Ascl2 expression 
levels and E/P ratio were revealed. A broad survey of 15 imprinted DMDs in DNMT1o-deficient 
placentas confirmed the epigenetic mosaicism previously postulated to occur in this model. 
DMD methylation was higher in the E17.5 than E12.5 placental cohorts suggesting selection 
against certain hypomethylated epigenotypes. In addition, methylation at some DMDs (e.g. Dlk1 
and Nespas) appeared less mutable than others. Ultimately, I used regression analysis to reveal 
novel associations between individual DMDs and placental phenotypes. Amongst the more 
notable associations were: a relationship between loss of Peg10 DMD methylation and both 
reduced fetal viability and diminished labyrinth central volume at E12.5; a relationship between 
loss of Kcnq1 DMD methylation and TGC accumulation at E12.5; and a relationship between 
loss of Mest DMD methylation and triacylglyceride accumulation at E17.5. These results provide 
an impetus to further dissect these three imprinting clusters for roles in placental development. 
 In my final results section, Chapter 4, I focused on the generation and study of a novel 
targeted deletion of the imprinted Klf14 gene. I used this model to confirm previous assertions 
that Klf14 is an imprinted gene expressed in the placenta. Although Klf14 null mice were viable 
and fertile even in homozygous genotypes, I observed changes in the placenta. Both homozygous 
conceuptuses from heterozygous intercrosses, and heterozygous conceptuses from homozygous 
maternal null dams had significantly heavier placentas at E17.5 than wild-type littermates. In 
addition, placentas from homozygous null dams fed HFD were enriched in lipids. These results 
suggest a role for Klf14 in regulating placental growth and metabolism and highlight the need for 
further investigation of this model. 
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The results presented within my dissertation significantly add to the scientific 
understanding of the role of genomic imprints in placental development. In characterizing the 
range of phenotypic and molecular abnormalities seen in DNMT1o-deficient placentas I have 
explicitly demonstrated that disruption of the inheritance of genomic imprinting has direct 
biological effects on trophoblast differentiation and metabolism and the balance of placental and 
fetal growth. Using this data, I was able to reveal novel associations between individual 
imprinted DMDs and specific placental phenotypes. This analysis revealed particular importance 
of the Kcnq1, Peg10, and Mest imprinting clusters for placental development. This study 
demonstrates the feasibility and importance of epigenotype-phenotype association studies. 
Lastly, my work developing and studying the imprinted Klf14 gene revealed its role in regulating 
placental growth. My findings are summarized in Figure 47 demonstrate that mosaic loss of 
imprinting in the Dnmt1Δ1o maternal effect model lead to placental abnormalities, some of which 
can be replicated by deletion of Klf14.  
 
Figure 47.  Dissertation summary model. The Dnmt1Δ1o maternal effect model results in partial 
and mosaic loss of genomic imprinting early in embryonic development. This influences 
abnormal placental development at early and late gestational time points resultin in specific 
phenotypes. Deletion of the Klf14 gene also results in late gestation placenta overgrowth and 
when confronted with high fat diet increases lipid stores. 
 
Dnmt1Δ10
Mosaic
Loss of Imprinting
Placental Abnormalities
Early: SpT and Lz maldevelopment, TGC accumulation
Late: E/P ratio, Pl overgrowth, Glycogen and Lipid content
Klf14null HFD
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5.2.1  Coevolution of genomic imprinting and placentation 
Genomic imprinting is a fascinating molecular phenomenon that has co-evolved with 
mammalian placentation. It is of note that prototheria (monotremes), metatheria (marsupials) and 
eutherian (placental mammals) have an increasing number of genomic imprints and reliance on 
in utero gestation (436). Furthermore, the boundaries of imprinted clusters are expanded to 
impose parent-of-origin specific expression to additional neighboring genes in extraembryonic 
tissues including the placenta and vitelline yolk sac (307, 309). For example, in extraembryonic 
tissues the Igf2R imprinted cluster includes Slc22a1 and Slc22a3, the Kcnq1 imprinted cluster 
includes Th, Ascl2, Tspan32, Nap1l4, and Osbpl5, the Peg10 imprinted cluster includes Tfpi2, 
Ppp1r9a, Pon2 and Pon3, the H19 imprinted cluster includes Ins2 and the Grb10 cluster inclues 
Cobl (307, 309). The mechanisms by which this expansion occurs may have to do with unique 
nuclear architecture and chromatin topology in extraembryonic lineages that enable long distance 
interactions of ICs with expanded sets of imprinted genes and distant enhancers and repressors 
(437). Revealing the full scope of genomic imprinting within the placenta and the mechanisms 
that enable the expansion of imprinting boundaries will aide in the effort to ascribe placental 
functions to imprinted loci. 
 By understanding the evolutionary history of genomic imprinting we should be better 
equipped to understand the function of genomic imprints in mammalian biology. Therefore, I 
5.2  FUTURE DIRECTIONS 
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think it is important to better grasp what placental physiological adaptations coincide with the 
acquisition of specific imprints. For example, the H19 imprint (and paternal allele-specific Igf2 
expression) originated in the common ancestor of metatherian and eutherians possibly reflecting 
the changes in maternal/offspring resource allocation with the evolutionary acquisition of 
placentation (438-440). Peg10 (but neither Sgce nor Ppp1r9a) and Mest are also imprinted in 
metatherians, but members of the Snrpn, Kcnq1 and Dlk1 cluster are not, suggesting the former 
are involved in early placentation while the latter are involved in eutherian-specific phenomena 
such as prolonged in utero development (441, 442). Furthermore, the Impact and Zrsr1 imprints 
are specific to rodents (442). Intriguingly, strict IGF2R allele specific expression has been lost in 
primates, despite retention of imprinted IGF2R DMD methylation, perhaps indicative of changes 
in placental and fetal growth and maternal resource allocation in extended gestation of single 
conceptuses (383, 439). It is interesting to question whether the relaxation of Igf2r imprinting 
was due to a different adaptation to limit its expression, or changes in the threshold of IGF2 
signaling, or to differences in the recognition of imprints in primates versus other mammals. The 
answers to these questions and more should help us understand our own genome and aid in the 
era of genomic medicine 
The expansion of imprinted clusters to regulate additional genes in murine 
extraembryonic lineages is not conserved in humans. For example, in humans, the Igf2r DMD is 
maternally imprinted but expression of IGF2R, SLC22A2 and SLC22A3 is polymorphic and only 
imprinted in some but not all human term placentas (383). The expanded placenta-specific 
imprinting within the Kcnq1 cluster is also lost in humans resulting in only the core KCNQ1 
cluster (KCNQ1ot, KCNQ1, PHLDA2 and CDKN1C) and not the centromeric (NAP1/4 and 
OSBPL5) nor telomeric (CD81, TSPAN32 and ASCL2) adjacent genes retaining monoallelic 
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expression in trophoblast cells in vivo and in vitro (383, 443). Similarly, the extraembryonic 
paternally imprinted X chromosome inactivation phenomenon found in rodents is not conserved 
in humans, rather random inactivation analogous to the embryo proper occurs (444). The 
commonality of extraembryonic imprinted X-chromosome inactivation and expanded 
extraembryonic imprinted clusters processes suggests a co-evolution of an extraembryonic-
specific imprinting mechanism that was lost during human evolution (436). The possibility of a 
mechanism involving ncRNA and repressive histone modifications that spread imprinting 
beyond core loci is particularly attractive (436). 
There are three theories that explain how genomic imprinting arose during evolution 
(440). Each one postulates in its own way a selective advantage to the inheritance of parent-of-
origin specific epigenetic information (440). The most prominent theory is the kinship theory in 
which a conflict of interest over maximizing reproductive fitness in maternal and paternal 
genomes exists (411, 440). In this paradigm the maternally inherited genome will be most 
successful if there are a large number of siblings across multiple litters from the same mother and 
favors an allocation of maternal resources that limits fetal growth so that it is not an impedance 
on future litters (411, 440). Paternally inherited genomes, particularly in non-monogamous 
mammals such as mice, maximize reproductive fitness by producing large vigorous offspring at 
the expense of future litters from the mother (411, 440). The kinship theory thus predicts and is 
validated by the fact that paternally expressed genes promote growth (e.g. Igf2, Peg1), whereas 
maternally expressed genes restrict growth (e.g. Grb10, Phlda2, Cdkn1c, Igf2r) (440). However, 
kinship theory is contradicted by the findings that many paternal UPDs result in growth 
restriction and/or embryonic lethality (261). Another argument against kinship theory is that it 
invokes a teleological argument that animates maternal and paternal genomes to selfishly direct 
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their own evolution towards different reproductive strategies. Theoretically, it is in the best 
interest of the species as a whole to have a balance of intra-litter and inter-litter fecundity to 
maximize species vitality. 
 The ovarian bomb theory is an alternative explanation to the evolution of genomic 
imprints (445). The central tenet to this theory is that genomic imprinting arose to prevent 
parthenogenetic oocyte activation from producing viable conceptuses or invasive trophoblastic 
diseases (i.e. ovarian teratomas) (445). This would limit trophoblastic disease to those derived 
from pregnancy (i.e. choriocarcinomas and molar pregnancies) (445). Like kinship theory, the 
ovarian bomb theory predicts that maternally expressed genes are growth limiting, and paternally 
expressed genes are growth promoting in order to overcome limitations the maternal genome has 
to promote growth (445). While this theory limits active selection to those genes involved in 
trophoblast development it does allow for new imprints to be acquired as passengers due to 
proximity or sequence similarity (445). 
The authors of both the kinship and ovarian bomb theories focus entirely on the function 
of maternally and paternally expressed genes rather than the genomic imprints (i.e. DMD 
methylation) per se because the maternal imprints (e.g. Kcnq1, Grb10, and Igf2r) associate with 
expression of maternal genes and paternal imprints (e.g. H19) associate with expression of 
paternal genes often through indirect ncRNA or secondary epigenetic mechanisms. The 
evolution of maternal genomic imprints may have had as much to do with silencing of repressive 
ncRNAs (e.g. Kcnq1ot) than with the maternally expressed genes themselves. Similarly, the H19 
and Dlk1 paternal imprints may have formed to silence the H19 and Meg3 ncRNAs rather than to 
promote the neighboring paternally expressed genes. I suggest that it may be more informative to 
ask how DMD methylation itself influences life history strategies to determine how genomic 
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imprints evolved. My results showed that loss of the maternal Kcnq1 imprint was associated with 
TGC accumulation which in many ways looks like hydatidiform molar trophoblastic disease. 
This evidence fits the ovarian bomb theory better than the kinship theory. However, loss of the 
Peg10 maternal imprint in DNMT1o-deficient mice results in diminished LZ development and 
fetal lethality, a result that neither the kinship nor ovarian bomb theory can adequately explain, 
suggesting that both theories may be too rigid. 
 A third theory on the evolution of genomic imprints suggests that haploid (monoallelic) 
expression enables rapid gene evolution (446). This theory is not mutually exclusive with the 
prior two. It is generally accepted among biologists that one of the benefits of diploid genomes is 
the robustness imparted by having two copies of each gene. However, when one allele is masked 
it can be mutated in compound fashion and bypass recessive lethal intermediates by not being 
expressed for multiple generations (446). In fact, it has been determined that many imprinted 
genes, including Klf14, are undergoing rapid evolution (270). It is also of note, although 
somewhat circumstantial, that most tissue-specific imprinted genes are either involved in 
placenta or the brain, the two fastest evolving organs in mammals (447). 
 Regardless of how genomic imprints initially evolved and what their selective fitness 
benefits are, they are clearly involved in reproductive isolation (448). In deer mice (Peromyscus) 
hybrids of Peromyscus maniculatus and P. polionotus have reciprocal parent-of origin effects 
(448-451). In crosses of  P.maniculatus females with P. polionotus males offspring are viable but 
growth restricted and their JZ is reduced at E13 (449-451). In contrast, the reciprocal cross of P. 
polionotus females with P.maniculatus males are overgrown and dysmorphic with altered E/P 
ratio and disorganized hemorrhaging labyrinth (449-451). These overgrown mice have abnormal 
imprinting at the Peg3, Mest, Snrpn, H19 and Plagl1 imprinting clusters (450, 451). It has been 
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suggested due to the broad nature of loss of imprinting that there is a maternal effect locus 
(possibly Dnmt1o or Dnmt3l) responsible for the interspecific hybrid phenotypes (450). 
Furthermore, the placental dysplasia resulting from loss of imprinting is the main reason for the 
reproductive isolation of these two species (448). One explanation for these findings of 
incomplete loss of imprinting is that a differential expression difference in DNMT1o protein and 
interacting maternal/zygotic partners (e.g. DMAP1 or ZFP57) in the two species when interbred 
do not reach a sufficient threshold to maintain more sensitive imprints. 
 Many imprinted genes arose through retrotransposition. This mechanism generates new 
genes by reverse transcribing mRNA and integrating the resulting cDNA into the genome at a 
new site. This process is mediated by LTRs that flank transposable elements and are recognized 
by retroviral transposases. Essentially, these gene duplications events enabled the evolution of 
novel functions and/or or expression profiles. There are three classes of imprinted 
retrotransposed genes. The first class are transposed copies or endogenous retroviral genes 
(ERVs) that have been coopted to serve unique mammalian function (e.g. Peg10, Rtl1) (289, 
290, 373). A second class of retrotransposed imprinted gene were derived from X-chromosome 
parent genes and inserted within introns of host genes (e.g. Nap1l5 and Zrsr1) (452). A third 
class of retrotransposed imprinted gene as exemplified by Klf14 are intronless transposed copies 
of autosomal genes (270). Each of these types of imprinted genes acquired imprinting following 
transposition. 
Both Peg10 and Rtl1 are copies of a Ty3/gypsy retrotransposon most similar to the Sushi-
ichi retrotransposon family found in other vertebrates (289, 290). Of the 9 mammalian Sushi-like 
retrotransponons 5 are located on the X chromosome, 2 are imprinted and 2 are autosomal non-
imprinted (289). It is likely that Peg10 initiated the formation of an imprinted loci to block its 
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expression after transposition, although the Peg10 DMD sequence does not have homology to 
other Sushi-ichi family members (289). The Peg10 locus is present in eutherian and marsupial 
mammals but not in monotremes further suggesting a link with placental evolution (453). Rtl1 
does contain a CGI, however there is no evidence of parent-specific methylation (289). Rtl1 
retrotransposition was an ancestral event to the acquisition of the intergenic DMD regulating the 
Dlk1 cluster and insertion of miRNAs and snoRNAs in eutherians (368). 
Retrotransposition of Nap1l5 and Zrsr1 resulted in novel micro imprinted domains that 
imposed parent-of-origin transcriptional effects on their host genes (454). The rodent-specific 
retrotransposition of Zrsr1 led to direct imprinting of Commd1. In the case of Nap1l5 
retrotransposition resulted in imprinted allele-specific polyadenylation of Herc3. The Nnat 
microimprinted domain is similar in structure to Nap1l5 and Zrsr1, and imprints its host gene 
Bclap. No ancestral gene has been identified, although a Nnat pseudogene exists on mouse 
chromosome 7 (239, 454, 455). It is perhaps not coincidental that alternative polyadenylation and 
transcriptional interference that occurs in these less complicated imprinted domains also occurs 
in the larger Kcnq1, Mest, and Igf2r domains. These findings on microimprinted domains have 
been interpreted as suggesting that such retrotranspositon events may have been the impetus for 
the earliest genomic imprints in eutherian development. My results showed that the Nnat, 
Nap1l5, and Zrsr1 DMDs are approximately 40- 60% methylated in wild-type placentas which is 
in line with expected levels of a genomic imprint (Figures 32 Q-S). However, only the Zrsr1 
DMD had significant loss of methylation in DNMT1o-deficient placentas indicating that the 
Nnat and Nap1l5 DMDs are either insensitive to loss of preimplantation maintenance 
methyltransferase activity or that they are absolutely required for TE development. 
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The final class of retrotransposed imprinted genes are copies of autosomal parent genes. 
For example, Klf14 most likely acquired imprinting status upon its transposition in proximity of 
Mest, which may have been beneficial to limit the dosage of the ancestral gene product Klf16 and 
enable its rapid evolution (270). Furthermore, retrotransposition of other genes have been vital to 
placental development in particular the syncytins SynA and SynB were coopted from viral 
envelope proteins to enable cell fusion of SynT progenitors within the labyrinth (210, 211). The 
syncytin 5′ LTR sequences are promoters dynamically regulated by DNA methylation in the 
human placenta (456). 
 It is also of note that species specific ERVs, or portions of their LTRs, are present in the 
promoters of many trophoblast expressed genes. These ERV promoters are enriched in binding 
sites for the placenta master transcriptional regulators ELF5, CDX2 and EOMES (457). These 
findings suggest a relationship between intergenic ERV transposition and adoption of trophoblast 
specific expression in mammalian genomes. It is clear from the above findings that 
retrotransposition had a strong impact on the evolution of both placentation and genomic 
imprinting. The placenta is a suitable target for live retroviruses and ERVs as it enables direct 
passage between generations as well as enabling horizontal transfer from heterozygous 
individuals to littermates in utero (458). In addition, the placenta may provide access to germline 
integration (458). ERVs once established would be maintained by positive selection if they were 
coopted to unique functions, efficiently silenced or genetically degraded (458). 
Retrotranspostition may be a key in the evolution of genomic imprinting because DNA 
methylation evolved as host genome defense mechanism used to silence transposable elements 
(459, 460). While not all imprinted loci contain transposed elements it is possible they are 
recognized by the same methylation machinery due to sequence similarities. It is still unclear 
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how imprinted DMDs, unlike the majority of the genome (including most ERVs), escape erasure 
and de novo DNA methylation during reprogramming. 
5.2.2  Imprint-like sequences 
Recently, imprint-like sequences that convey heritable epigenetic information from parental 
gametes have been identified. Methylation at these regions are similar to imprints in that they 
acquire parent-specific methylation patterns and are protected from DNA demethylation during 
preimplantation development. Much of the evidence of imprint-like sequences comes from the 
study of TET-off Dnmt1 cell culture model of early perimplantation development (110, 111). In 
the TET-off system addition of tetracycline reduces genomic DNA methylation in ES cells 
within days of tetracycline application, however DNA methylation is also lost at imprinted 
DMDs (110, 111). After removal of tetracycline, genomic DNA methylation gradually recovers 
due to the combined activity of de novo and DNMT1 methyltransferase activity. However, 
genomic imprints and a larger group of imprint-like sequences do not recover DNA methylation 
to prior levels (111). Among 90 genomic loci that have greater than 80% reduction in DNA 
methylation following transient DNMT1 inactivation in ESCs as measured by RRBS 15 are 
imprinted loci and the remainder are imprint-like sequences (111). Zfp787 is one imprint-like 
gene previously identified as a transient maternal DMD using the Dnmt3l maternal effect model 
(98). Zfp787 is maternally imprinted in gametes and is protected from preimplantation 
demethylation, but acquires paternal methylation methylation at implantation such that 
embryonic livers are biallelically methylated by E9.5 (98). Unfortunately, the Zfp787 DMD 
methylation status has not been determined in any extraembryonic lineage. A number of other 
221 
 
loci were co-identified in the TET-off and Dnmt3l maternal effect models but have not been 
further validated as imprinted DMDs or transient DMDs (98, 111). 
DNA methylation at a limited set of these imprint-like sequence was measured in 
DNMT1o-deficient embryos and placentas to determine if the loci identified in the TET-off 
system are similarly effected by loss of maintenance methyltransferase activity during early 
reprogramming events (111). Many of these loci showed partial loss of methylation in both 
compartments (e.g. Rnf216, Bbs9, Stk10 and Zfp676) while others showed loss of methylation 
only in the placenta (e.g. Xlr4a, Xlr4b, and Prdm1) or in the embryo (1700018B08rik) (111). 
This may indicate that the epigenetic status of some transient DMDs are inherited exclusively in 
embryonic or extraembryonic lineages while others are perpetuated in all lineages and are likely 
true DMDs. Intriguingly, Prdm1 is a transcriptional repressor that is critical for differentiation of 
SpA-TGCs (461). I propose to identify the full set of imprinted DMDs and imprint-like 
sequences that is disrupted in Dnmt1Δ1o maternal effect offspring (both fetal and placenta tissues) 
using a global DNA methylation analysis method such as RRBS. This data may even be used to 
determine if any of the imprint-like sequences associate with placental phenotypes. 
5.2.3  Role of placenta in imprinting disorders 
It was my hope that some of my dissertation results would shed light on human imprinting 
disorders. Many imprinting disorders alter prenatal and/or postnatal growth rates. For example, 
BWS manifests as overgrowth and sometimes occurs with placentomegaly (114). This syndrome 
can have epigenetic etiologies based on loss of methylation of the Kcnq1 DMD and gain of 
methylation of the H19 DMD (114). My results showed a correlation with loss of Ascl2 
expression in DNMT1o-deficient placentas and increased E/P ratio suggesting loss of imprinting 
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within the Kcnq1 cluster may increase placental efficiency in late gestation (Figure 29A). It was 
also intriguing that late gestation expression of both Ascl2 and Phlda2 was increased in 
DNMT1o-deficient placentas, as opposed to the decrease of expression expected with loss of 
Kcnq1DMD methylation, suggesting compensatory mechanisms that may alter late gestation loss 
of imprinting expression profiles and fetal and placental growth trajectories. I observed a strong 
correlation between loss of Kcnq1 methylation and TGC accumulation during mid-gestation was 
made (Table 4 and 36G). and it would be interesting to determine if the abundance of the 
analogous extravillous cytotrophoblast in BWS cases is altered. 
The SRS growth restriction clinical phenotype is due to loss of methylation at the H19 
DMD in the majority of cases and due to matUP7 or gain of Mest DMD methylation in a 
minority of cases (125, 130). I showed that loss of maintenance methyltransferase activity in 
DNMT1o-deficient conceptuses results in mosaic loss of Igf2 expression in the placental 
compartment (Figures 4 and 28). However, I did not find an association between H19 DMD 
methylation with either placental or fetal weight. I did however find an association between loss 
of H19 DMD methylation and JZ layer development at E12.5 (Table 4). In addition, higher E/P 
ratio was associated with increased Mest expression and loss of Mest DMD methylation was 
associated with placental lipid accumulation (Figures 29B and 39). These results in combination 
with the placental overgrowth phenotype observed in the Klf14 deletion (Figures 44A and 45A) 
suggest that the Mest cluster is involved in the growth phenotype of matUPD7 SRS cases where 
one would expect increased genetic dosage of Klf14 and decreased Mest expression. It would 
certainly be worthwhile to examine SRS associated placentas for changes in cytotrophoblast 
histology and in sycytiotrophoblast lipid content. 
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 The imprinting diseases PHPIa and Ib are caused by loss of imprinting at the Nespas and 
Gnas locus (148). I was intrigued to find that the Nespas DMD methylation was largely 
immutable in DNMT1o-deficient placenta, perhaps suggesting a developmental requirement 
(Figures 32M and 32N). While the placenta takes on some functions of thyroid and kidney 
during prenatal development it remains unclear what if any function the imprinted genes in this 
cluster do in the placenta. I revealed a positive association between loss of Nespas DMD 
methylation and spongiotrophoblast at E12.5 (Table 4). 
 Similarly, no known placental functions for the PWS/AS loci containing the SNRPN 
imprinting cluster have been described. My results using stepwise linear regression modeling 
suggest that both Kcnq1 and Snrpn are informative to predicting TGC accumulation (Table 5). 
Although it is possible that the Snrpn association is due to close linkage with Kcnq1 it may be 
informative to examine placentas associated with PWS/AS for abnormal extravillous trophoblast 
proliferation. Recently it has been shown that snoRNAs from the Snrpn cluster regulate 
alternative splicing of the serotonin receptor 5Htr2c, and separately that the placenta is a 
transient source of serotonin during early forebrain development (324, 462-464). I conjecture 
based on those two lines of evidence that the SNRPN cluster may regulate serotonin levels during 
prenatal development and be altered in PWS/AS conceptuses. It would be interesting to examine 
fetal and placental serotonin receptor isoform expression and serotonin levels in DNMT1o-
deficient offspring (with loss of Snrpn DMD methylation) and in Snrpn locus targeted mutation 
models (e.g. Snrpn DMD deletion, Snord114/116 deletion). I also propose that some imprinting 
disorders cases may be caused by failure to maintain imprints during preimplantaion. The 
findings of mosaic loss of imprinting, particularly in BWS and SRS cases, suggests that the 
severity of phenotypes may be based on the degree of mosaicism and the tissue types (including 
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the placenta) in which loss of imprinting is found. Finally, I suggest that there may be distinct 
epi-alleles in the population that are more prone to loss of imprinting during preimplantation 
development due to environmental factors and maternal effects. 
 The separation of placental and fetal phenotypes in the DNMT1o-model is difficult due 
to the entanglement and codependence of their development. One tool to better ascertain the 
placenta autonomous phenotypes from those that are intertwined or the result of fetal 
maldevelopment is through tetrapoloid trophoblast complementation. It would be informative to 
determine if the partial fetal lethality observed at E12.5 in DNMT1o-deficient placentas could be 
rescued by tetrapolid complementation of Dnmt1Δ1o maternal effect blastocysts. If survival to late 
gestation and neonatal time points was observed at a greater frequency, placental phenotypes 
could firmly be attributed as the main antagonist of early fetal lethality associated with loss of 
imprinting. Similarly, the reciprocal experiment could be performed and normal ES cells injected 
into Dnmt1Δ1o maternal effect blastocysts and examined for developmental outcome. If abnormal 
wild-type fetal development was observed in such conceptuses it would be arguably caused by 
placental imprinting defects, however this system would likely result in at least partially chimeric 
fetuses with some cells having partial loss of imprinting. I also suggest the development of both 
ESC and TSC lines from DNMT1o-deficient conceptuses that have loss of imprinting at a small 
number of loci with clinical relevance (e.g. Snrpn, H19, Kcnq1, Mest, Plagl1, Nespas). These 
cell lines could be studied for their potential to generate normal chimeric fetal or trophoblast 
tissue after blastocyst injection. The experiments I have proposed above may yield results that 
are informative on the contribution of genomic imprinting in the placenta on fetal development. 
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5.2.4  Reproductive technologies 
It has been reported that within the population of BWS patients there is enrichment for 
individuals conceived by assisted reproductive technologies (ART) (465-468). Although this 
suggests an increased incidence of imprinted diseases associated with ART, not all clinical 
research corroborates these findings (recently reviewed by (469, 470)). Nearly all cases of BWS 
associated with ART are concomitant with loss of methylation at IC1 (KCNQ1), whereas this is 
the case for only half of all BWS cases in the naturally conceived population (114, 471). 
Furthermore, loss of methylation in BWS cases from children born after ART is observed at a 
broad range of DMDs including Mest, Snrpn and Plagl1 (471, 472). This multigenic, and 
sometimes mosaic effect suggests that loss of imprinting occurs post-fertilization within the 
embryo. It is important for future studies to calculate the ART associated risk of SRS and 
TNDM1, which are most commonly associated with loss of methylation at the H19 and PLAGL1 
loci respectively (469). The gamete and embryo manipulation performed in ART procedures 
such as superovulation, in vitro fertilization and intra-cytoplasmic sperm injection directly 
expose both gametes and embryos during the window of time crucial for the maintenance of 
genomic imprints (473, 474). My results clearly show that the majority of DMDs, including 
Kcnq1, H19, Mest and Plagl1 can be affected, either in isolation or in tandem, by loss of 
DNMT1o activity Therefore, it is rather intuitive to suggest that ART may be detrimental to 
DNMT1o maintenance methyltransferase activity. 
 Similarly, both ART and cloning in mouse alter imprinted DMD methylation. Mouse 
embryos generated from IVF and cultured during preimplantation development in Whittens 
medium have lower levels of H19 methylation, and their placenta are afflicted with loss of 
imprinting to a greater degree than the fetus, showing biallelic expression of H19, Snrpn, Ascl2 
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and Peg3 (475, 476). Likewise, aberrant imprinted gene expression is observed in 
preimplantation embryos cultured in M16+FBS (477). Blastocysts, mid-gestation embryos and 
placentas derived from superovulated oocytes developing in vivo have a modest partial loss of 
imprinting at the Snrpn and H19 loci (478, 479). Both biallelic expression and loss of DMD 
methylation is greater in the placental compartment than in the embryo proper (478). 
Superovulated oocytes harbor normal imprinted DMD methylation ruling out superovulation 
induced effects on the establishment of imprints (480). Imprinted genes are overrepresented in 
those transcripts whose expression is increased or decreased more than 2-fold in placentas 
derived from in vitro fertilized superovulated oocytes (481). These results taken together suggest 
that environmental influences subject the early embryo to loss of imprinting during 
preimplantation development and that the maintenance of imprints is less robust in the TE than 
the ICM. It would certainly be of interest to determine the amount of DNMT1o present in 
superovulated oocytes and its activity in preimplantation in vitro culture. 
Reconstitution of an enucleated oocyte with a donor nucleus (either ES or somatic cell) 
reformats the epigenetic state of the donor genome to one that emulates a nascent zygote in a 
process known as “reprograming” (482, 483). Cloning by nuclear transfer is an inefficient 
process (484). Only10-20% of ES cell nuclear donors and 50-70% of somatic cell nuclear donors 
mature into blastocysts (484). Of uterine transferred blastocysts 5-20% of ES nuclear donor and 
1-3% of somatic nuclear donors survive to term and even fewer to adulthood (484). The majority 
of clones develop abnormally with fetal and placental overgrowth concomitant with altered 
imprinted gene expression and DMD methylation (484-487). Cloned placentas are overgrown 
almost 2-fold, have an expanded JZ enriched with GCs with SpT extensions into the LZ, have 
enlarged TGCs and a disorganized LZ (488). ESCs cultured from SCNT derived blastocysts are 
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epigentically equivalent to naturally fertilized blastocyst derived ESCs and can produce all fetal 
lineages when complemented with tetraploid TE further suggesting that extraembryonic 
development is the limiting factor in reproductive cloning (489, 490). The similarities between 
cloned mice and the JZ and GC expansions I observed in late gestation DNMT1o-deficient 
placentas is striking.  
My results also showed a disruption of E/P ratio and a general overgrowth of DNMT1o-
deficient placentas and fetuses surviving to late gestation which mirrors the findings in cloned 
animals and suggest that abnormal maintenance of imprints during preimplantation may be the 
central cause of cloning developmental failures. The work on reproductive cloning has 
implications for the large offspring syndrome observed in cloned livestock and in conservation 
efforts to restore native fauna and endangered species (491, 492). Interestingly, SCNT porcine 
embryos undergo replication dependent preimplantation partial demethylation of the H19 DMD 
(493). Because this demethylation occurs during the first two cell cycles and is mimicked by 
DNMT1 GV oocyte RNAi injection it implies that maternal DNMT1s activity is decreased in 
SCNT embryos (493). The above results taken together indicate that it is critical for reproductive 
biologists to better understand the details of maintenance methyltransferase activity in 
preimplantation development to improve the safety and efficacy of clinical ART and animal 
cloning. It would be insightful to determine if DNMT1o activity is altered in ART or nuclear 
transfer in mice, and whether ART or oocyte reconstitution can modulate the Dnmt1Δ1o maternal 
effect. 
 Reprogramming of somatic nuclei can also be carried out by transfection of the 4 
Yamanaka pluripotency factors (Oct3/4, c-Myc, Sox2 and Klf4) (494). A small percentage of 
these induced pluripotent stem (iPSCs) cells can generate high percentage chimerism when 
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injected into blastocysts and yield all iPSC pups from tetraploid TE complementation (495, 496). 
The most prominent transcriptional difference between iPSCs incapable of generating all iPSC 
pups via tetraploid complementation and genetically identical ESCs is found in the expression 
levels of maternally expressed Meg3 and Rian transcripts within the Dlk1 imprinting cluster 
(380, 381). Biallelic Dlk1 DMD methylation represses maternal ncRNA transcription in these 
iPSCs (380, 381). However, the subset of iPSCs that are competent to generate chimeras and all 
iPSC tetraploid complemented offspring have normal monoallelic methylation and Meg3 
expression (380, 381). The incompetent iPSCs can be made to generate all iPSC offspring by the 
addition of the HDAC inhibitor valproic acid (381). Lastly, the addition of ascorbic acid (vitamin 
C), a potent histone methyltranferase and TET enzyme cofactor, during iPSC induction prevents 
Dlk1 DMD hypermethylation and yields developmentally competent iPSCs (497). The fact that 
the Dlk1 DMD becomes biallecially methylated during iPSC reprogramming suggests that there 
are molecular mechanisms during in vivo reprogramming that prevent de novo methylation at 
this locus. My results that Dlk1 DMD methylation is invariable in DNMT1o-deficient placentas 
is in line with these findings and suggests an early selection against loss or gain of methylation at 
the Dlk1 DMD (Figures 32O and 32P). Furthermore, parthenogenetic development can be 
induced with inheritance of one allele of Dlk1 and H19 DMD deletion (both of which mimic the 
paternal imprinted state). I interpret these results to suggest that paternal imprints are required for 
embryonic development and as supporting evidence to the ovarian bomb theory.  
The limited developmental potential of SCNT and iPSCs is perhaps not surprising given 
that ES cells themselves, particularly inbred and long term passaged lines, are restricted in their 
fetal chimera contribution when injected into host blastocysts or complemented with tetrapoloid 
TE (484, 498, 499). Mice derived from ES cells are often overgrown and riddled with epigenetic 
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defects including at imprinted loci (498, 499). Clearly these results suggest that the maintenance 
of genomic imprints during reprogramming is a requirement for full embryonic developmental 
potential. It would be interesting to determine the extraembryonic developmental potential of ES, 
SCNT and iPSCs with imprinting defects that have been transformed via iRas to a TSC like 
state. 
5.2.5  Mechanisms of imprinting 
There are a number of unresolved issues regarding the molecular mechanisms involved in the 
maintenance of genomic imprints during preimplantation development. I have presented a 
summary of the factors present in the imprinting maintenance machinery including DNMT1, 
UHRF1, DNMT3, DMAP, ZFP57, TRIM28, and histone modifiers (Section 1.1.2). The 
maintenance of parent-of-origin specific monoallelic methylation during the dynamic genomic 
demethylation and remethylation events that occur with preimplantation reprogramming require 
that imprinted alleles be protected from demethylation and faithfully propagated, and the non-
imprinted allele to be resistant to de novo methylation. Genetic ablation of the factors involved in 
these processes effects imprinted DNA methylation. Deletion of either Zfp57 or Trim28 results in 
partial loss of DMD methylation with certain loci more affected than others (71, 72, 74). It is 
therefore reasonable to hypothesize that different imprinted loci have unique effectors and 
epigenetic readout, and that some are more robust than others. Furthermore, the maternal-zygotic 
lethality of compound Dnmt1v and Dmap null alleles suggests that the interaction between 
DMAP and maternal DNMT1s is essential for early reprogramming either via maintenance of 
imprints or the formation of the TIP60 epigenetic complex (107). Detailed clarification of the 
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epigenetic components involved in preimplantation and their interactions although difficult to 
procure from early embryos will be essential to fully elucidate this process.  
 The role of ncRNA in the establishment, maintenance and expansion of genomic imprints 
is also unresolved (500-502). The macro long ncRNAs Kcnq1ot, Airn, and Nespas have been 
implicated to act in cis to silence neighboring genes directly by transcriptional interference and 
through recruitment of heterochromatin factors including EHMT2 (500). The expansion of the 
Airn and Kcnq1ot ncRNA spread across chromatin in extraembryonic tissue is one plausible 
explanation for larger imprinted domains at the Igf2r and Kcnq1 clusters in placenta (500). In 
addition, the ncRNA may function in modulating nuclear architecture and long range chromatin 
interactions (437). Both the Kcnq1ot and Airn ncRNA are expressed in spermatagonia where the 
X-chromsome is imprinted via the Xist ncRNA and may share a common mechanism in 
regulation of their promoter (436). 
Other imprinted ncRNAs like the snoRNAs and miRNAs in the Snrpn and Dlk1 cluster 
likely function in trans to modulate alternative splicing, mRNA editing and overall gene 
expression levels of important developmental factors. For example, the miRNAs processed from 
the extended Meg3 transcript have are thought to modulate PRC2 components that influence 
expression of numerous genes (380). The snoRNA genes Snord114 and Snord116 within the 
Snrpn cluster alter alternative splicing and mediate prominent PWS/AS phenotypes (324, 325, 
464). The role of snoRNAs derived from Meg8 within the Dlk1 cluster nor the role of miRNAs 
from the same cluster are well defined. The snoRNAs from both the Dlk1 and Snrpn clusters 
form unique imprinted chromatin architecture in which one allele is transcriptionally active and 
produces long transcripts that are found at nuclear foci near their respective imprinted domains, 
that are spliced into snoRNA products and distributed throughout the nucleus (503). The H19 
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ncRNA is processed into Mir675, a miRNA that influences placental development (306). Other 
ncRNA antisense transcripts including Peg3as, Mestit, and Nespas are even less studied. 
Furthermore, the large primate specific C19MC miRNA cluster is imprinted and is involved in 
placental exosome mediated fetal and maternal immunity (504, 505). I conjecture that future 
research will better define the functional roles of imprinted ncRNAs in health and disease.   
 
5.2.6  Role of the Kcnq1 cluster in TGC development 
 One of the major findings in my dissertation was an association between loss of 
methylation at the Kcnq1 and Snrpn DMDs and accumulation of TGCs (Tables 4 and 5; Figures 
36G and 36H). The TGC accumulation phenotype mimicked the Dnmt3l maternal effect and 
Ascl2 targeted deletion models suggesting that loss of Aslc2 expression in trophoblast is the 
underlying cause. In humans, Ascl2 is expressed highly by intervillous and extravillous 
trophoblast but is not imprinted (506, 507). Complete hydatidiform molar pregnancies (which 
have a diploid paternally inherited genome) that are noninvasive do not express ASCL2, whereas 
invasive complete hydatidiform molar pregnancies do express ASCL2 (506). Although the lack 
of ASCL2 expression in the noninvasive molar pregnancies suggests paternal imprinting, it is 
more likely due to the predominance of microvillous-like cysts containing SynT and villous 
cytotrophoblast and the lack of extravillous cytotrophoblast which do not express ASCL2. The 
expression of ASCL2 in intervillous cytotrophoblast is congruent with Ascl2 expression in 
murine SpT, where it acts to repress TGC differentiation, but its expression in extravillous 
cytotrophoblst seems contradictory given their similar to TGCs. It would be interesting to 
determine if ASCL2 is absent from more specialized endovascular extravillous cytotrophoblast 
subtypes. 
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Other members of the KCNQ1 imprinted cluster that are imprinted in mouse 
extraembryonic lineages are not imprinted in humans including CD81, TSSC4, NAP1/4 and 
CARS (383). However, CDKN1C and PHLDA2 that are closer to the KCNQ1 imprinting center 
are ubiquitously imprinted in human and are normally expressed in various cytotrophoblast 
lineages (383, 508, 509). In complete hydatidiform moles neither CDKN1C nor PHLDA2 are not 
expressed (508, 509). Their expression is also limited in incomplete hydatidiform moles (triploid 
with diploid paternal and haploid maternal chromosome set) due to the single active maternal 
allele (508, 509). Although these correlative results suggest a possible role in molar pregnancies 
more profound evidence would be needed to rule out coincidental or passive associations. Many 
of the DNMT1o-deficient placentas collected at E9.5 presented hydatidiform molar-like cysts 
when viewed under the dissecting microscope (data not shown). I suspect that these may have 
been similar to the samples with expanded TGCs and flattened labyrinths, and diminish Ascl2 
and Phlda2 expression (Figure 4). Based on the E9.5 DNMT1o-deficient phenotypes and the 
E12.5 associations between loss of Kcnq1 DMD methylation and TGC accumulation along with 
the above hydatidiform molar molecular imprinting abnormalities I infer that loss of the KCNQ1 
imprint contributes to hydatidiform molar pregnancies.  
 The role of P-TGCs in mouse placenta development is to form a protective barrier 
between maternal endometrium and produce placental hormones (231, 232). Specifically, TGCs 
secrete choriogonadotropin hormone and the related family of prolactins (225, 227). In rodents 
this family of hormones has grown to include of 23 members in a large cluster and 3 additional 
members in a smaller cluster on mouse chromosome 13qA1 (225, 227, 236). While humans have 
a more limited set of prolactins their function in placenta development are poorly understood. 
The extravillous cytotrophoblast are similar to mouse TGCs and are polypoloid, but not to the 
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same extent as TGCs. Extravillous cytotrophoblast are however more invasive than their mouse 
counterparts extending into and taking up residence in the myometrium where they integrate into 
the maternal vascular system (177). Most studies on extravillous trophoblast have focused on 
their angiogenic and vascular remodeling properties in health and disease (e.g. PE). I think there 
may be crucial insights to be gained by studying their proliferation and secretion in loss of 
imprinting disorders. Given that placentomegaly is a common feature of BWS it would be 
pertinent to examine BWS associated placentas with loss of IC1 loss of methylation for 
extravillous cytotrophoblast numbers and examine whether Ascl2 expression is disrupted.  
5.2.7  Role of the Peg10 cluster in labyrinth development and fetal viability 
My regression studies revealed associations between loss of the maternal Peg10 imprint and 
diminished labyrinth development and embryonic lethality at E12.5 (Table 4; Figure 36E). While 
deletion of Peg10 results in similar neonatal lethality, loss of methylation is expected to lead to 
biallelic transcription of Peg10 and Sgce and suppression of paternal Pon2, Pon3 and Ppp1r9a 
transcription (288, 293). In fact, I found that Pon2 was significantly down regulated at E9.5 
(Figure 28). The study of commercially available Pon2, Pon3, and Ppp1r9a targeted deletion 
mouse models for placental phenotypes may be informative. I also suggest the generation of a 
Peg10 DMD deletion model which would likely replicate the imprinted allele due to the deletion 
of Peg10 and Sgce promoter elements, and phenocopy embryonic lethality in the paternal Peg10 
null and 6q bimaternal translocation models. The Peg10 DMD deletion may also reveal 
additional phenotypes from biallelic expression of maternally expressed genes in this cluster, 
particularly if crossed with a single copy Peg10 transgene to rescue early lethality. Transgenic 
overexpression of Peg10 and Sgce could mimic the loss of Peg10 DMD methylation phenotypes 
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observed in DNMT1o-deficient placentas and would be worthwhile to pursue. Lastly it has been 
presented in the literature that the Peg10 DMD regulates an expanded set of imprinted genes in 
extraembryonic tissues including Ppp19ra, and possibly other genes (e.g. Dlx5, Calcr and Asb4), 
therefore it is imperative to determine the exact boundaries of the Peg10 imprinted cluster in 
mouse placenta (263, 510). This could be done by examining expression of genes in proximity of 
Peg10 in DNMT1o-deficient E9.5 placentas with near complete loss of Peg10 DMD 
methylation. 
5.2.8  Identification of KLF14 transcriptional targets in mouse. 
My results in Chapter 4 show that Klf14 is an imprinted negative regulator of placental growth 
and that its deletion results in a significant increase in placental weight. It is important to 
determine what transcriptional targets are regulated by Klf14 during placental development. To 
these ends I am currently working on comparing the genome-wide gene expression profiles of 
Klf14 homozygous null and wild-type littermate placentas derived from heterozygous null 
intercrosses. Once significantly altered genes are identified I will test for enrichment of gene 
ontology pathways. I will also examine the promoters of up and down regulated genes for the 
presence of CACCC KLF14 DNA-binding sequence motifs. Transcriptional targets could be 
confirmed using luciferase reporter assays in trophoblast stem cells co-transfected with Klf14 and 
luciferase reporters driven by the promoter of putative KLF14 targets. Additionally, it would be 
of interest to examine the presence of the KLF14 interacting partners SIN3A and p300 as well as 
various histone modification at target genes of interest in homozygous null and wild-type 
placentas using chromatin immunoprecipitation. These experiments should further reveal the 
functional role of Klf14 in placental development. 
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 During my thesis research I was unable to determine where in the placenta Klf14 is 
expressed. It has been reported that Klf14 is present in the placental labyrinth, which is an 
amalgam of trophoblast and fetal derived cells. I attempted to use commercially available 
polyclonal antibodies to identify KLF14 localization by immunofluorescence to no avail (data 
not shown). I had mixed results using these antibodies in western blotting as well (data not 
shown). Here I propose three different experiments to determine whether Klf14 is expressed in 
trophoblast or fetal derived labyrinth cells. Heterozygous Klf14flox females could be crossed to 
male Sox2:CRE transgenics to generate epiblast specific Klf14 maternal null conceptuses. If the 
fetal vascular endothelial cells in the labyrinth are the only cell type that express Klf14 then 
fetuses that are heterozygous Klf14 null would lack placental Klf14 expression. Additionally, I 
could generate a trophoblast specific conditional deletion by crossing heterozygous Klf14flox 
females with Cyp19, Tpbpa, or Gcm1 driven CRE transgenic males to generate ubiquitous 
trophoblast specific deletion or targeted deletion within SpT or SynT layer II respectively (511). 
A second method to generate trophoblast specific null mice is through the use of peripheral 
blastocyst lentiviral CRE infection (a new technique that specifically targets the mural and polar 
TE at the blastocyst stage) (512). Finally, I could attempt to isolate either SynT or fetal 
endothelial cells by using various cell capture methods (ie. antigen specific magnetic bead 
capture, or flow cytometry) and examine Klf14 expression. 
 I also propose the construction of additional models to determine the role of the Mest 
imprinting cluster at large within the placenta. I think it would of interest to attempt to develop a 
Klf14 transgenic overexpression model, although this may be difficult given the mitotic 
catastrophe revealed in HeLa cell Klf14 overexpression (434). Engineering a targeted Mest DMD 
deletion model, while complicated due to the overlap with exon 1 and intron 1, would be 
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expected to generate an allele that replicates the methylated maternal allele. Paternal inheritance 
of a Mest DMD null might influence fetal and placental growth given the expected decrease in 
Mest expression and increase in Klf14. It is also important to define the function of MEST using 
biochemical in vitro experiments to determine putative hydrolase substrates. A Mest 
overexpression transgenic model may recapitulate the DNMT1o-deficient placental lipid 
accumulation phenotype and be insightful to determine causative mechanisms in a less 
heterogenous model. It would also be of particular interest to delete the placenta specific Mest 
promoter and/or exon and investigate whether placenta and/or fetal growth restriction still occurs 
similarly to the constitutive deletion. Each of these models suggested here could also be fed HFD 
to see whether metabolic phenotypes can be induced. Although I have focused on placental 
biology, it is likely that the Mest imprinting cluster has important roles in other organs.  
In conclusion, I have surveyed the placental morphological and epigenetic abnormalities in 
DNMT1o-deficient placentas and revealed unique roles for the Kcnq1, Peg10 and Mest 
imprinting clusters. My work to generate and study a targeted deletion of Klf14 has demonstrated 
a role for it in regulating placental growth. These findings add to the growing body of evidence 
that genomic imprints are vital for placental development. I hope that my dissertation research 
has added to our understanding of the mammalian genome. I look forward to further 
investigations by myself and others that resolve the functional roles and mechanisms involving 
the phenomenon known as genomic imprinting.   
5.3  CONCLUDING REMARKS 
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Primer Name Primer Sequence 
Dnmt1o Genotyping 
  
Egg6 AGGAAAACAGTGGAGGAAC 
Egg7 TACTTTGCACAGGGCTGTCCT 
Sex Genotyping   
ZFYfwd CCTATTGCATGGACAGCAGCTTATG 
ZFYrev GACTAGACATGTCTTAACATCTGTCC 
Sox2:CRE Genotyping   
SOX2fwd AGGTGTAGAGAAGGCACTTAGC 
SOX2rev CTAATCGCCATCTTCCAGCAGG 
Klf14 Genotyping   
HB3fwd CTGCTCTTCCTTTCCTCACT 
HB4rev GAGAGACTTTTCTTCGCAGC 
HB6rev TGATTAGGAGGGGGAAAACAC 
 
  
APPENDIX A 
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Primer Name Primer Sequence  
qPCR   
Peg10 TGCTTGCACAGAGCTACAGTC CTGAATCCAGCCATGTGGTAGA 
Sgce CGGATTCTTTGAAAAGCCGAGA GTCTGTGTGCATGGGAGGTAT 
Pon2 GCTCTGAGTTTGCTGGGCAT GGCAGTTTGGAAGGTCTACAGAT 
Dlk1 GGAACCATGGCAGTGCATCT CGAACGTCTATTTCGCAGAATTT 
Meg3 TCCTCACCTCCAATTTCCCCT GAGCGAGAGCCGTTCGATG 
Rtl1 CCTGTGCCAGGGGCTCAACG CTTGGGCGCGACTCAGGTGG 
Igf2 GTGCTGCATCGCTGCTTAC ACGTCCCTCTCGGACTTGG 
H19 GAACAGAAGCATTCTAGGCTGG TTCTAAGTGAATTACGGTGGGTG 
Igf2r AGCCTCGGCAGATTTATTTT CCCCATTGGTCCTCATGTCT 
Slc22a2 GAACGCTGAGCTGTACCCTACA GGGCAGAGCACACCATCAT 
Mest TCTCCAAAAGCTCCTCAAAG ATGAATGGGGATGGACACAG 
Klf14 CTCCGTGTGCCTCAACTAGC CAGGCGCATCCAGGATAGC 
Phlda2 CTCCGACGAGATCCTTTGCG ACACGTACTTAGAGGTGTGCTC 
Ascl2 AAGCACACCTTGACTGGTACG AAGTGGACGTTTGCACCTTCA 
Grb10 CCTGCCAAGCATGATGTCAAA CCAGGCACCTCTCTAATCCCA 
RT-PCR   
Klf14 TGGACACCCTCTCCAAAGTC AAGCGACATCAGTGCTCCTT- 
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Primer Name Primer Sequence  
Bisulfite Genomic Sequencing (nested)   
H19_R1 GAGTATTTAGGAGGTATAAGAATT ATCAAAAACTAACATAAACCCT 
H19_R2 GTAAGGAGATTATGTTTATTTTTG CCTCATTAATCCCATAACTAT 
Kcnq_R1 GGTTTAAAGGGTTTTAAGATTATTTTTG CTTCTTTTCCCTCTATAsTAATTCTAC 
Kcnq_R2 GTTTTTGTAAGTTTGGGTTATAAAG AACTTTTCTATTCAACTTAATTCCC   
Snrpn_R1 TATGTAATATGATATAGTTTAGAAATTAG AATAAACCCAAATCTAAAATATTTTAATC 
Snrpn_R2 AATTTGTGTGATGTTTGTAATTATTTGG ATAAAATACACTTTCACTACTAAAATCC 
Mest_R1 GATTTGGGATATAAAAGGTTAATGAG TCATTAAAAACACAAACCTCCTTTAC 
Mest_R2 TTTTAGATTTTGAGGGTTTTAGGTTG AATCCCTTAAAAATCATCTTTCACAC 
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Primer Name Primer Sequence for EpiTYPER Mass Array  
Primer 5′ tag    
 5' FWD Tag AGGAAGAGAG  
 
5' REV Tag 
(T7) CAGTAATACGACTCACTATAGGGAGAAGGCT 
Imprinted gDMR  Sequence (5' to 3') Genomic Coordinates (GRCm38) 
Dlk1.A FWD ATAGTATTGGTTTGGTATATATGGATG 12:109527424-109527853 
 REV CCATAACATAAACATAAAAATCCACAA 
Dlk1.B FWD GATGTGTTGTGGATTTAGGTTGTAG 12:109528138-109528138 
 REV ATCCCCTATACTCAAAACATTCTCC 
Grb10 FWD AGGAGTTGTTTATTATTTGGATTATTGT 11:12025702-12026046 
 REV CTCTAAACTCCAAAACCCTTTTTCT 
H19(*) FWD GTTGATGGTTTTAGAATTTTATAAGTTAG 7:142581609-142581931 
 REV CACAATACCACTAAAAAAACAAAACA 
Igf2r FWD GATAGGAGGATTTAGAGGGTTTTGT 17:12742752-12743024 
 REV AACCCCATTATCTACAACTCAAACA 
Impact.A FWD TTTGTATTAAGTAGGTTGTTTTAGGG 18:12972913-12973111 
 REV ACAACCAAACTAAAATTAACCAAACAA 
Impact.B FWD TTGTTTGGTTAATTTTAGTTTGGTT 18:12973084-12973497 
 REV TCATATAACAATACAACAAAACCTACTC 
Kcnq1 FWD TGGAGAGTTTTTTTGTTTAGTTTGG 7:150481809 -150481430 
 REV CAAAACCACCCCTACTTCTATAAAC 
Nespas.A FWD TGGGGGTTTTTGATTTTTTTATTTTG 2:174295281-174295599 
 REV TAAATCTCAACCACTAACCCACTCC 
Nespas.B FWD TTTTTTTTAGGGTTTTGTAGGTTAGATTTG 2:174295985-174296393 
 REV CCCCTCCTCCTTCTATTATAAACACC 
Mest FWD ATATGTTGGGGAGGGATTTTTTTAG 6:30737763-30738178 
 REV CAACAAAAACAACAAACAACAACTC 
Peg3 FWD GATTTTGTTTGGGGGTTTTTAATATTGAT 7:6683342 -6683054 
 REV CCACCAACCCAAAATAAACATCTCT 
Plagl1 FWD TATTTTTGTGGGGATGGAGGAATTA 10:13090467-13090791 
APPENDIX D 
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 REV ATCCCAACCCAAACTAAATAACAAA 
Peg10 FWD TTAGGATTTGGTTATTGAAGGTTTG 6:4697732 -4697319 
 REV CCCCTCCTAAAATCTCTCTATATAAAAC 
Snrpn FWD TGTGATGTTTGTAATTATTTGGGAG 7:67150146 -67149901 
 REV CTAAAATCCACAAACCCAACTAACC 
Nnat FWD TTTAGGTGGTAAGAGGGTATTTAAGG 2:157560062-157560273 
 REV AATACATACTCACCTACAACAACAC 
Nap1l5 FWD AGTTTGGAATTTTTTGTTAAATTTGG 6:58906694-58907060 
 REV CAACTACAAAACCTCTCTAAACCAAC 
Zrsr1 FWD GGTAAGGTAGATAATTATTGTTTTAGTTGT 11:22972131-22972559 
 REV CATAAACCTACCCATACAATTACCC 
(*) From McGraw et al (2013)   
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